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ABSTRACT

The MMTV/neu transgenic mouse line is a well-documented animal model for
studying HER2/neu-related breast cancer. It has been reported that a small percentage,
approximately 20%, of the virgin female MMTV/neu mice seems resistant to the
development of mammary gland adenoma, despite the overexpression of the neu
oncogene.
To identify the factors that are responsible for the tumor resistance in these
MMTV/neu female transgenic mice, comparative genetic profiling was used to screen the
alterations in gene expression in the mammary gland.

A novel gene named the RAS

Association domain (RalGDS/AF-6) Family 3 (Rassf3), which belongs to a family of
RAS effectors and tumor suppressor genes was identified in this study. Data presented in
this dissertation show: 1) that the Rassf3 gene is overexpressed in the mammary gland of
the tumor-resistant MMTV/neu mice compared to their tumor-susceptible MMTV/neu
transgenic littermates or age-matched non-transgenic FVB mice, and 2) that the Rassf3
gene is significantly up-regulated in neu-specific mouse mammary tumors compared to
adjacent normal tissues.
To further confirm the role of the Rassf3 gene in mammary carcinogenesis, a
series of in vitro and in vivo experiments were explored.

The results show that

overexpression of RASSF3 inhibits cell proliferation in HER2 positive human and mouse
breast cancer cell lines. The inhibitory effect of RASSF3 seems to be through induction
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of apoptosis. In addition, co-transfection of the Rassf3 gene with the activated H-RAS
gene in SKBR3 human breast cancer cells decreased H-RAS protein level, suggesting
that RASSF3 protein can indirectly interact with H-RAS protein.

A novel

MMTV/Rassf3-neu bi-transgenic mouse line, overexpressing both Rassf3 and neu genes
in mammary glands, was also established. The mammary tumor incidence in virgin
female bi-transgenic mice was delayed compared to their MMTV/neu+/- littermates.
Together, these data suggest that Rassf3, a RAS effector, is a candidate gene that may
influence the mammary tumor incidence in virgin female MMTV/neu transgenic mice.
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1.

1.1.

INTRODUCTION

Cancer
Cancer can be defined as a collection of diseases characterized by unregulated cell

growth leading to invasion of surrounding tissues and spread to other part of the body,
which are life-threatening.

The process by which cancers are generated is called

carcinogenesis and is a multi-step mechanism resulting from the accumulation of errors
(altered DNA bases or mutations) in vital regulatory pathways. It is initiated in a single
cell (clonal origin) which then multiplies and acquires additional changes that give it a
survival advantage over its neighbors (Huang D. et al., 1997). The altered cells must be
amplified to generate billions of cells that constitute a tumor. The age distribution of
several cancers indicates that cancer risk increases with age and cancer is often defined as
a disease of old age (King R., 2000). However, there are exceptions in that some cancers
are characterized by onset in childhood, such as cancers of the eye and certain leukemias.
In addition, certain cancers are prevalent in different countries, suggesting that
environment, lifestyle and diet have an impact on cancer development. For example,
breast and prostate cancers are common in Western countries while cancer of the cervix
and stomach are more prevalent in Asia and notably in China (King R., 2000). Also, men
and women have different cancer patterns, which indicate the major role of sex
hormones. For instance, breast cancer represents approximately 32% of all cancers in
women but less than 1% in men in Western countries. Some tissues are also more prone
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to develop cancer than others. The four most common cancers (breast, lung, colon and
prostate cancers) in both sexes are of epithelial origin; however, most cell types are
susceptible to develop cancer.
Carcinogenesis is often divided into initiation and promotion stages and is
followed by progression, often leading to invasion and metastasis. The initiation stage
corresponds to genetic alterations caused by an initiating agent (i.e. carcinogenic
chemicals) which then requires cell proliferation, triggered by the promoting agent (i.e.
hormones, viral infection), to transform a single potential cancer cell into a multicellular
tumor. As they progress, cancers continue to change their behavior and acquire a higher
degree of autonomy, which reflects the genetic instability of the cells involved. The
concept of initiation has generated an industry devoted to the identification of agents that
cause it. There are some clear examples for which the initiating agents have been
identified such as the lung cancer (tobacco smoke), bladder cancer and leukemia
(ionizing radiation) (King R., 2000). However, in some cancers such as colon cancer,
leukemia unrelated to radiation or hormone-related breast and prostate cancers, it remains
difficult to define the initiating agents. Considerable data indicate that the progression
from pre-malignancy to malignancy is a slow process, which is consistent with a natural
selection model.

Evidences suggest that cancer development follows a “multi-hit”

model, implying that multiple mutations or errors in the cellular machinery are required
for cancer to develop and that damaging and proliferative influences must be continuous
throughout cancer progression in order to reach full metastatic potential (Huang D. et al.
1997).
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Mutations in genes can occur in single somatic cells, resulting in sporadic tumors
or in the germline, resulting in hereditary predispositions to cancer. The great majority of
cancers are sporadic. Hereditary or familial cancers represent a minority of cancers (10%
of total cancer) and tend to occur at a younger age than if generated in a somatic cell.
The offspring are most often heterozygous, carrying one defective allele from the
affected parent and one normal allele. The human retinoblastoma (Rb) gene was the first
gene identified as a defective gene in familial retinoblastoma cancer; however, mutations
of the Rb gene are also observed in sporadic cells. Similarly, mutation in the adenoma
polyposis coli (APC) gene is responsible for familial colon cancer but also for some
sporadic forms of colon cancer. Germline mutations in BRCA1 or BRCA2 genes are
linked to familial breast cancers; however, mutations in these two genes have not been
found in sporadic cases, but BRCA1 gene expression has been found to be reduced in
some sporadic cancers, implying that the gene regulation and not only the gene function
can influence the disease.
1.2.

Oncogenes, Tumor Suppressors and Stability Genes
In the last decade, many important genes responsible for the development of

various cancers have been discovered, their mutations precisely identified, and the
pathways through which they act characterized.

Three groups of genes have been

identified, in which alterations can contribute to tumorigenesis: oncogenes, tumor
suppressor genes and caretaker or stability genes (Vogelstein B. and Kinzler K., 2004).
Oncogenes are normal regulatory genes whose activity is increased as a
consequence of genetic alteration in either their coding region or regulatory sequences.
This mutation results in a gain of function. The activation of oncogenes can result from
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chromosomal rearrangement (e.g. acute and chronic myelogenous leukemia), gene
amplification (e.g. ERBB2/Her2) or from intragenic mutation affecting crucial residues
that regulate the activity of the gene product (e.g. B-RAF). An activating mutation in one
allele of an oncogene is generally sufficient to confer a selective growth advantage to the
cell.
Tumor suppressor genes encode for inhibitory proteins whose function is to
inhibit cell functions by complexing with other effector proteins and blocking their
actions. A mutation in a tumor suppressor gene results in a loss of function. Such
inactivation can arise from misense mutations at residues that are essential for its activity,
from mutations that result in a truncated protein, from deletions or insertions of various
sizes, or from epigenetic silencing. The mutation acts in a recessive manner, meaning
that a mutation in both alleles is required to block the gene function.

For tumor

suppressor-related cancers, individuals usually inherit one mutant copy of the tumor
suppressor gene and the second mutation occurs sometime during life in the target cell.
However, recent data have shown that for some tumor suppressor genes (e.g. p53),
mutation and inactivation of one allele is sufficient to block the full gene function
(haploinsufficiency) (Largaespada D., 2001; Paige A., 2003).

Epigenetic silencing

results in a decrease in gene expression through modifications that doesn’t affect the
DNA sequence. Silencing can be achieved by different mechanisms including DNA
methylation, histone acetylation or deacetylation, histone methylation and poly(ADPribosyl)ation (Tycko B., 2000; Eberharter A. and Becker P., 2002).

It has been

demonstrated that numerous tumor-suppressor genes (e.g. Rb, APC, BRCA1, and
RASSF1A) are silenced by DNA methylation in different types of cancers.

DNA
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methylation of regions rich in cytosine-guanine doublets, called CpG (phosphodiesterlinked cytosine and guanine pairs) islands, in the promoter region of a gene is a common
mechanism of epigenetic silencing. Cancer cells often display aberrant patterns of DNA
methylation, with hypomethylation throughout most of the genome and site-specific
hypermethylation in CpG islands. It has been proposed that promoter hypermethylation
is a frequent pathway alternative to loss of heterozygosity (LOH) for the somatic “second
hit” in tumorigenesis, since, in many cases, the heterozygote tumors have lost the
expression of the non-mutated allele via promoter hypermethylation.
Thus, the mutations in oncogenes and tumor suppressor genes operate in a similar
way at the physiologic level by conferring a selective growth advantage to the cell by
stimulating cell proliferation or inhibiting cell death or cell-cycle arrest.
In comparison, caretaker or stability genes promote tumorigenesis in a completely
different way when mutated or epigenetically silenced.

This group includes the

mismatch repair (MMR), the nucleotide-excision repair (NER) and the base-excision
repair (BER) genes which encodes for enzymes that are responsible for sensing and
repairing subtle mistakes in DNA made during normal DNA replication or induced by
exposure to mutagens. It also includes other stability genes which control processes
involving large portions of chromosomes, such as those responsible for mitotic
recombination and chromosomal segregation. The role of these stability genes is to
correct genetic alterations to preserve the genetic integrity. Thus, when these genes are
inactivated, mutations in other genes such as oncogenes and tumor suppressor genes will
occur at a higher rate. A common example is the Lynch syndrome (also called hereditary
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non-polyposis colorectal cancer, HNPCC), which results from the germline mutation in
two mismatch repair genes (MSH2 and MLH1) (Viel A. et al., 1997).
1.3.

Hallmarks of Cancer
There are multiple pathways by which cells can acquire biological capabilities

that promote the development of cancer. These capabilities are defined as the hallmarks
of cancer (Hanahan D. and Weinberg R., 2000). The first hallmark consists of the selfsufficiency in growth signals of cancer cells. Indeed, tumor cells have a greatly reduced
dependence on exogenous growth stimulation. This autonomy can be achieved by three
molecular strategies. First, they can show altered extracellular growth signals. Some
cells can synthesize many of their own growth signals to which they are responsive
(autocrine stimulation), therefore reducing their dependence on stimulation from their
normal tissue microenvironment. Second, tumor cells can show altered trans-cellular
transducer of those signals, such as deregulated growth factor receptors on their surface.
Many growth factor receptors (e.g. EGFR and HER2) are found to be overexpressed in
many cancers, which render cells hyper-responsive to ambient levels of growth factors.
Third, they can have altered intracellular signaling pathway that translate those growth
signals into action. For instance, the SOS-RAS-RAF-MAPK cascade has been shown to
be structurally altered in about 25% of cancers and to enable tumor cells to release a flux
of mitogenic signals into the cells (Medema R. and Bos J., 1993).
The insensitivity of tumor cells to antigrowth signals constitutes the second
hallmark. These anti-growth signals include soluble growth inhibitors and immobilized
inhibitors embedded in the extracellular matrix and on the surface of nearby cells. They
can stop cell proliferation by either blocking cells into the quiescent state (G0 phase) of
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the cell cycle, or inducing cells to enter into post-mitotic states associated with
acquisition of specific differentiation traits. The anti-proliferative signals (i.e. TGFβ) are
almost all funneled through the retinoblastoma protein (pRb) and have been shown to be
disrupted in a majority of human cancers.
The third hallmark is the evasion of apoptosis or programmed cell death.

This

evasion occurs by alteration in sensors and effectors of the apoptotic machinery. The
sensors include cell surface receptors that bind survival signals (e.g. IGF1/2, IL-3) or
death signals (FAS ligand, TNFα) whose signaling will consequently regulate the
effectors of apoptotic death. Abrogation of pro-apoptotic effectors (eg.. Bax, Bid, Bak
and p53) can provide cells with resistance to apoptosis. The tumor suppressor p53 is the
most common pro-apoptotic regulator found to be abrogated in tumors.

This has

important implications since signals evoked by DNA damage, hypoxia and oncogene
expression are all funneled via p53 to the apoptotic machinery (Levine A., 1997). As a
consequence, inactivation of p53 is one crucial way to allow cells to evade apoptosis.
Tumor cells appear to be immortalized and to have acquired a limitless replicative
potential during tumor progression. This aspect is referred to as the fourth hallmark.
Evidences suggest that telomerase enzymes play a role in cell immortalization and their
expression is up-regulated in 85-90% of all tumors (Harley C. and Kim N., 1996; Shay J.
and Bacchetti S., 1997). In fact, their activity allows maintaining telomeres at a length
above a critical threshold which in turn permits unlimited multiplication of descendant
cells. Conversely, shortened telomeres activate cell senescence.
A prerequisite to the rapid clonal expansion associated with the formation of
macroscopic tumors, is the supply of nutrients by the generation of new blood vessels or
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angiogenesis. It is documented that tumor cells acquire the ability to induce and sustain
the growth of new blood vessels during tumor development via an “angiogenic switch”
from vasculature quiescence (Folkman J., 2002). This characteristic is referred as the fifth
hallmark. The induction of angiogenesis is an early to mid-stage event in many human
cancers and it is realized by a change in the balance of angiogenesis inducers (e.g. VEGF,
FGF) and countervailing inhibitors (e.g. Thrombospondin-1, β-interferon) through a
change in gene expression. In addition, this switch seems to be also controlled by integrin
signaling, cell-cell adhesion and extracellular proteases which demonstrate a complex
homeostatic regulation of normal tissue angiogenesis and vascular integrity, and to differ
at the molecular mechanism level depending on the tumor cell type.
The sixth hallmark is defined by the capability of cancer cells to escape the
primary tumor mass, invade adjacent tissues and colonize new terrain in the body to form
distant settlements of tumor cells, called metastases. This process involves changes in
the physical interactions of cells to their microenvironment and activation of extracellular
proteases. The function of cell-cell adhesion molecules such as E-cadherin has been
found to be lost in most epithelial cancers (Christofori G. and Semb H., 1999). Ecadherin acts as a suppressor of invasion by epithelial cells and its functional elimination
represents a key step in the acquisition of this capability. Cell-matrix interactions also
play an important role in invasiveness. Indeed, successful colonization of new sites by
tumor cells has been shown to be possible through a shift in integrin expression (Varner
J. and Cheresh D., 1996). Matrix-degrading proteases genes are also up-regulated and
proteases inhibitors genes are down-regulated in tumors, which facilitate invasion of
cancer cells into the stroma, across the blood vessel walls and through normal epithelial
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layers. Of these different acquired abilities, invasion and metastasis of cancer cells are
the major causes of cancer-related deaths and yet, the least well understood at the
molecular level
The six previous capabilities are directly or indirectly acquired through mutations
in the genome of cancer cells. This increased mutability implies a malfunction of specific
components of the genomic “caretaker” system. It has been found that the caretaker
genes are often lost in different cancers, resulting in genomic instability.

This

phenomenon is referred as the seventh hallmark of cancer.
In addition, some tumor cells seem to have acquired the capacity to initiate new,
full-fledged tumors. These cells differ from the other tumor cells in that their behavior is
similar to that of normal stem cells, which have the unique ability to differentiate into any
number of cell types, and, importantly, possess an unlimited capacity for self-renewal.
These rare cancer-initiating cells are named cancer stem cells. They can originate either
from mutation of normal stem cells or from differentiated cells or restricted progenitors
that acquired stem cells characteristics (Reya T. et al., 2001). The acquisition of stem
cell characteristics by tumor cells can be considered as the eighth hallmark of cancer.
Finally, tumor cells have an altered metabolism, referred to as the ninth hallmark,
compared to normal cells. They live in an oxygen-poor (hypoxic) and highly acidic
environment. They have adapted to this environment and they survive by obtaining
energy through a much less efficient anaerobic glycolysis which requires much higher
levels of glucose. This altered metabolism is due to a change in gene expression profile
of genes involved in metabolism. It is characterized by a higher rate of glycolysis, an
increased rate of glucose transport, an increased gluconeogenesis and lactic acid
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production, a reduced fatty acid oxidation and a modified amino acid metabolism.
Mitochondria which play a role in the oxidative metabolism are involved either directly
or indirectly in many aspects of the altered metabolism, and demonstrate several notables
differences at the genetic, molecular and biochemical levels in normal and in cancer cells
(Warburg O., 1956; Zanssen S. and Schon E., 2005).
1.4.

Breast Cancer

1.4.1. Incidence and Risk Factors
Breast cancer is the most common form of cancer in females, affecting
approximately one out of eight women who reach age ninety in the United States
(http://www.cancer.gov/cancertopics/factsheet/Detection/probability-breast-cancer). It is,
after lung cancer, the second most fatal cancer in women. On the other hand, the lifetime
risk for men to get breast cancer is about one hundred time less than for women. There
are marked geographical differences in breast cancer incidence which reflect the
difference in cancer causes. The rate of increase of breast cancer incidence slowed in the
1990s even though, at the same time, the incidence of ductal in situ breast lesions
increased. The mortality rate also significantly decreased in the early 1990s, probably
due to early diagnosis and continuing new therapeutic approaches. Nevertheless, the high
death rate of women with invasive form of breast cancer remains a sobering fact and
indicates the need to understand this disease in greater depth and to develop new
interventions, both preventive and therapeutic.
Epidemiological observations have demonstrated that the risk factors associated
with breast cancer are the age of first pregnancy (lower risk if under 30), total number of
pregnancies, early menarche, late menopause, family history or genetics, breast feeding
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(lower risk in premenopausal women) and diet (reviewed by Kelsey J. et al., 1993;
reviewed by Medina D., 2005). These risk factors imply a strong association between
breast cancer risk and hormone exposure during a lifetime. It has been estimated that
breast cancer risk is reduced 10-20% for each year of delay in the onset of menarche and
it has been shown that the high calorie Western-style diet is responsible for the predisposition of children to an earlier puberty. The early age of menarche translates into
earlier hormone exposure (estrogen and progesterone) and breast epithelial cell growth.
On the other hand, early age of first full-term pregnancy is a strong protective factor,
especially observed in postmenopausal women, corresponding to the peak of incidence
(reviewed by Russo J. et al., 2005b). Studies have estimated that every year that first
birth childbearing is delayed results in a 3.5% increase in lifetime breast cancer risk. In
addition, epidemiological literature on the history of breast-feeding in humans shows that
prolonged breast-feeding is additionally protective against breast cancer among
premenopausal women (Perez-Escamilla R. and Guerrero M., 2004).
These observations led to a rush to further understand the molecular basis for
hormone-mediated breast cancer protection or protective effect of pregnancy and led to
the

establishment

of

two

different

parity/hormone-induced protection.

experimental

systems

that

demonstrate

The first model, the pre-treatment model is

characterized by hormonal stimulation followed by carcinogen administration, whereas
the second model is characterized by carcinogen assault followed by hormone treatment
for a specified time period (Medina D., 2005). Numerous studies performed in rats or
mice showed that pregnancy had a preventive effect since it reduced mammary
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carcinogenesis incidence by more than 75% and prolong the latency in a pre-treatment
model (Russo I. et al., 1991; Thordarson G. et al., 1995; Medina D. and Smith G., 1999).
During pregnancy, there is a dramatic increase in the level of several circulating
hormones such as estrogens, progesterone, prolactin, growth hormone and placental
lactogens, which cause proliferation, development and differentiation of the mammary
gland in preparation of lactation. At the end of pregnancy, the mammary gland under the
influence of lactogenic hormones becomes fully lactational.

After weaning of the

offspring, the highly differentiated lobuloalveolar structures subsequently involute as a
result of the decrease in lactogenic hormones. It has been shown that hormone treatments
to mimic pregnancy using either estrogen and progesterone or chorionic gonadotropin are
also effective in reducing mammary tumor incidence in rodents (Russo I. et al., 1991;
Guzman R. et al., 1999; Sivaraman L. et al., 1998).

In the case of estrogen and

progesterone, the use of single hormone treatment showed that both hormones are
necessary for the protective effect in a pre-treatment model whereas, single hormone
treatment could be useful in post-treatment models (Rajkumar L. et al., 2004). Prolactin
(PRL) is another hormone intimately involved in the regulation of normal breast growth,
development and differentiation. The study of its role in human breast cancer has been
controversial and some evidences show a positive association between prolactin and
breast cancer risk in post-menopausal women (Kelly P. et al., 2002; Tworoger S. and
Hankinson S., 2006).

It is believed that hormone stimulation of mammary gland development can
induce sufficient changes in cell type and/or regulatory pathways to create a significantly
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resistant cellular phenotype, which persists in cells and progeny (Medina D., 2005).
Russo J. et al. (2005b) hypothesized that the mechanisms of protection was due to the
differentiation of the mammary gland, induced by the hormonal milieu of pregnancy,
which resulted in the permanent removal of a population of cancer-susceptible cells. The
search for the identification of the type, origin and localization in mammary gland
structures of those cancer-susceptible cells have led to the hypothesis of breast cancer
stem cells (Kordon E. and Smith G., 1998; Russo J. et al., 2005a; Russo J. et al., 2005b).
The same group showed experimentally that pregnancy induces the expression of a
specific genomic signature in the breast and that the same signature was also induced by
treatment with chorionic gonadotropin (Russo J. et al., 2005a). In addition, Thordarson
G. et al. (1995) emphasized that the resistance is caused by persistent changes in the
mammary gland hormonal environment since decreased levels of circulating PRL,
growth hormone (GH), estrogen receptor (ER) and epidermal growth factor receptor
(EGF-R) were detected in parous rats compared to age-matched virgin rats.

Also,

Schedin P. et al. (2004) reported that the reproductive state does persistently alter the
composition and function of the mammary stroma extracellular matrix.
Another hypothesis was introduced, the “cell fate hypothesis”, suggesting that
each time a woman undergoes a pregnancy, a portion of the undifferentiated stem-celllike cells are induced to differentiate into cells that are no longer susceptible to neoplastic
transformation. While both pregnancy and menstrual cycle contribute to the risk of
transforming the undifferentiated cells to a neoplastic state, the probability of this
occurring decreases with each pregnancy because of the progressive depletion of the pool
of undifferentiated susceptible cells. Thus, in the absence of pregnancy, the size of the
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population of undifferentiated cells, which are susceptible to transformation, remains
undiminished, and the cumulative risk of breast cancer increases steadily until menopause
(Russo J. et al., 2005a; Russo J. et al., 2005b; Medina D., 2005; Weinberg R., 2006).
This discovery that differentiation may be a powerful inhibitor of cancer initiation
has some major consequences in prevention of human breast cancer because it provides
the basis for the strategy using endogenous hormones. However, some major challenges
still remains such as the translation of the basic concepts developed in animal models to
the human population and identifying the optimal age-window at which young women
are the most sensitive to hormone-mediated prevention to cancer.
1.4.2. Subtypes
Due to its numerous causes, breast cancer is considered as a collection of
complex, heterogeneous diseases. Epidemiological evidences suggest three possible
groups of genetic, endocrine and exogenous factors responsible for breast cancer
development. Many efforts have been made to distinctly classify breast tumors. The
multiple changes in gene structure and gene function identified in breast tumors have
been used to classify breast cancers into either inherited or sporadic forms of cancer.
Inherited gene changes in germ cells have been reported in three tumor suppressor genes,
the BRCA1, BRCA2 and p53 (Li-Fraumni Syndrome) genes and are responsible for the
rare familial forms of breast cancer which represent approximately 5% of all breast
cancer cases. Sporadic forms of breast cancer, resulting from changes in somatic cells,
have been classified based on the presence of oncogene (HER2/neu) and on hormone
receptor status (estrogen receptor (ER), progesterone receptor (PR)). Numerous studies
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have shown an intriguing interrelationship between ER and HER2, and, to a lesser extent,
PR.
Comprehensive gene expression profiles, obtained using DNA microarrays and
hierarchical clustering, have revealed new ways to classify this heterogeneous disease
into subtypes of breast cancer. The different subtypes identified are the basal-like (ER
negative, PR negative and HER2 negative), the HER2 positive, luminal A (ER positive)
and luminal B (ER positive) types of breast cancer (Sorlie T. et al., 2001). It has been
shown that these subtypes are characterized by specific biological behaviors and that they
show different relationships with age, pregnancy, genetic history, postmenopausal
hormone use and body mass index after menopause. The ER negative breast cancer type
represents 30-40% of all breast cancer in U.S. women. The expression of these markers
(ER, PR and HER2) and the following categorization of breast tumors are of clinical
significance as they directly influence therapeutic choices. Unfortunately, the etiology
and growth-promoting pathways of these cancers are not fully elucidated, impeding
development of new successful therapies.
The histology of the breast of a normally cycling woman is classically composed
of 15 to 20 lobes composed of smaller structures called lobules linked by ducts. The
lobular structure is generally classified into three identifiable types of lobules:

the

undifferentiated type (Lobule 1), the intermediate or more developed type (Lobule 2) and
the differentiated type (Lobule 3) (Russo J. et al., 2005a). The histopathological pattern
is also used to classify breast cancers into different subtypes. The subtypes are: Ductal
Carcinoma In Situ (DCIS), Lobular Carcinoma In Situ (LCIS), invasive ductal carcinoma,
invasive lobular carcinoma, inflammatory breast cancer and Paget’s disease.

15

Approximately 80% of all breast cancers are of ductal origin and only 10% are of lobular
epithelium origin. DCIS, which is confined to the ducts, corresponds to the most rapidly
growing subgroup of breast cancer. The invasive ductal cancer is the most common of all
breast cancers and makes up about 70 to 80 percent of all newly diagnosed cases. The
invasive lobular carcinoma is a form of breast cancer which occurs at the ends of the
ducts or in the lobules and accounts for 5 to 10% of cases. The invasive Paget's disease is
a rare form (only 1%) which develops in the ducts beneath the nipple. The inflammatory
type is an especially aggressive type of breast cancer (1-3% of all cases) that occurs in
women of any age. It is unique because it often does not present a lump and therefore is
often not detected by mammography or ultrasound. It presents the signs and symptoms of
infection of the breast skin which is swollen due to blockade of lymph vessels by cancer.
1.4.3. Therapeutic Strategies
The choice of therapy to treat breast cancer depends on a number of factors such
as the stage and type of breast cancer, the estrogen receptor and progesterone receptor
levels in the tumor tissues, the women’s age and menopausal status and whether it is
primary or recurrent. The prognosis is also determined by these factors. Four types of
standard treatments used today are surgery, radiation therapy, chemotherapy and
hormone therapy. Most of the patients with breast cancer have surgery to remove the
cancer from the breast. Often patients who underwent surgery will receive another type
of treatment, termed adjuvant therapy, following surgery to try to prolong survival.
Radiation therapy is a cancer treatment that uses high-energy X-rays or other
types of radiation to kill cancer cells. There are two types of radiation therapy: external
radiation therapy which uses an apparatus outside the body to send radiation towards the
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cancer, and the internal one which uses a radioactive substance sealed in needles, seeds,
wires or catheters that are placed directly into or near the cancer.
Chemotherapy is a treatment that uses non-specific cytotoxic drugs to stop the
growth of cancer cells, either by killing cells or blocking cell division. It is distinguished
into a systemic chemotherapy in which the drugs taken by the mouth or injected into a
vein or muscle enter the bloodstream and reach cancer cells throughout the body, and a
regional chemotherapy in which the drugs are placed directly into the spinal column, an
organ or a body cavity, so that the drugs mainly affect cancer cells in those areas.
Among the most common chemotherapeutic drugs used in breast cancer, there are the
anti-metabolites 5-fluorouracil and methotrexane, the anti-neoplastic antibiotic
doxorubicin, the alkylating agent cyclophosphamide and the mitotic inhibitor paclitaxel.
Even though a response of breast tumors is common with the use of chemotherapeutic
drugs, a cure is not common. This is due in part to a lack of selectivity of the
chemotherapeutic drugs, attacking cancer cells as well as normal cells, causing
considerable negative side effects and limiting the tolerated doses. So far, chemotherapy
has shown a better response on estrogen receptor (ER) negative breast cancers than on
ER positive breast cancers.
Currently, the rapid expansion in the understanding of the molecular basis of
breast cancer biology provides potential targets for novel therapies and allows to improve
specificity by targeting drugs to cancer cells and key drivers of the disease. For example,
hormone therapy, which aims at removing hormones or at blocking their action in order
to stop hormone-responsive cancer cells from growing, is the first and most successful
example of targeted therapy. Hormone or endocrine therapy is the first-line therapy for
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patients with estrogen receptor (ER) positive or progesterone receptor (PR) positive
metastatic breast cancer. The use of pure ER antagonists and novel selective ER
modulators (SERMS) (tamoxifen and aromatase inhibitors) which target the estrogen
receptor, are already available or currently in clinical trials and have shown more promise
in ER positive breast cancer patients (Hussain S. et al., 2004).
Tamoxifen is the standard endocrine therapy for hormone receptor-positive breast
cancer and is one of the most widely used drugs for the treatment of early stages and
advanced breast cancer in both pre- and post-menopausal women. Tamoxifen competes
for the binding of estrogen to the receptor, resulting in inhibition of hormone action.
However, the partial estrogenic properties of tamoxifen limit its use and effectiveness
because it increases the risk of endometrial cancer and stroke.

In addition, the

development of resistance to tamoxifen in many patients is another key limitation in the
treatment of advanced breast cancer.
Fulvestrant, which is an ER antagonist that down-regulates the receptor without
agonistic effect, is the new type of endocrine treatment (Howell A. et al., 2000). It was
shown to be effective in inhibiting the growth of tumors resistant to tamoxifen and to
increase treatment efficacy in postmenopausal women with advanced breast cancer
(Morris C. and Wakeling A., 2002). Therefore, it may be integrated into the therapeutic
sequences prior to, or subsequent to other hormonal therapy. This type of treatment is
described as successive drug therapies.
The use of aromatase inhibitors (AIs) has also been investigated as an alternative
to tamoxifen treatment. AIs block the synthesis of estrogen by blocking the aromatase
enzyme that catalyses the conversion from androgen to estrogen, and have no estrogenic
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activity. AIs (Formestane, anastrozole, and letrozole) have been shown to cause a
decrease in the amount of circulating estrogen in postmenopausal women. The efficacy of
AIs in the treatment of hormone receptor-positive breast cancer has already been
demonstrated in various trials enrolling postmenopausal patients with metastatic breast
cancer who had failed tamoxifen treatment (Smith I., 2004). These observations lead to
an important change in the treatment of advanced breast cancer corresponding to a shift
from adjuvant tamoxifen to adjuvant aromatase inhibitors in post-menopausal women.
Unfortunately, in premenopausal women, the use of AIs does not translate to a reduction
in circulating estrogen because the cycling ovary is negatively regulated by estrogen.
Therefore, a decrease in circulating estrogen up-regulates hormone-dependent stimulation
of estrogen synthesis (Hussain S. et al., 2004). Although, AIs have presented a major
breakthrough for post-menopausal women with ER positive advanced breast cancer, the
endocrine options for premenopausal women remain limited.
Another type of cancer treatment is the use of monoclonal antibodies as adjuvant
therapy. Antibodies can be directed against accessible extracellular domain of molecules
on cancer cells (receptor) or normal substances (ligand) that promote cancer cells grow.
Blocking the action of these molecules by antibody binding can lead to cell growth
inhibition, cell death or prevention of cancer cell invasion and metastasis. Monoclonal
antibodies are given by infusion and may be used alone or to carry drugs, toxins or
radioactive material directly to cancer cells.
A large number of monoclonal antibodies have been developed to target the EGF
receptor for cancer therapy (Gill G. et al., 1984; Mendelson J., 2000; Ciardiello F. and
Tortora G., 2001). Generally, the antibodies are directed to the extracellular domain of
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the EGF receptor (EGFR) and bind with high affinity, thereby blocking the activation of
the receptor intracellular tyrosine kinase by EGF or transforming growth factor alpha
(TGF-α).

For instance, the IMC-225, a chimeric human-mouse monoclonal IgG1

antibody, has been the first anti-EGFR targeted therapy to enter clinical evaluation in
cancer patients in Phase II and III studies. Another example of monoclonal antibody is
trastuzumab (Herceptin), which bocks specifically the effects of the growth factor
receptor, HER2, overexpressed on the surface of breast cancer cells in some human
breast cancers (Debrin J. et al., 1986; Hudziak R. et al., 1989; Harries M. and Smith I.,
2002). The vascular endothelial growth factor (VEGF) has also emerged as a key target
for the treatment of cancer. A humanized monoclonal antibody to VEGF, bevacizumab
(Avastin), which has been used in Phase II clinical trials in patients with refractory
metastatic breast cancer and has produced encouraging results leading to a Phase III trial
(Rugo H., 2004).
The development of drug-resistant cells to endocrine therapy remains a major
limitation for the treatment of advanced metastatic breast cancer. Until recently, the only
option following the development of resistance to an endocrine agent was to change the
endocrine drug (sequential manner), and upon exhaustion of endocrine sensitivity, to
move to chemotherapy. Today, increased understanding of the molecular mechanisms
underlying the development of resistance is now emerging and new strategies to
overcome endocrine resistance are in development. In addition, secondary targets in
critical pathways are identified to allow the elaboration of new drugs that can substitute
for the primary treatment in order to deal with resistance. Evidence have shown that
there are some cross-talks between the growth factor receptors (e.g., EGFR, HER2 and
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insulin-like growth factor (IGF-1)) and ER signaling, which is responsible for endocrine
therapy resistance phenomenon (Hussain S. et al., 2004; Osborne C. et al., 2005). When
breast cancers become resistant to endocrine therapy, growth signals, which work
through growth factor receptors and downstream kinases, become dominant pathways.
This discovery provided the basis for the identification of new therapeutic targets and led
to the development of novel drugs, the tyrosine kinase (TK) inhibitors (Levitzki A., 1992;
Ciardiello F. and Tortora G., 2001). These inhibitors target the large family of kinases
and are competitors with ATP for binding to the intracellular catalytic domain of the
tyrosine kinase. To date, three Phase II clinical trials have examined the use of gefitinib,
erlotinib or iressa, potent specific inhibitors of EGFR TK, in patients with advanced
breast cancer (Hussain S. et al., 2004). Several other clinical trials are underway to
investigate the role of combined endocrine therapy plus EGFR TK inhibition for patients
with advanced breast cancer and also to examine gefitinib in combination with
trastuzumab in patients with HER2-positive hormone-refractory breast cancer (Arteaga
C. et al., 2002).
The farnesyltransferase inhibitors (FTIs) are a different type of drugs developed
to target the RAS signaling pathway by blocking RAS activation through farnesylation.
Some FTI are currently used in Phase II trial in combination with the anti-estrogen
letrozole in patients with ER positive, tamoxifen-resistant breast cancer (Johnston S. and
Kelland L., 2001).

Another approach to cancer treatment under development is the use of gene
therapy (Hussain S. et al., 2004). This therapy is reliant upon an efficient vector system
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to deliver the therapeutic effect specifically to tumor cells. One of its aspects corresponds
to genetic ablation to correct the molecular lesion contributing to carcinogenesis. For
example, antisense oligonucleotides can be used to target and sequester an oncogene at
the transcriptional level (mRNA), blocking its activity.

For breast cancer, several

potential targets have been investigated, notably the HER2 receptor protein and the
transforming growth factor (TGF) alpha (Kenney N. et al., 1993; Bertram J. et al, 1994;
Roh H. et al., 2000; Tanabe K. et al. 2002). Other studies have used dominant-negative
proteins to target HER2 and EGFR TKs at the post-transcriptional level.

These

dominant-negative proteins can heterodimerize with wild type receptor to reduce its
affinity for ligand and thereby inhibiting signaling.
Immunotherapy for metastatic breast cancer treatment is under investigation. The
aim of immunotherapy is to activate a systemic and tumor-specific immune response,
which may be either cell mediated or antibody dependent. Immune responses to HER2
have been detected in some patients with advanced breast cancer, which suggest that
HER2 is a potential target antigen for vaccine therapy. Preclinical studies have been
performed using dendritic cells transduced with the HER2 gene as a vaccine.
Subcutaneous injection of the vaccine into mice was able to induce protective immunity
against subsequent challenge with HER2-positive breast cancer cells. These findings
indicate a potential role for dentritic cell-based vaccination for advanced breast cancer
and also for treatment in the adjuvant setting (Chen Y. et al., 2001; Sakai Y. et al., 2004).
These examples emphasize the advantage to develop combination therapies,
which consist of using multiple drugs that target more than one trait of cancer cells and
which interfere with signal transduction, gene function, angiogenesis or cytokine action
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at the same time. In some cases, a greater effect was achieved by giving a combination
of two or more drugs at the same time.
1.5.

HER2/neu Oncogene

1.5.1. Receptor Tyrosine Kinase Signaling Pathways
The tyrosine kinase receptor (RTK) family is constituted of four receptors:
HER1/ErbB1 also known as EGFR, HER2/ErbB2, HER3/ErbB3 and HER4/ErbB4.
These receptors are involved in regulation of a number of different cellular processes,
including mitogenesis, tumorigenesis and differentiation. It has been recognized that
ErbB receptors cooperate in in vitro cellular transformation and that alterations in their
activation and expression have been implicated in numerous human malignancies,
including breast cancer, lung cancer and glioblastoma.
The four receptors share an overall structure consisting of a ligand-binding
extracellular domain, a single hydrophobic transmembrane α-helix and an intracellular
domain composed of juxtamembrane region, a tyrosine kinase domain and a carboxyl tail
harboring autophosphorylation sites (Lodish H. et al., 2001; Bazley L. and Gullick W.,
2005). ErbB3 is an exception because it doesn’t possess any tyrosine kinase domain.
The receptors are activated by a variety of soluble or membrane-bound protein ligands,
including epidermal growth factor (EGF), HB-EGF (heparin binding), fibroblast growth
factor (FGF), platelet-derived growth factor (PDGF), transforming growth factor-α (TGFα), nerve growth factor (NGF), beta-cellulin, amphiregulin, epiregulin, epigen, insulin
and the neuregulins (NRGs) 1–4 (Olayioye M. et al. 2000). A significant proportion of
these are initially expressed as membrane-anchored proteins that require proteolytic
cleavage either to achieve activity in solution or bind to cell surface proteoglycans from
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where they can act as a ligand-reservoir available for receptor binding. These ErbBligands are structurally divergent for the most part with the exception that they all encode
an extracellular EGF-like domain, which confers ligand-binding capacity. ErbB1 has
been shown to bind and become activated by different members of the EGF family of
ligands, including EGF, TGF-α, epiregulin, amphiregulin and beta-cellulin. ErbB3
functions as a receptor for neuregulin 1 (also known as heregulin (HRG)) and neuregulin
2. ErbB4 serves as a receptor for HRG 1, 2, 3 and 4, as well as for beta-cellulin and
epiregulin (Belsches-Jablonski A. et al., 2001). ErbB2 is the only one for which no
known ligand has been identified. Such diversity of interaction between ligands and their
receptors dictates the strength of the signaling kinetics and consequently the magnitude
and specificity of the biological activity.
These receptors can homodimerize or heterodimerize with each other forming 10
different combinations: four homodimers and six heterodimers. ErbB2 activation is most
likely occurring through homodimerization or heterodimerization with ligand-activated
ErbB1, ErbB3 or ErbB4. The ErbB2/ErbB3 heterodimer is preferred and has been shown
to be the most tumorigenic of the possible combinations. The binding of a ligand can
stimulate receptor intrinsic protein kinase activity, which subsequently stimulates a
signal-transduction cascade leading to changes in cellular physiology and/or patterns of
gene expression, triggering a specific biological response (Figure 1). Upon dimerization,
the protein kinase of each receptor monomer phosphorylates a distinct set of tyrosine
residues in the intracellular domain of its dimer partner, a process termed
autophosphorylation (Lodish H. et al., 2001). The receptor tyrosine kinase then
phosphorylates other sites in the cytosolic domain. The resulting phosphotyrosines serve
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as docking sites for other proteins that contain conserved Src homology (SH) 2 domain or
phophotyrosine-binding domain (PTB). It has been reported that the pattern and the
sequence context of phosphorylated tyrosines on the receptor will determine the type of
SH2 or PTB domain-containing proteins that are recruited to the receptor and
consequently, the downstream pathway activated (Olayioye M., 2001a). Furthermore,
the phosphorylation pattern on a given receptor is modulated by the dimerization partner.
These SH2 and PTB domain-containing proteins include the adaptor proteins such as
GRB2, GRB7, SHC, GAB1, the lipid kinases such as Src and phosphatidylinositol 3kinase (PI3K), phospholipase C and the protein phosphatases such as SHP1 and SHP2
(Lodish H. et al., 2001). They serve to transmit the signal received at the receptor to
either the cytoplasm or the nucleus.
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Figure 1. Schematic representation of the Receptor Tyrosine Kinase (RTK)
signaling pathway. In response to stimuli, the RTK forms homo- or hetero-dimers with
other family members. Dimerization results in the activation of the phosphotyrosine
kinase followed by autophosphorylation of the receptors cytosolic domain. The resulting
phosphotyrosine residues serve as docking site for various adaptor proteins (indicated as
green circles) which can initiate distinct downstream signaling pathways. The Grb2
adaptor protein coupled to Sos guanine nucleotide exchange factor can bind directly to
phosphotyrosine sites in the receptor. These protein interactions bring Sos in close
proximity to RAS, allowing for RAS activation, which subsequently activates the RAFMAPK and JNK signaling pathways. The activation of these pathways further activates
various transcription factors (indicated as white circles) that control gene expression and
contribute to cell proliferation and differentiation. The PI3K can also be recruited to and
activated by RTKs, leading to consequent activation of AKT which sends survival signals
and block pro-apoptotic effectors. Other adaptor proteins such as the phospholipase C
(PLC), the Src tyrosine kinase and the Janus kinase (Jak2) can be recruited to and
activated by RTKs to initiate various downstream cascades which activate gene
transcription.
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For example, the GRB2 adaptor protein has one SH2 and two SH3 domains
which can bind to the phosphotyrosine residues on the activated receptor and then to the
Sos cytosolic protein through the SH3 domains. SOS is activated by binding to GRB2
and functions as a guanine nucleotide-exchange factor (GEF) which can participate in the
conversion of inactive GDP-bound RAS to the active GTP-bound form.
The type and amplitude of activated downstream signaling cascades depend on
the type and the number of receptors expressed in a particular cell and on the type and
amount of each ligand that stimulates the cells.

Two major downstream signaling

pathways of the ErbB family, commonly referred to, are the RAS-RAF-MAPKK-MAPK
pathway and the PI3K-AKT pathway (Bazley L. and Gullick W., 2005). All of the HER
receptors can activate the RAS-RAF-MAPKK-MAPK pathway which plays a critical role
in the regulation of cell growth and differentiation. The MAP kinases function in a
mitogen activated protein cascade and are activated by phosphorylation by upstream
MAPK kinases (also called ERK kinases), themselves activated by RAF-like molecules.
Aberrations of these enzymes or of the signaling cascades that regulate them have been
implicated in a variety of human diseases. Activated MAP kinases can translocate to the
nucleus and phosphorylate various nuclear transcription factors such as c-FOS, c-JUN,
E2F, ETV1 and ELK-1 which then bind to DNA response elements resulting in
transcriptional activation of downstream genes that contribute to proliferation. AKT, also
referred to as PKB, plays a critical role in controlling the balance between survival and
apoptosis.

The activated phosphoinositide 3-kinase (PI3K) converts the membrane-

bound PIP2 to PIP3 whose formation can regulate the AKT kinase. The PI3K-AKT
pathway promotes cell survival by inhibiting apoptosis and by regulating cell cycle entry
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through up-regulation of cyclin D1. In addition, the stress-activated protein kinase/Junamino-terminal kinase (SAPK/JNK) can be activated by growth factors and G-protein
coupled receptor (GPCR) agonists, although it is potently and preferentially activated by
a variety of environmental stresses. Evidence suggests that the pathway can also be
activated following ErbB family activation (Karunagaran D. et al., 1996). When active
as a dimer, SAPK/JNK translocate to the nucleus where it regulates gene transcription
through its effects on c-JUN, ATF-2 and other transcription factors.

There is also

evidence for a functional interaction between c-Src family of non-receptor tyrosine
kinases and ErbB family members in breast cancer cell lines leading to the activation of
the MAPK pathway (Belsches-Jablonski A. et al., 2001; Olayioye M., 2001a). Another
target of the ErbB receptors signaling is the JAK-STAT pathway (Bazley L. and Gullick
W., 2005; Yamauchi T. et al., 2000), which plays a major role in tumorigenesis.
Activated JAKs (Janus kinases) phosphorylate tyrosine residues on STAT proteins
(Signal Transducers and Activators of Transcription) and other downstream signaling
proteins such as GRB2 adaptor protein. Phosphorylated STAT proteins dimerize and
translocate to the nucleus where it binds to DNA response elements resulting in gene
transcription.
Although active homodimers can naturally form for both ErbB1 and ErbB4,
ligand-stimulated heterodimerization is a prerequisite for active signaling for both ErbB2
and ErbB3 receptors. ErbB2 binds no known ligand with high affinity and can only be
recruited as a co-receptor with another ErbB member. No known ligand can activate
ErbB2 homodimers. Conversely, ErbB3 binds a number of ligands with high affinity, but
has a defective tyrosine kinase and thus, requires co-recruitment with another ErbB
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member to be transactivated.

Various developmental genetic studies support the

“heterodimerization model”, which implies that a receptor requires two other signaling
components in order to be activated: a co-receptor and a high affinity ligand (Harari D.
and Yarden Y., 2000). This model is important for understanding early stages of HER2related cancers since it dictates that ErbB2 must be activated in concert with at least two
other molecular components.
Overexpression of ErbB2 in cell culture leads to cell transformation (Hudziak R et
al., 1987). The mechanism underlying ErbB2 overexpression at the cell surface and its
tumorigenic action has been investigated. It has been shown that ErbB2 overexpression,
in the absence of exogenously added ligand, correspond to a relatively high basal level of
ErbB2 tyrosine kinase autophosphorylation (Lonardo et al., 1990). The overexpression
of ErbB2 at the cell surface may induce spontaneous formation of homodimers and
increases ErbB2 availability for forming heterodimers when a ligand binds for its direct
receptor. In fact, the transforming ability of ErbB2 has been shown to be significantly
increased when co-expressed with either ErbB1 or ErbB3 in the presence of a respective
ligand (Wallasch et al., 1995). This implies that ErbB2 overexpression may promote
tumorigenesis primarily in the context of a ligand-driven heterodimer.
Studies showed that ErbB2 can interact strongly with the MAPK and PI3K
pathways supporting the fact that ErbB2 can activate cell proliferation and cell survival.
ErbB2 signaling abilities appear unique and are believed to result from a decrease in the
normal inactivation processes, which typically include dissociation of ligand-receptor
complexes, dephosphorylation of the activated receptor, rapid internalization through
clathrin-coated pits and degradation of active receptors (Harari D. and Yarden Y., 2000).
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It has been documented that ErbB2 overexpression slow down the processes, with the
exception of the dephosphorylation step. The stability of ErbB2 dimers and especially
heterodimers with ErbB2 is higher than that of other receptor combinations. Thus,
overexpression of ErbB2 decreases the ligand dissociation rate causing a prolonged
intracellular signal. In addition, the internalization rate of ErbB2 receptors is reduced
which impairs efficient down-regulation of ErbB2 homodimers and heterodimers at the
plasma membrane, resulting in long-lived intracellular signal. The receptor degradation
of ErbB2-containing heterodimer is also reduced due to impaired lysosomal targeting.
The sequences contained within the carboxyl terminus of ErbB-2 confer a weak and
ineffective coupling between the receptor and the c-Cbl (ubiquitin ligase) and prevent the
association with the AP-2 plasma membrane-coated pit adaptor complex, impairing
receptor internalization. On the contrary, the receptor recycling to the cell surface is
increased. In summary, several distinct mechanisms allow prolonged retention of ErbB2
at the cell surface and thereby extend the duration of signaling by the heterodimeric
partners.
The ability of ErbB receptors to form both homodimers and heterodimers with
distinct signaling properties in response to a myriad of ErbB-specific ligands, generates a
complex signaling network with an enormous potential for signal amplification and
diversification. The mapping of intracellular pathways activated by this family of RTKs
is further complicated by the observations that it exists some crosstalks between ErbB
receptors and other classes of receptors such as integrin receptors (Yarwood S. and
Woodgett J., 2001), G-protein coupled receptors, and prolactin (PRL) and growth
hormone (GH) cytokine receptors (Yamauchi T. et al., 2000; Huang Y. et al., 2006).
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1.5.2. HER2/neu Breast Cancer
The human epidermal growth factor receptor-2 (HER2) oncogene, also called
erbB2, encodes a 185 kDa transmembrane glycoprotein with intrinsic tyrosine kinase
activity (p185). The HER2 gene was originally identified as a viral oncoprotein of cerbB2, which is involved in carcinogenic transformation. Therefore, the official name of
this gene is “v-erb-b2” which stands for avian erythroblastic leukemia viral oncogene
homolog 2.
Slamon D. and colleagues (1987) initially reported that the ErbB2 receptor was
overexpressed in 20-30% of human breast cancers.

In the vast majority of cases,

overexpression of the receptor is due to amplification of the HER2 gene in multiple
copies in the nuclei of affected cells. Amplification results in increased levels of mRNA
and, consequently, protein. It was estimated that HER2 amplification results in a 50 to
100-fold increase in the number of surface ErbB2 receptors on cancer cells compared to
the normal mammary epithelium (Wilson C. et al., 2005). HER2 gene amplification is a
relatively early event in the clinical pathogenesis of human breast cancer based on its
frequent occurrence in pre-invasive lesion, ductal carcinoma in situ (DCIS). However, its
amplification in invasive DCIS has been reported to be as high as 77%. The observation
of a positive correlation between HER2 overexpression and the DCIS subtype of breast
cancer suggests that HER2 aberrant activity plays a functional role in breast cancer tumor
initiation and progression. The overexpression of HER2 in breast cancer correlates with
a number of histological prognostic features including tumor size, high grade, high
percentage of S-phase cells, aneuploidy and lack of steroid receptors (Slamon D. et al.,
1987). Importantly, HER2 overexpression has been associated with a poor prognosis, an
aggressive tumor type and resistance to chemotherapy. Increased expression of HER2 is
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also implicated in tumor progression of other human epithelial cancers including ovarian,
gastric, lung and prostate cancers.
The “heterodimerization model” is important for understanding early stages of
HER2-related cancers since it dictates that ErbB2 must be activated in concert with at
least two other molecular components, leading to the assumption that another type of
ErbB receptor is implicated in HER2-dependent cancers.
analysis of different ErbB receptors was investigated.

Therefore, co-expression
It was found that ErbB1

overexpression or amplification was often observed in DCIS and that it correlated with
poor prognosis and inversely correlated with estrogen receptor status. However, coexpression analyses did not find any positive or negative correlation between ErbB1 and
ErbB2 overexpression.

These results implied that ErbB1 played a similar, but not

necessarily inter-dependent, role in HER2-related cancer, although their synergy in a
subset of tumors with more aggressive phenotype did indirectly implicate co-receptor
interaction (Harris A. et al., 1989; Torregrosa et al., 1997). There are conflicting reports
as to the clinical significance of ErbB3 and ErbB4 overexpression in breast cancer
(Gasparini et al., 1994; Travis A. et al., 1996; Knowlden J. et al., 1998; Vogt U. et al.,
1998); however, a positive correlation with estrogen receptor status and tumor size was
observed for both receptors and an increased survival rate for ErbB3 (Knowlden J. et al.,
1998). It remains an open question whether or not ErbB3 and/or ErbB4 play a significant
role in the co-activation of ErbB2 in breast cancers.
Aberrant signaling through these receptors is believed to play a direct role in
malignant transformation and/or progression. Overexpression of ErbB2 receptors in
tumor cell was shown to induce important phenotypic changes, including increased
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growth in vitro, decreased anti-estrogen response, increased production of angiogenic
factors, as well as increased tumorigenicity and metastatic potential in vivo (Hudziak R.et
al., 1987; Pierce J. et al., 1991). These changes parallel the observed aggressive clinical
behavior of human tumors that contain an amplified HER2 gene. Other experimental
data, supporting the role of HER2 in breast cancer initiation, comes from transgenic
experiments in which wild-type or activated HER2 expressed in mouse mammary
epithelium leads to a high frequency of mammary carcinomas (Muller W. et al., 1988;
Guy C. et al., 1992).
The HER2 gene amplification and oncogenic mutations (Val 664 to Glu) can
constitutively activate the ErbB2 homodimeric tyrosine kinase in a ligand-independent
manner (Lonardo F. et al., 1990). Elevated HER2 activity can reduce the growth factor
dependence of ErbB2 amplified cells and prolonged stimulation of the Ras-Raf-MAPK
pathway (Di Fiore P. et al., 1987; Ben-Levy R. et al., 1994). It is also increasingly clear
that the high cell-surface ErbB2 density that accompanies gene amplification alters the
normal equilibrium of ErbB dimers in favor of ErbB2 containing heterodimers, thus
altering ligand dependent signaling mechanisms. The oncogenic potency of heterodimers
such as ErbB1/ErbB2, is significantly enhanced compared to ErbB1 homodimers by
several processes that prolong receptor signaling activity.
It has been documented that HER2 overexpression can promote the growth and
malignancy of mammary epithelial cells in part by conferring resistance to the growth
inhibitory effects of TGF-β signaling, which corresponds to the dominant system
opposing the stimulatory effect of growth factors and early oncogene activation in many
tissues including the mammary gland (Brandt R. and Ebert A., 1998; Wilson C. et al.,
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2005). Resistance to the anti-proliferative effects of TGF-β appears at an early stage of
tumor progression in a number of human malignancies.
In addition, a link between HER2 amplification and cyclin D1 overexpression in
breast cancer has also been established. The cyclin D1 gene has been reported to be
amplified in up to 20% of human breast cancer, while cyclin D1 protein is overexpressed
in over 50% of human mammary carcinomas and particularly in DCIS (75%) (WeinstatSaslow D. et al., 1995; Harari D. and Yarden Y., 2000; Yu Q. et al., 2001). Aberrant
overexpression of D-type cyclins can reduce or overcome the dependency of mitogenic
stimulation for a cell and, thus, play a role in the process of oncogenic transformation. It
is believed that ErbB2 amplification results in hyper-activation of a signaling network,
which deregulates the G1/S checkpoint of the cell cycle by up-regulation of cyclin D and
of the cyclin-dependent kinase partners (CDK-4 and -6) (Harari D. and Yarden Y., 2000;
Yang C. et al., 2004). Furthermore, ErbB2-overexpressing breast tumors can evade
apoptosis and resist to chemotherapeutic cytotoxic agents such as Taxol. The CDK
inhibitor, p21Waf1, which plays a central role in ErbB2’s anti-apoptotic machinery, was
found up-regulated in a number of ErbB2-overexpressing cell lines (Yu Q. et al., 2001).
Interestingly, a negative correlation between HER2 and ER expression has been
observed in breast cancers.

Patients with ErbB2 overexpressing tumors have

demonstrated poor response to endocrine therapy, commonly used for ER-positive
patients.

This inverse relationship may reflect the existence of different molecular

programs responsible for the development of distinct breast cancer subtypes. However,
this inverse relationship is not absolute. Studies on ER-positive/HER2-positive breast
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tumors suggested that ErbB2 signaling can override the tumor-inhibitory effect of antiestrogen since the patients responded poorly to endocrine therapy.
The main therapeutic strategy for targeting HER2 positive breast cancer is the use
of trastuzumab (Herceptin), a humanized monoclonal anti-HER2 antibody that targets
cell surface ErbB2 receptors (Miles D., 2001; Harries M. and Smith I., 2002).
The first inhibitory antibody against the product of an oncogene (growth factor)
was developed in the early 1980s. In 1986, Debrin J. et al. produced a monoclonal
antibody against the mutated rat HER2 receptor and showed that it was inhibiting the
growth and the tumorigenic potential of HER2/neu-transformed breast cancer cells
implanted into nude mice.

Later on, several groups raised a number of murine

monoclonal antibodies to the extracellular domain of HER2 (Hudziak R. et al., 1989).
These antibodies were able to inhibit the growth of cells overexpressing the receptor but
had very little or no effect on cells without elevated levels of ErbB2. One of them, the
muMab 4D5 demonstrated to be a potent inhibitor of growth of human breast cancer
xenografts, and selected for further clinical development (Baselga J. and Mendelsohn J.,
1994). To reduce the potential for generating a human anti-mouse immune response, the
4D5 murine monoclonal was humanized to form a chimeric antibody, called trastuzumab,
which is 95% human and 5% murine, with retained a high affinity for the HER2 epitope
(Carter P. et al., 1992; Sandhu J., 1994). The hypervariable region of the antibody was
conserved but the kappa light chains and the IgG1 constant region were replaced by
human version. Trastuzumab showed anti-proliferative effect in in vivo breast cancer
xenografts as well as significant therapeutic effects in patients with strongly HER2positive breast cancer.
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Several putative mechanisms by which trastuzumab exerts its anti-tumor effects
have been hypothesized and correspond to: 1) down-regulation of ErbB2 receptors by
accelerating endocytic degradation; 2) reduction of homo- and heterodimers capable of
signaling, 3) induction of G1 cell cycle arrest which blocks cell division and growth and
4) induction of a host tumor response via antibody-dependent cell cytotoxicity (ADCC)
(De Santes K. et al., 1992; Petit A. et al., 1997; Harries M. and Smith I., 2002).
Trastuzumab is the only FDA-approved therapeutic for HER2 overexpressing
metastatic breast cancer. It is approved for first-line treatment in combination with the
chemotherapeutic drug paclitaxel, and as a single treatment for heavily pre-treated
patients with advanced breast cancer. Its use has been shown to be effective and is
associated with higher response rates, longer time to progression and improved survival
when compared to chemotherapy alone (Miles D., 2001). In a recently published joint
efficacy, the benefits of combining trastuzumab to standard adjuvant chemotherapeutic
agents have been calculated to correspond to a 52% reduction in events (i.e. recurrence,
second primary cancer, or death before recurrence) (Slamon D. et al., 2006).
1.6.

RAS Oncogene

1.6.1. RAS Small GTPase Family
The RAS gene codes for proteins involved in signal transduction. RAS proteins
belong to a large superfamily of small GTPases which comprise more than 150 proteins
identified to date.

This family is structurally organized into at least five families

including the RAS, RHO, RAB, RAN, and ARF families. These proteins are involved in
different cellular process such as apoptosis, cell proliferation and differentiation,
cytoskeleton reorganization and movement and membrane and vesicle trafficking. They
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are small proteins (20-25 kDa) that act as molecular switches, cycling between an
inactive guanosine diposphate (GDP)-bound state and an active guanosine triposphate
(GTP)-bound state. The exchange of GDP for GTP induces a conformational change in
the proteins that allows them to interact with downstream effectors and carry various
specific biological functions. The activation state is normally tightly regulated by the
concerted action of guanine nucleotide exchange factors (GEFs) such as SOS and
GTPases-activating proteins (GAPs) such as NF1. GEFs catalyze the release of GDP,
allowing the binding of the more abundant GTP and the activation of the proteins,
whereas GAPs catalyze their inactivation (Lodish H. et al., 2001).
The RAS family now includes at least 21 members, including the most common
H-RAS, K-RAS (A and B isoforms), N-RAS, R-RAS, TC21/R-RAS2, R-RAS3/M-RAS,
RAP1 (a and b), RAP2 (a, b and c), RIT, RIN, and RAL (A and B) (Rodriguez-Viciana P.
et al., 2004). K-RAS, H-RAS and N-RAS (21 kDa) are commonly referred as the RAS
proteins. In normal cells, they can be activated by a wide variety of extracellular stimuli
including the receptor tyrosine kinases and G-protein coupled receptors to cause transient
activation of RAS. In turn, RAS associates with and activates multiple effectors that
stimulate cytoplasmic signaling pathways that regulate cell proliferation and
differentiation, survival and apoptosis.
RAS proteins are synthesized as a precursor with a C-terminal CAAX motif (C=
cysteine, A= aliphatic amino acids, X=variable) that undergoes a series of posttranslational modifications. The first and most crucial modification is catalyzed by the
farnesyltransferase (FTase enzyme) and corresponds to the covalent attachment of a
farnesyl isoprenoid lipid (hydrophobic chain) to the cysteine residue at the carboxyl
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termini of RAS proteins. This modification facilitates RAS attachment to the inner face
of the plasma membrane which is required for its activity. In some cases the 15-carbon
farnesyl chain is substituted by a 20-carbon geranylgeranyl chain. These post-translation
modifications differ slightly between the different RAS isoforms (H-, N- and K-isoforms)
due to sequence differences in the carboxyl terminus (Choy E. et al. 1999).
1.6.2. RAS Effector-mediated Signaling Pathways
RAS proteins can interact with a wide array of effectors. These effectors have
been classified into two groups depending on their ability to regulate the anti-apoptotic or
apoptotic actions of oncogenic RAS (Figure 2). The best characterized effectors are the
RAF kinases, the p110 catalytic subunit of class I PI3Ks and a family of RAL guanine
nucleotide exchange factors (RalGEFs). Other effectors have been described and include
RIN1, Tiam1, phospholipase C (PLC), AF6, NORE1 and RASSF1 (Katz E. and
McCormick F., 1997; Lodish H. et al., 2001; Rodriguez-Viciana P. et al., 2004). RAS
effectors interact with RAS protein through a small region of approximately 100 amino
acids called the RAS binding domain (RBD) to induce diverse cellular signals. Among
the effectors, three distinct domains have been found which share structural topology of
an ubiquitin superfold but little primary sequence identity: 1) the RAF-type of RBD, 2)
the PI3K-type of RBD, and 3) the RA (RalGDS/AF6, Ras associating) domain
(Rodriguez-Viciana P. et al., 2004; Herrman C, 2003). The RA domain is found in a
wide variety of proteins including RalGEFs, Rin1, AF6, PLC, NORE1 and RASSF1.
There is an incredibly large number of proteins with RBD domain and thus potential
existence of other Ras effector not identified yet. In order to recognize a molecule as
RAS effectors, a set of three conditions must be demonstrated: 1) interaction between
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endogenous RAS with the full-length effector; 2) modulation of the effector’s function by
interaction with Ras; and 3) dependence of RAS biological activity on effector’s function
(Repasky G. et al., 2004).
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Figure 2. Schematic representation of the RAS activation of multiple effectormediated signaling pathways. Activated GTP-bound RAS can bind to and regulate
diverse downstream effectors to mediate pro- or anti-apoptotic functions. RAS can bind
to the RAF kinase and activate the RAF-MAPK cascade which ultimately leads to the
activation of various transcription factors that promote gene expression. MAPK can also
phosphorylate RSK leading to cell cycle arrest and differentiation. RAS interacts with
and activates the PI3K which converts the membrane-bound PIP2 to PIP3, whose
formation can regulate AKT kinase. AKT has an anti-apoptotic action which is achieved
by phophorylation of multiple targets. AKT blocks the pro-apoptotic effects of Bad,
inactivates caspase-9 (casp9) and the forkhead transcription factor (FKH). AKT also
activates IKK, which leads to NF-κB release and the expression of anti-apoptotic genes.
Activated RAS can bind to Tiam effector and activate the anti-apoptotic effect of Rac that
activates NF-κB. RalGEFs represent another group of RAS downstream effectors.
RalGEFs are GDP-GTP-exchange factors and activators of Ral GTPases involved in
proliferation/survival and in cell cycle division through Cdc42 activation. In contrast to
the anti-apoptotic effectors, NORE1 and RASSF1 effectors up-regulate apoptosis.
Activated RAS can bind to NORE1 and RASSF1. NORE1 and RASSF1 form homo- and
hetero-dimers, which form a complex with and regulate the pro-apoptotic
serine/threonine kinase MST1.
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To study these biochemical properties, different experimental approaches have
used Ras effector domain mutants, dominant negative mutants (S17N), pharmacological
inhibitors and ectopic overexpression of activated mutant (G12V) form of RAS.
It is increasingly recognized that RAS proteins can mediate positive and negative
functions in modulating cell growth and death (Cox A. and Der C., 2003). These
opposing biological actions are achieved by interaction with and activation of distinct
specific effectors. In normal conditions, RAS signaling results in a constant balance
between the anti-apoptotic and the apoptotic effects. Whether oncogenic RAS promotes
proliferation or cell death is also influenced by cell type, context, signals nature, signaling
intensity, and tissue origin. Therefore, to understand the biological functions of the
different RAS proteins and their individual contributions to human diseases, such as
cancer, it is crucial to understand which effector pathway they can regulate.
Voice J. et al. (1999) demonstrated that the four Ras homologs (H-RASA, HRASB, N-RAS and K-RAS) significantly differ in their abilities to activate RAF-1
effector, induce focus formation, anchorage-independent growth or cell migration in a
distinct hierarchy manner. Results showed that K-RASB was the most effective for
RAF-1 activation and cell migration, whereas H-RAS was most effective for focus
formation but weak for RAF-1 activation and enable to induce anchorage-independent
growth.
The differences in post-translational modification of the RAS isoforms seem to be
responsible for distinct compartmentalization within the plasma membrane subdomains
and may explain the different functions of the RAS isoforms in vivo (Jiang X. and Sorkin
A., 2002). The complexity of RAS signaling is also reflected by the overlap in the
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abilities of RAS proteins to activate different effectors pathways (Gille H. and Downward
J., 1999). It is clear that RAS proteins interact with effectors in a very specific manner
and even with some striking isoform-specific differences (Yan J. et al., 1998). This adds
to the already complex system since different isoforms tend to show different pattern of
expression. These selective interactions may have important biological consequences,
depending on the specific properties and functions of different isoforms, the pattern of
expression of the various GTPases and the effector isoforms in different cell types.
The use of fragments of effectors, typically the RBD domain only, to study in
vitro interactions between RAS proteins and RAS effectors have revealed some
conflicting results between laboratories. It has been shown that these minimal binding
regions may not accurately reflect interaction with the full-length proteins (Linneman T.
et al., 1999; Rodriges-Viciana P. et al., 2004). It is suggested that these differences in
results highlight the possibility that another domain may interact with RAS proteins,
aside from the higher-affinity RBD, as for instance, the lower-affinity cysteine-rich
domain (CRD) present in RAF-1 effector which may play a role in modulating specificity
(Hu D. et al., 1995; Chong H. et al., 2003a). Plus, most assays do not account for
possible contributions from the post-translational modifications or subcellular
localization of the RAS proteins (Pacold E. et al., 2000).
The three RAF serine/threonine kinases, A-RAF, B-RAF and c-RAF (RAF-1) are
the main effectors recruited by GTP-bound H-RAS, N-RAS and K-RAS which activate
the MAP kinase pathway, resulting in either apoptosis or survival. Activation of RAF-1
is the best understood and involves phosphorylation at multiple activating sites (Chong
H. and Guan L., 2003b). Other RAS proteins such as TC21, R-RAS3 and Rit have been
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found to activate the RAF-1 effector as well (Rodriguez-Viciana P. et al., 2004).
However, not all RAS proteins can activate RAF-1 and more importantly, the magnitude
of their stimulation varies greatly (Woods D. et al., 1997; Sewing A. et al., 1997;
Pritchard C. et al., 1997). The lipid kinase PI3K is another RAS effector in many cell
types and appears to provide an universal survival signal downstream of RAS by
activating the AKT kinase which inhibits apoptosis by inhibiting the actions of Bad and
Caspase 9. RAS protein can also activate RAC protein, independently of PI3K, through
direct interaction with Tiam1, leading to the activation of the transcription factor NF-κB
which produces potent pro-survival signals (Lambert M. et al., 2002). RalGEF is another
group of well-studied RAS effector, with guanine-nucleotide exchange factor activity for
RAL proteins (Linneman T. et al. 2002). H-RAS, N-RAS and K-RAS, TC21, R-RAS3
and Rit proteins can interact with the three members of the RalGEF family: RalGDS,
RGL and RGL2/Rlf (Repasky G. et al., 2004). However, these studies indicate that the
ability to associate with the protein in vivo does not correlate with the ability to stimulate
the enzymatic activity of the downstream effector (Rodriguez-Viciana P. et al., 2004).
Eckert L. et al. (2004) highlighted that elevated activity of RAS protein was not always
associated with activation of RAF-MAPK and PI3K-AKT pathways, the two key RAS
effector pathways in human breast cancer cell lines. Thus, this underlines the significant
cell context variations and suggests that other effector pathways may be important for
RAS-mediated oncogenesis.
The pathways mediating RAS regulation of apoptosis remain poorly understood.
Recent studies have indicated that RAS effectors include protein products not only of
oncogenes, but also of putative tumor suppressor genes. Thus, such effectors might
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account for the growth inhibitory and apoptotic activity of RAS (Cox A. and Der C.,
2003).

This suggests that RAS proteins may directly regulate proteins with tumor

suppressor properties. Indeed, a new family of genes, the Ras Association domain
(RalGDS/AF-6) Family (RASSF 1-6) has been discovered and four of its members,
RASSF1, RASSF2, RASSF4 (also known as AD037) and NORE1 (also called RASSF5)
have been identified as RAS effectors and tumor suppressors (Hesson L. et al., 2003; Vos
M. et al., 2003; Eckfeld L. et al. 2004; Agathanggelou A. et al., 2005). They are all
located on different chromosome and RASSF1 has been the most studied one of all the
members. The proteins are all characterized by a RA (RalGDS/AF-6, RA associating)
domain at the C-terminus followed by a SARAH (Sav/RASSF/Hpo) domain. The RA
domain mediates interactions with RAS proteins and other small RAS GTPases, whereas
the SARAH domain is a novel interaction motif that can mediate heterotypic and
homotypic interactions.
The role of the RASSF genes as tumor suppressors is supported by the loss of
expression in human tumor cell lines and tumors due to hypermethylation of CpG islands
in the promoter region (Agathanggelou A. et al., 2005). The identification of the RASSF
proteins as RAS effectors is demonstrated by their interaction with specific RAS proteins
in a GTP-dependent manner (Vos M. et al., 2000; Vos M. et al., 2003; Eckfeld K. et al,
2004). The evidence that RASSF proteins facilitate RAS-mediated growth inhibition
and/or apoptosis are diverse and restricted to ectopic overexpression analyses. It was
shown that ectopic overexpression of NORE1 or RASSF1 caused growth inhibition and
apoptosis, effects which where enhanced by co-expression of activated H-RAS and
antagonized by co-expression of dominant inhibitory H-RAS (Vos D. et al., 2000). A

44

number of studies have started to investigate the molecular mechanism leading to their
growth-inhibition effects (Agathanggelou A. et al., 2003).

Evidence show that

RASSF1A can interact with different target molecules including microtubules to increase
their stability, MST1 pro-apoptotic kinase to induce apoptosis and with cell cycle
regulators to arrest cell cycle progression (Ortiz-Vega S. et al., 2002; Shivakumar L. et
al., 2002; Vos D. et al., 2004; Agathanggelou A. et al., 2005). Finally, the physiological
significance of the RASSF proteins as RAS effectors is unclear since it was shown that
NORE1- and RASSF1A-mediated growth inhibition of human tumor cells did not require
interaction with RAS proteins. Thus, whether the RASSF proteins are physiological
important effectors that influence the role of mutated RAS in cancer development is still
under debate (Repasky G. et al., 2004).
1.6.3. RAS in Cancer
RAS mutations are observed in approximately 40% of all human cancers and
often translate to poor prognosis and treatment outcome. The highest incidence of RAS
mutations are found in adenocarcinomas of the pancreas (90%), the colon (50%) and the
lung (30%) as well as in thyroid tumors (50%) and in myeloid leukemia (30%) (Bos L.,
1989). The high frequency of RAS mutations supports a critical role for aberrant RAS
activation (GTP-bound form) in the progression and maintenance of these cancers.
Constitutively activated RAS can induce multiple facets of malignant transformation by
promoting cell cycle progression, uncontrolled cellular proliferation and by deregulating
processes that control apoptosis. The most common oncogenic RAS mutation found in
tumors corresponds to a change of glycine 12 to aspartate (G12D), which prevents RAS
inactivation by the GAP proteins, possibly by increasing the overall rigidity of the protein
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(Lodish H et al., 2001). Different alleles of RAS gene are mutated in cancers with KRAS and N-RAS in most cancers and H-RAS in head/neck cancers (King R., 2000). KRAS mutations have been found in colorectal cancer, non-small-cell lung cancers
(NSCLC), melanomas and ovarian cancers (McLellan E. et al., 1993; Aviel-Ronen S. et
al., 2006; Reifenberger J. et al., 2004; Cuatrecasas M. et al., 1997). Other RAS proteins
such as TC21, R-RAS3 and RIT have been found to be activated by mutation in human
cancers and thereby to induce transformation of a variety of cells (Rodriguez-Viciana P.
et al., 2004).
Interestingly, RAS and RAF mutations have been reported in the same types of
human cancers, suggesting that mutationally activated RAS and RAF are functionally
equivalent. For example, approximately 70% of melanomas harbor mutated alleles of BRAF and 25% harbor N-RAS mutations but in essentially non-overlapping occurrence.
Similar observations of non-overlapping mutations of these two genes have been
described for colorectal cancers, papillary thyroid carcinomas, ovarian carcinomas and
other cancers (Repasky G. et al., 2004; Reifenberger J. et al., 2004). This suggests that
B-RAF and RAS mutations share equivalent roles in oncogenesis and that oncogenic RAS
involves RAF activation.
Some cancers have aberrant activation of RAS signaling even though they don’t
have mutated forms of RAS.

Aberrant activation have been found to result from

alterations in other molecules such as in NF1, whose defect leads to a loss of its GTPaseactivating potential, in childhood chronic leukemia (King R., 2000). In breast cancers,
RAS mutations are rarely found (less than 5%); however, there is considerable evidence
that aberrant RAS activation and signaling may promote breast cancer development
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(Clark G. and Der C., 1995; Von Lintig F. et al., 2000). In fact, RAS can be activated by
persistent upstream signaling from EGFR, ErbB2 and ER receptors which are often
overexpressed in breast cancer and thereby promote tumor formation (Von Lintig F. et
al., 2000).
The identification of mutated RAS genes in human tumors prompted great interest
in the development of anti-RAS targeted strategies for cancer treatment. Among the antiRAS strategies under evaluation in the clinic, a number of pharmacologic inhibitors
where tested to prevent: 1) RAS association with the plasma membrane (FTases
inhibitors (FTI)), 2) downstream signaling pathways (RAF and MEK protein kinase
inhibitors), 3) autocrine growth factor signaling (EGFR inhibitors), or 4) gene expression
of H-RAS and RAF-1 (Caponigro F., 2002; Dancey E., 2002; Cox A. and Der C., 2002;
Wickstrom E., 2001). Although a number of these inhibitors have demonstrated potent
anti-tumor activities in preclinical models, Phase I-III clinical trials have revealed
unexpected complexities in RAS function and targeted therapies (Cox A. and Der C.,
2002).
1.7.

The Use of Transgenic Mouse Technology in Cancer Research

1.7.1. Transgenic Mouse Technology
Transgenic technologies have a broad range of applications, from studying the
basic mechanism of gene regulation to the generation of the models for human diseases,
and are used to create systems utilized in pathophysiological and therapeutic studies. The
study of a transgene function in the context of an intact organism provides a much more
complete and physiological relevant picture than any other methods could achieve. The
use of transgenic techniques has evolved from the development and convergence of the
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gene-transfer methods in murine cell culture systems, the methods to manipulate early
mouse embryo and the embryonic stem cell technology (Hofker M. and Van Deursen J.,
2002). The molecular genetic approaches towards the study of gene function in mice
have traditionally relied on either overexpression or gene ablation using transgenic mouse
or knockout mouse strategies respectively.
The first transgenic lines of mice containing foreign genes were produced in 1976
by infecting pre-implantation stages of embryos with a retro-virus (Jaenisch R., 1976).
The retro-virus method showed numerous limitations and led to the development of a
new dominating technique consisting in microinjection of DNA into the pronucleus of a
developing zygote (Hofker M. and Van Deursen J., 2002). Gordon J. and colleagues
were the first to report in 1980 the establishment of a transgenic mice line with stable
integration of foreign DNA in the mouse genome by pronuclear microinjection (Gordon
J. et al., 1980). The stable integration led to the expression of the foreign genes and was
transmitted to the offspring. Therefore, by definition, a transgenic animal is an animal
that has a foreign gene (transgene) stably incorporated into its genome through human
intervention (Gordon J. et al., 1980; Auerbach A., 2004). The microinjected DNA
integrates at random insertion sites and usually at more than one site in the genome.
Usually integration occurs in only one chromosome resulting in the development of
hemizygous founders for the transgene (Gordon J. and Ruddle F., 1981).
Although the technique of DNA pronuclear microinjection is widely used, a
number of disadvantages have been reported (Auerbach A., 2004). For instance, it has a
low efficiency of transgenic mouse production, with a low number of transgenic mice
founders expressing the transgene appropriately, i.e. with suitable levels and correct
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spatial/temporal expression. Many studies have also demonstrated dramatic differences
in the expression levels of the same transgene in a given tissue between lines or even
between individual founder siblings due to different integration loci (Auerbach A., 2004).
Plus, the location of transgene insertion can play a great role in influencing the transgene
expression and phenotype between the lines (Palmiter R. et al., 1983). Therefore, it is
recommended to generate several independent founders from the same construct and to
compare the observed phenotypes of independent transgenic lines.
Many of the transgenic models have used different regulatory regions called
promoters to control the transgene expression and define the tissue and the cell type
affected, plus the temporal onset of the phenotype.

For example, there are the

“ubiquitous” cytomegalovirus (CMV) (Furth P. et al., 1991), immediate early and
metallothionein (MT) promoters (Hennighausen L., 2000), the lineage-specific Eµimmunoglobulin heavy chain gene enhancer/promoter for the B-cell lineage (Adams J. et
al., 1985), the tissue-specific promoters such as the mouse mammary tumor virus long
terminal repeat (MMTV LTR) (Stewart T. et al., 1984), the whey acid protein (WAP)
gene and the bovine lactoglobulin promoter for the mammary gland (Hennighausen L.,
2000; Largaespada D., 2003).
The knockout technique, which consists in disrupting a target gene in the
germline by the insertion of a selectable marker, is a useful technique in defining the
effects of repressor genes (Capecchi M., 1989; Kuhn R. and Schwenk F., 2003). Since
the conventional knockout mice are usually homozygous for a null allele in the germline,
they proved very useful to study inherited disease, leading to embryonic or early postnatal lethality (Kuhn R. and Schwenk F., 2003). The two first knockout models were the
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Rb1 and the p53 tumor suppressor knockouts (Jacks T. et al., 1992; Jacks T. et al., 1994).
The latter demonstrated that not all tumor suppressor knockouts are lethal in the
homozygous state since homozygous p53-/- mice are all fertile and viable. However, it
appeared that the germline knockout mice did not constitute the best technical approach
for analyzing other aspects of the repressor genes function in the adult mice. Therefore, a
refined knockout strategy, termed conditional gene targeting, was developed that permits
the inactivation of the target gene in somatic cells, only at a specific developmental stage
and/or in a specific organ.
The latest technologies involve the ability to turn transgenes (e.g. oncogenes) on
and off in vivo or to inactivate genes (e.g. tumor suppressor) in specific tissues (Kuhn R.
and Schwenk F., 2003; Largaespada D., 2003). This was achieved by the development of
conditional and inducible systems which allowed a spatial (tissue specific) and temporal
control of the onset of transgene expression.
Common examples of these novel systems involve inducible promoters such as
the tetracycline transactivator-responsive promoters and conditional system utilizing sitespecific DNA recombinases such as the Cre-recombinase or Flp recombinase (Kilby N. et
al., 1993; Utomo A. et al., 1999; Auerbach A, 2003). For example, in the case of
tetracycline-regulated transgene, treatment with doxycycline, an inhibitor of Tet
transactivator, can block the expression of a specific oncogenic transgene (Gossen M. and
Bujard H., 1992).

This system is reversible and allows to determine if continued

oncogene expression is required for the maintenance of the transformed phenotype in
vivo.

The Cre-recombinase tool can also be used to keep a transgene from being

expressed (Kilby N. et al., 1993; Largaespada D., 2003). For example, if the transgene is
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separated from the promoter with a recombination-activated gene expression (RAGE)
cassette which contains stop codons in all three reading frames and flanked by LoxP
sites, the in vivo induction of Cre-recombinase will cause the excision of the RAGE
cassette at the LoxP sites and thereby, the expression of the transgene. In the opposite,
the Cre-recombinase system can also be used to inactivate the expression of tumor
suppressor genes by excision of a critical exon in the gene (Largaespada D., 2003). In
addition, this can be achieved in a tissue-specific manner by controlling Cre-recombinase
expression by tissue-specific promoter and in a controlled temporal manner by placing
the Cre-recombinase under an inducible promoter (Utomo A. et al., 1999). Controlled
temporal systems are useful when the inactivation of the two alleles of a tumor
suppressor gene is lethal at the embryonic stage (Kuhn R. and Schwenk F., 2003).
1.7.2. Transgenic Mouse in Cancer Research
Transgenic mouse models have offered tremendous opportunities for studies of
the genetic basis of cancer. They proved useful in the characterization of the biological
function of oncogene and tumor suppressor in specific tissues. Transgenic animals have
been used for overexpression studies of genes encoding transcription factors (c-Myc), cell
surface receptors (HER2/neu) and structural proteins, as well as for loss-of function
experiments by utilizing constructs encoding antisense RNA or dominant negative genes
and also by DNA interference (Largaespada D., 2003). There has been a growing trend
for using such models in cancer research over the last decade and more models are
generated. Transgenic mice models carrying the c-Myc oncogene were among the first
one to be published (Stewart T. et al., 1984). These models proved, for the first time, that
putative cancer genes could actually initiate bona fide cancer in a living organism
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(Largaespada D., 2003). However, one single model does not cover alone the full
spectrum of cancer, but individual models address distinct aspects.
Considering that cancer development is a complex multi-step process involving
more than one genetic alteration, researchers have developed mouse models that carry
more than one transgene in order to study the cooperativity between genetic alterations in
tumorigenesis. Leder and colleagues were the first one to develop bi-transgenic mouse
models carrying the c-Myc and Ras oncogenes and to demonstrate a synergy between the
two oncogenes (Sinn E. et al., 1987). These models confirmed that tumor progression is
a multistep process involving different pathways and, most importantly, helped to
identify parallel and interconnected pathways in tumor progression.
The mouse models have demonstrated many advantages over human genetic
studies which include the controlled crosses, the ability to control environmental
variables, the use of recombinant inbred and the ability to generate large numbers of
genetically identical animals.

However, some challenges come from the variability

observed from different mouse strains which can translate into different tumor latency
and even tumor type for one transgenic oncoprotein (Threadgill W. et al., 1995). Plus,
the biology of tumors of genetically engineered mice has indicated some similarities but
also some differences compared to human tumors (Hennighausen L., 2000).
Genetically engineered mouse models of mammary cancer have been precious in
elucidating molecular pathways and signaling events associated with the initiation,
promotion and progression of breast cancer. The different mouse models helped to
identify some of the agents that can induce mammary tumors in transgenic mice (growth
factors, growth factor receptors, lactogenic hormones and cell cycle regulators) and deep
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insight into their function has been deduced from the different mouse models. A number
of mouse models for studying genetic alterations, pathway activations and
pharmacological agents in breast cancer have been developed. For example, the mouse
models of neu overexpression, targeted to the mammary gland under the direction of the
murine mammary tumor virus (MMTV) promoter, have been used to test the tumorigenic
potential of the neu oncogene in the mammary epithelium (Guy C. et al., 1992).
However, it is important to note that mouse models of breast cancer have some
potentially important limitations relative to human cancer.

For instance, there are

endocrinological, hormonal and life style differences represented in the two biological
systems (Hennighausen L., 2000). In addition, the histopathology descriptions of mouse
mammary tumors do not mirror the most frequent forms of human breast tumors, e.g.
invasive ductal carcinomas (Hennighausen L., 2000). Therefore, the extrapolation of the
genetics of the mouse mammary tumorigenesis to human breast cancer must be done with
caution.
1.8.

The Use of Gene Expression Profiling in Cancer Research
Cancer is a highly variable disease with multiple heterogeneous genetic and

epigenetic changes. Functional studies are essential to understanding the complexity and
polymorphisms of cancer. The development of DNA microarray technology a decade
ago has led to the establishment of functional genomics, one of the most active and
successful scientific disciplines today (De Risi J. et al., 1996). Microarray technology is
a new powerful method that provides researchers with the opportunity to analyze the
expression patterns and the interactions of tens of thousands of genes in a short time and
in one experiment that is impossible using conventional analysis.
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Cancer causes the deregulation of normal cellular processes such as growth,
proliferation, migration, differentiation and apoptosis.

These different processes

correspond to gene expression changes that cause and/or result from this deregulation.
The changes in the expression of the large number of genes involved in the particular
processes can be detected and quantified by cDNA microarray technologies in concert.
This technique is used to identify particular expression patterns leading to genomic
signatures of many systems.

The correlation of the genomic signatures to specific

features of phenotypic variation can provide the basis for an improved classification of
cancers or of a particular type of cancer into subtypes. For example, Sorlie T. et al.
(2001) reported that variations in gene expression patterns in 40 grossly dissected human
breast carcinomas analyzed by cDNA microarrays and hierarchical clustering provided a
distinctive ”molecular signature” of each tumor and that the tumors could be classified
into subtypes based solely on differences in these patterns. Furthermore, the tumor
characteristics could be correlated to clinical outcome. In a similar manner, Dressman M.
et al. (2003) were able to differentiate breast tumor types by gene expression profiling of
breast biopsies in patients and demonstrated that this technology is valuable for adequate
characterization and further prediction of prognostic and treatment choice.
The identification of genes regulated by a particular oncogene or tumor
suppressor gene can reveal several novel targets for potential therapeutic interventions.
A number of studies have used cDNA microarray technology to identify the genes that
are associated with HER2 overexpression or amplification in breast cancer cells and
tumors (Mackay A. et al., 2003; Kauraniemi P. et al., 2002). Alaoui-Jamali M. and
colleagues (2003) assessed the gene transcriptional changes upon ErbB receptors and
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looked at markers involving angiogenesis, signaling and cell-cell structure. They showed
that the overall number of cancer related genes affected by ErbB receptors was higher in
cells and xenograft tumors expressing paired combination of ErbB receptors, compared to
single receptor. This correlated with the finding that heterodimers are more mitogenic.
They were able to identify a unique gene expression profile for each specific heterodimer
combination and reported that the affected genes corresponded to genes known to play a
key role in signaling, angiogenesis, and cell-cell interaction. In addition, their results
highlighted the existence of a broad diversity of ErbB-regulated cancer- associated genes.
Other researchers have used genetic profiling to define a metastasis signature,
specific to bone marrow, by identifying distinct profiles between primary breast tumors
with bone marrow metastasis and primary breast tumor without metastasis. They found
that the bone marrow metastasis positive signature was mainly characterized by
transcriptional repression, implying the role of protein as metastasis suppressors (Woelfle
U. et al., 2003). Some scientifics studied the dysfunction of transcription factors, key
regulators of cell growth and differentiation, following different treatments (estrogen vs.
tamoxifen) in order to obtain a comprehensive view of the differences in response of
cancer cell lines to these two treatment agents (Jiang X. et al., 2006). This emphasized
the use of this technique as a tool for the prediction of response to treatment and for the
identification of novel therapeutic targets.
In conclusion, microarray technology is a promising tool to discover and study the
underlying molecular mechanisms of tumorigenesis and in addition this technique has
allowed the identification of an increasing number of molecular markers with prognostic
and diagnostic potential in a broad range of human cancers. Thus, there are great
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expectations from the use of this technology in clinical oncology. However, routine
application of microarrays in clinical practice requires significant improvements to
standardize the array manufacturing techniques, assay protocols and analytical methods
used for the interpretation of the data. This new technology still faces major challenges,
for example, the design of experimental controls that will permit comparison of
quantitative expression profiles obtained from diverse biological contexts (Lee P. et al.,
2001).
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2.

HYPOTHESIS AND OBJECTIVES

To study HER2/neu-related breast cancer, we chose the MMTV/neu transgenic
mouse line from The Jackson Laboratories (N#202) as an animal model. It has been well
documented that the overexpression of the neu oncogene leads to the development of
mammary gland adenoma in approximately 50% of virgin female MMTV/neu transgenic
mice at the age of 7 months (t50=205 days) and nearly 80% at the age of 11 months or
older. We turned our attention towards the fact that a small proportion of the virgin
female MMTV/neu transgenic mice did not develop mammary tumors despite the
presence of high levels of the neu oncogene.
The hypothesis of this study is that there may be one or more tumor suppressor
genes that are somehow activated or overexpressed in the mammary gland of these
tumor-resistant MMTV/neu transgenic mice.
The objectives of this study are first, to use comparative microarray technology to
identify the alterations in gene expression in the mammary gland of tumor-resistant
MMTV/neu female transgenic mice and possibly identify the candidate genes which may
be responsible for the resistance to HER2/neu-initiated mammary tumor development,
and secondly, to select one candidate gene for further characterization of its role in
HER2/neu-initiated breast cancer through in vitro and in vivo studies.
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3.

3.1.

MATERIAL AND METHODS

Animal Model
The virgin female MMTV/neu transgenic mice from The Jackson Laboratories

(N#202) were chosen as an animal model to study HER2/neu-related breast cancer. In
this study, the virgin female MMTV/neu transgenic mice were divided into 2 groups: the
tumor-susceptible MMTV/neu transgenic mice (S) that develop mammary tumors and the
tumor-resistant MMTV/neu transgenic mice (R) that do not develop tumors (Figure 3A).
Concerning the tumor-susceptible MMTV/neu transgenic mice, a further distinction was
made between the tumor tissue and the adjacent normal mammary gland. The latter is
defined as tumor-resistant mammary gland (R-MG). A third group of mice, the FVB
non-transgenic mice was used as control (C).
3.2.

RNA Isolation

3.2.1. Total RNA Isolation from Tissue
Approximately 100-150 mg of tissue or 50-70 mg of tumor tissue was
homogenized using a Polytron PT1200 motorized homogenizer (Polytron; Bad Wildbad,
Germany) in 2 ml of cold TRIzol (Invitrogen, Carlsbad, CA). Four hundred µl of
chloroform (Fisher Scientific, Pittsburgh, PA) was used to extract the RNA from the
homogenate. Samples were centrifuged at 12,000 times gravity (g) for 15 min at 4˚C.
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The aqueous upper phase (~600 µl) was collected and RNA was precipitated with 900 µl
of isopropyl alcohol (Sigma, St. Louis, MO). Samples were centrifuged again at 12,000
g for 15 min at 4˚C. RNA precipitates were washed twice with 1 ml of cold 75% ethanol
and allowed to dry thoroughly. The RNA precipitates were dissolved in 100 µl of DEPC
water (ICN Biomedicals, Irvine, CA) and stored at -80˚C. RNA was quantified by UV
spectrophotometry.
3.2.2. Total RNA Isolation from Cells
Approximately 375 µl of cold TRIzol was added per well (35 mm) to lyse cells.
Cell lysates were then collected and RNA was extracted with 100 µl of chloroform.
Samples were centrifuged at 12,000 g for 15 min at 4˚C. The aqueous upper phase (~200
µl) was collected and RNA was precipitated with 250 µl of isopropyl alcohol (Sigma).
Samples were then handled in a similar manner than for the tissue RNA as described
above.
3.3.

Microarray Analysis
Microarray technology was used to compare the gene expression profiles of the

mammary glands (R-MG, R and C) of the three groups of mice specified in 3.1. above.
The experimental design is schematically represented in Figure 3B.
3.3.1. Sample Preparation
The mammary gland tissues were dissected from three mice (n=3) of 11 months
old for each group of mice (R-MG, R and C). Total RNA was extracted from each
mammary gland and equal amounts of the three total RNA samples were pooled into one
sample per group. Pooling of samples was performed to help control for variations from
one mouse to the other and for variations in the stages of mammary gland differentiation
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depending on the period of the estrous cycle. These RNA samples were further purified
with Qiagen RNeasy cleanup procedure following manufacturer’s instructions (Qiagen,
Valencia, CA). The purity and quantity of each sample was assessed on an Agilent
Technologies Bioanalyzer and the RNA 6000 Nano Lab Chip, following manufacturer’s
instructions (Agilent Technologies, Santa Clara, CA).

Sample concentration was

adjusted to approximately 1 µg per µl with DEPC water.
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A.

MMTV/neu transgenic mice

Non-transgenic mice
C

Tumor-Susceptible Mice
S
Resistant-MG
R-MG

B.

Tumor-Resistant Mice
R

Tumor
T
1. Isolation of
Mammary Glands
2. Total RNA Extraction
3. Microarray Analysis
(GeneChip MOE430A, Affymetrix)
4. Comparison of Gene
Expression Profiles

Figure 3. Nomenclature of the different groups of mice used in the study and flow
chart of the experimental design. A) Three groups of virgin female mice were defined
as follows: 1) Tumor-susceptible MMTV/neu transgenic mice that develop mammary
tumors (S), 2) Tumor-resistant MMTV/neu transgenic mice that do not develop tumors
(R) and 3) non-transgenic FVB mice used as control (C). Mammary gland isolated from
the S group is defined as resistant mammary gland (R-MG). B) The experimental design
consisted in the following steps: 1) dissecting the mammary glands from mice (R-MG, R
and C) (n=3/group), 2) extracting the total RNA, 3) microarray analysis (Affymetrix
Resource Group) and 4) comparison of the gene expression profiles.
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3.3.2. Affymetrix Microarray
Samples were sent to the Keck Affymetrix Resource Group at Yale University
(http:// info.med.yale.edu/wmkeck/affymetrix) which is a full service cost recovery unit
that carries out sample processing (cDNA and cRNA preparation), array hybridization
and array data analysis. The GeneChip Mouse Expression MOE430A (Affymetrix) was
employed for analysis.

It contains approximately 22,000 probe sets representing

transcripts and variants from over 14,000 well-characterized mouse genes.

The

Affymetrix Microarray 5.0 (MAS) software, which provides instrument control, data
acquisition and data analysis for the entire GeneChip platform, was used to inspect
hybridization artifacts and to detect changes in gene expression between samples by
comparison analysis of fluorescence intensity values for each probe.

The software

formats the comparative analysis of two samples into one .txt file which contains the
change fold, change call and the associated p-value which indicates statistical
significance for detection and change calls.

Microsoft Excel and GeneSpring GX

(Agilent Technologies) software programs were then used for further data analysis to
determine significant changes in gene expression profiles. The microarray analysis was
repeated with new total RNA samples prepared from a second set of mice in order to
obtain two sets of microarray data.
3.4.

Reverse Transcription-PCR (RT-PCR)
Reverse Transcription (RT)-PCR technique was used to determine the expression

levels of mRNA of various genes in a semi-quantitative manner. Specific pairs of
forward and reverse primers were designed for the various RT-PCR analyses as listed in
Table 1. One microgram of total RNA was added to the PCR mix included in the
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Reverse Transcription-PCR kit (Promega, Madison, WI) with 1 µl of appropriate primers
(10µM) and 0.5µl of reverse-transcriptase enzyme in a 25 µl total reaction. The RT-PCR
analysis was carried in a Gene Amp PCR System 9700 (Applied Biosystems, Foster City,
CA). Total RNA was first reverse-transcribed for 45 min at 48˚C. The cDNAs were
initially denaturated at 95˚C for 1 min and then amplified by 35 cycles of PCR using the
following standard conditions: denaturation at 94˚C for 1 min, annealing for 30 sec
(optimal annealing temperatures varied depending on the melting temperature of the
primers) (see Table 1), and extension at 72˚C for 1 min. A final extension step at 72˚C
for 6 min was added. PCR conditions were modified for the amplification of the Rassf3
gene and consisted of: denaturation at 94˚C for 1 min followed by a combined step of
annealing and extension at 68˚C for 1.5 min. The final extension step was carried at 68˚C
for 6 min. RT-PCR samples were stored at -80˚C until further use. Ten µl of the RTPCR product was resolved on a 1% agarose gel-electrophoresis and visualized by
ethidium bromide staining and autoradiography. To control the total amount of RNA
used, amplification of the G3PDH housekeeping gene was carried simultaneously.
Total RNA samples from pairs of human tumors and adjacent normal tissues were
purchased from Ambion Inc. (Austin, TX). For these samples, RT-PCR analyses were
conducted in duplicate with 0.5 µg of total RNA and with specific human RASSF3
primers. The number of PCR cycles was limited to 25 cycles. The photographs of gel
electrophoreses were further analyzed with the Kodak 1D Image Analysis software
(Eastman Kodak Company Molecular Imaging Systems; Rochester, NY) to compare the
mean intensity of the bands. The mean intensity was set to 100% for the normal breast
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tissue. The data were calculated as relative percentage of RASSF3 expression in the
different samples.

Table 1. Pairs of primers used for RT-PCR and PCR analyses with mouse (m) or
human (h) tissues and cell lines and corresponding PCR annealing temperature.

Gene

Primers
Name

Sequences

Amplicon
(bp)

T
(°C)

mMup1

mMup1 for
mMup1 rev

5’-AAATGAAGATGCTGCTGCTG-3’
5’-ATTCTTCATTCTCGGGCCTG-3’

549

54

SOCS2*

Socs2 for
Socs2 rev

5’- TTGACTCATCTCCCATGACC-3’
5’-GCTGCATTCGGAGATAGTCT-3’

688

54

mEtv1

mEtv1 for
mEtv1 rev

5’-GGAGCAGAATGGATGGATTTT-3’
5’- GGGTTACTCATGTTAGTACAC-3’

1400

54

hETV1

hEtv1 for
hEtv1 rev

5’-GGAGCAGAATGGATGGATTTT-3’
5’-GTTAATACACGTAGCCTTCG-3’

1400

54

mRassf1

mRassf1 for
mRassf1 rev

5’-ACCTTCCTTCGAAATGACCTGGAGC-3’
5’-TGAAACAGGACGCACTAGTTTCAGC-3’

300

68

mRassf2

mRassf2 for
mRassf2 rev

5’-CAACGTGAGGACATCCAGTGACCAG-3’
5’-GAAGCTTTTAAGGACTGGCATCTCG-3’

400

68

mRassf3

mRassf3 for
mRassf3 for

5’-GCTAGCATGAGCAGCGGCTACAGCAG-3’
5’-ACCGGTGCCGGGCTTCCACACCTCGC-3’

690

68

hRASSF3

hRassf3 for
hRassf3 rev

5’-GCTAGCATGAGCAGCGGCTACAGCAG-3’
5’-GTCGACTTAATCAGGCTTCCACACCT-3’

690

68

mRassf4

mRassf4 for
mRassf4 rev

5’-CCTGGCACTCAACCTGCAAACAAGG-3’
5’-AATGTACTGGGCAACATCATGGGGC-3’

500

68

mRassf5

mRassf5 for
mRassf5 rev

5’-GCTGCGCTGCGCTAATTGTAAATTC-3’
5’-CGAGCAGACGAAGGTAGAGAGGATA-3’

600

68

G3PDH *

G3PDH for
G3PDH rev

5’-ACCACAGTCCATGCCATCAC-3’
5’-TCCACCACCCTGTTGCTGTA-3’

453

Varied

*: used for both mouse tissues and human cell lines or tissues.
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3.5.

Cloning and Plasmid Construction
The 699 bp mouse Rassf3 cDNA was first PCR amplified (Clontech PCR Kit,

Mountain View, CA) from 17 day-mouse embryo cDNA using a forward primer (5’-GCT
AGC ATG AGC AGC GGC TAC AGC AG-3’) with a Nhe I restriction site and a reverse
primer (5’-ACC GGT GCC GGG CTT CCA CAC CTC GC-3’) containing an Age I
restriction site, following the conditions described above. The stop codon of Rassf3 was
replaced with the Age I restriction site. The PCR product was ligated with pCR2.1 T/A
cloning vector and transformed into E. coli TOP10 cells obtained from Invitrogen.
Positive clones were identified by plating the cells on Luria-Bertani (LB) agar plates
containing 100 µg/ml ampicillin and 80 µg/ml 5-bromo-4-chloro-3-indolyl-bDgalactoside (X-gal). The plasmids were isolated using the QIAprep® Spin Miniprep Kit
(Qiagen). The Rassf3 DNA sequence was confirmed by sequencing analysis. The E. coli
TOP10 cell cultures, producing the positive clones, were mixed with glycerol and frozen
at -80˚C for storage.
The Rassf3 DNA was then subcloned into the pcDNA3.1-His Tag expression
vector (Invitrogen) and fused to the cytomegalovirus (CMV) promoter/enhancer. The
Rassf3 DNA was isolated by restriction digestion with Kpn I and Age I restriction sites,
separated by electrophoresis, purified from the agarose gel using the QIAquick® Gel
Extraction Kit (Qiagen), and ligated with Kpn I and Age I cut pcDNA3.1-His Tag vector
to create the pcDNA3.1/Rassf3-His Tag plasmid. Chemically competent E. coli TOP10
cells were transformed with pcDNA3.1/Rassf3-His Tag and propagated overnight at 37°C
with agitation in LB broth containing 100 µg/ml ampicillin.
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The positive clones were identified and handled in a similar manner as described
above. The Rassf3-His Tag DNA sequence was also confirmed by sequencing analysis.
To subclone the 723 bp Rassf3-His Tag DNA into the pMSG expression vector
(driven by the mouse mammary tumor virus long terminal repeat MMTV LTR)
(Amersham Biosciences, Arlington Heights, IL), the DNA fragment from the
pcDNA3.1/Rassf3-His Tag vector was amplified using the same forward primer as
described above, but with a different reverse primer (5’-CCG GAG TTA CTA CTA CTA
CTA CTA C-3’) which was designed to hybridize to the 6x Histidine Tag and stop
codon, containing an Xho I restriction site at the 3’ end. The PCR product was handled in
a similar manner as described above. The Rassf3-His Tag fragment was isolated by
restriction digestion with Nhe I and Xho I restriction sites, separated by gel
electrophoresis, purified and ligated with Nhe I and Xho I cut pMSG vector to create the
pMSG/Rassf3-His Tag plasmid. The sequence was confirmed by sequencing analysis as
well. The pcDNA3.1/H-RAS G12V-Ha vector and pcDNA3.1/H-RAS S17N-Ha vector
were purchased at UMR cDNA Resource Center (Rolla, MO). The maps of the different
plasmids are presented in Figure 4.
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Figure 4. Maps of the plasmids used in the study. The mouse Rassf3 gene was PCR
amplified from mouse embryo tissue and inserted into the pCR2.1 T/A cloning vector
(pcR2.1/Rassf3). After sequence verification, the Rassf3 cDNA was subcloned into a
mammalian expression vector (pcDNA3.1/Rassf3-His). The Rassf3 cDNA was further
subcloned into the bacterial expression pET22b(+) vector (pET22b(+)/Rassf3-His) for
production of the RASSF3 protein. The Rassf3 cDNA was also subcloned in the pMSG
expression vector (pMSG/Rassf3) for transgenic mice production. The pcDNA3.1/HRAS(G12V)-HA and pcDNA3.1/H-RAS(S17N)-HA were purchased from UMR cDNA
Resource Center and used for transient transfection assays.
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3.6.

RASSF3 Protein Production
The Rassf3 cDNA was amplified by PCR from the pcDNA3.1/His Tag vector

with specific primers. The forward primer sequence (5’-GAC ATA TGA GCA GCG
GCT ACA GCA G-3) was designed to contain a Nde I restriction site and the reverse
primer (5’-CCG GAG TTA CTA CTA CTA CTA CTA C-3’) was designed to hybridize
to the 6x Histidine Tag and stop codon, and contained an Xho I restriction site at the 3’
end. The NdeI-Rassf3-His Tag cDNA fragment was amplified by 30 cycles using the
following conditions: denaturation at 94˚C for 30 sec, annealing at 60˚C for 30 sec, and
extension at 72˚C for 1.5 min, followed by a final extension step at 72˚C for 6 min. The
PCR product was ligated with pCR2.1 T/A cloning vector, then excised using external
Nde I and Xho I sites and ligated into pET22b(+) vector (Novagen, Madison, WI). Fifty
microliters of chemically competent E. coli BL21 (DE3) Rosetta cells (Invitrogen) were
transformed with pET22b/Rassf3-His Tag plasmid and propagated overnight at 37°C
with agitation in LB broth containing 100 µg/ml ampicillin. The next morning, 20 ml of
starter culture was inoculated in 500 ml of LB broth for additional growth until the
O.D.600 reaches 1.0 and then induced for protein production with 1mM isopropyl
β−thiogalactoside (IPTG) (Alexis Biochemicals, San Diego, CA). After three hours of
induction the cells were harvested by centrifugation at 5000 g for 10 min and
resuspended in Solution 1 (0.2M NaPO4; 10 mM EDTA, pH 8.0; 0.5% Triton X-100; pH
8.0) to which was added 0.1 mg/ml lysozyme (Fisher Scientific).

The cells were

incubated for 1 hour at room temperature to weaken the cell membranes and then sheared
on ice with five 1-min ultra-sonic dismemberment using a 550 Sonic Dismembrator
(Fisher Scientific). The insoluble fraction containing the inclusion bodies was recovered
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by centrifugation at 12,000 g for 30 min at 4°C and resuspended in Solution 2 (0.2M
NaPO4; 10 mM EDTA, pH 8.0; 0.5% Triton X-100; 1 M urea; pH 7.0). The inclusion
bodies were then collected by centrifugation at 12,000 g for 30 min at 4°C and frozen at 80˚C. Approximately 0.01 g of pellet was solubilized and denatured in 10 ml of Solution
3 (0.2M NaPO4; 8 M urea; 1% v/v β-mercaptoethanol; pH 8.0) and the protein
concentration was determined by the Bradford method (Bio-Rad Protein Assay, Bio-Rad,
Hercules, CA). Protein was separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) (Pierce, Rockford, IL) and stained with SYPRO® Orange
staining (Molecular Probes, Eugene, OR) for purity identification. The RASSF3 protein
was used as a positif control for each immunoblotting with customized anti-RASSF3
antibody.
3.7.

Custom Antibody Design and Production
Custom polyclonal antibodies to mouse RASSF3 protein were produced by

Proteintech Group Inc. (Chicago, IL) (http://www.PTGLab.com). General rules were
used to select two antigen peptides: the RASSF3-Nt (Li621) peptide composed of the
following sequence N’-MSSGYSSLEEDEDFFFTART-C and the RASSF3-AA54
(Li622) consisting of the following sequence N’-KEKVHKYNSAVTDKLKMT-C.
Approximately 40 mg of the two antigen peptides were synthesized by Proteintech Group
Inc. at approximately 90% purity for 20 mer-peptides with Mass Spectrum data to ensure
the finest sample for immunization. Ten mg of peptide was conjugated with 5 mg of
Keyhole-limpet hemocyanin (KLH) carrier protein. The conjugated peptides were used
to immunize rabbits (#S1228-1, S1228-2, S1229-1, and S1229-2) (two rabbits per
peptide). The standard long protocol of 3.5 months was preferred. This protocol was
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composed of the following steps: Day 0: pre-immune bleed; Day 1: primary injection;
Day 28: boost 1; Day 42: boost 2; Day 56: test bleed and Elisa for Titer; Day 60: boost 3;
Day 74: production bleed; Day 78: boost 4; Day 88: production bleed; Day 102: Final
bleed.

Rabbits were given 4 booster injections to increase the success rate of the

immunization protocol.
Titer levels of the test bleeds were tested by ELISA as indicated in Figure 5A.
The titer levels are 1:1,000,000 for rabbit S-1228-1, 1:1,000,000 for rabbit S-1228-2,
1:1,000,000 for rabbit S-1229-1 and 1:100,000 for rabbit S-1229-2. Each rabbit yielded
approximately 13 ml of serum in each production bleed and 60 ml of serum in the final
bleed, corresponding to a total of about 86 ml of antiserum per rabbit per antigen peptide.
The crude antiserums were stored at -20˚C until use. Once thawed, sodium azide was
added to a final concentration of 0.02% and the antiserums were stored at 4 ˚C for up to a
month.
The RASSF3-Nt serum from rabbit S-1228-1 turned out to be more reactive
against RASSF3 protein than RASSF3-Nt serum from rabbit S-1228-2 and from
RASSF3-AA54 serums, determined by immunoblot analysis (data not shown). The
RASSF3-Nt (S-1228-1) from the first production bleed (day 74) was tested at a dilution
of 1:500 for blotting of a nitrocellulose membrane containing various amounts of
RASSF3 protein as indicated in Figure 5B. This latter antiserum was used as RASSF3
antibody throughout the experiments.
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A.

RASSF3-Nt
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(Li622)
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Figure 5. Elisa testing of the anti-mouse RASSF3 polyclonal antibodies and
Western blot analysis of RASSF3-Nt (S-1228-1) antibody. A) The titer levels of test
bleeds from rabbits immunized with either RASSF3-Nt (Li621) or RASSF3-AA54
(Li622) peptides were determined by ELISA. B) The specificity of RASSF3-Nt (S-12281) antibody to RASSF3 protein was tested by Western blot analysis. The RASSF3-Nt (S1228-1) serum from the first bleed was tested at a dilution of 1:500 for blotting of a
nitrocellulose membrane containing various amount of RASSF3 protein as indicated.
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3.8.

Cell Culture and Reagents
The following Human Breast Cancer cell lines, SKBR3, BT-474, MDA-MB-453,

BT-483, MDA-MB-134, T-47D, MCF-7, MDA-MB-468, MDA-MB-436 and MDA-MB231 were purchased from the American Type Culture Collection (ATCC, Manassas, VA)
and were maintained in medium containing 10 µg/ml gentamicin at 37°C with humidity
and 5% CO2 unless otherwise mentioned. HC11 Murine Mammary Cell line was kindly
provided by Dr. Ameae Walker (University of California, Riverside, CA) and the
MCNeuA and N202Fb3 Murine Mammary Cells by Dr. Mike Campbell (University of
California, San Francisco, CA).
All media and supplements were purchased from Invitrogen unless otherwise
mentioned. BT-474, SKBR3, T-47D, MCF-7 and MDA-MB-436 cells were maintained
in RPMI Medium 1640 supplemented with 10% fetal bovine serum (FBS) (Invitrogen).
BT-483 cells were maintained in RPMI Medium 1640 supplemented with 20% fetal
bovine serum (FBS), 2.5 mg/ml glucose (Sigma), 10 mM 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid (HEPES), 1 mM sodium pyruvate, and 10 µg/ml insulin
(Sigma).

MDA-MB-134 cells were maintained in Leibovitz's L-15 Medium

supplemented with 20% FBS without CO2. MDA-MB-453 and MDA-MB-231 cells
were maintained in Leibovitz's L-15 Medium supplemented with 10% FBS without CO2.
MDA-MB-468 cells were maintained in Leibovitz's L-15 Medium supplemented with
10% FBS and 2 mM L-glutamine without CO2. MCNeuA and N202Fb3 cells were
maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10%
FBS and 1 mM sodium pyruvate. HC11 cells were maintained in RPMI Medium 1640
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supplemented with 10% FBS, 1 mM sodium pyruvate, 10 µg/ml insulin and 10ng/ml
EGF.
EGF solution was purchased from Cambrex (East Rutherford, NJ) and prepared to
a final concentration of 200 ng/ml, aliquoted, and stored at -20˚C. Camptothecin was
purchased from Sigma and dissolved in dimethyl sulfoxide (DMSO) (20mM) and stored
at 4˚C. Working solutions of EGF (60 ng/ml) and camptothecin (50 mM) were prepared
in culture medium immediately before use.
3.9.

Protein Isolation and Western Blot Analysis

3.9.1. Protein Isolation from Tissues
Fresh mammary gland, brain or mammary tumor tissue was excised, frozen
immediately on dry ice, and stored at -80°C until use. Approximately 100-150 mg of
frozen tissue was used for protein extraction. Tissue was homogenized in 1ml of Lysis
Buffer (50 mM Tris·HCl, pH 7.4; 1% NP-40; 0.25% sodium deoxycholate; 150 mM
NaCl; 1 mM EDTA, pH 8.0) containing protease inhibitors (1 µg/ml aprotinin; 1 µg/ml
leupeptin; 1 µg/ml pepstatin; 170 µg/ml phenylmethylsulphonyl fluoride (PMSF); 180
µg/ml sodium orthovanadate; 50mM sodium fluoride), using a Polytron PT1200
motorized homogenizer. The lysates were transferred to 1.5 ml tubes, passed six times
through 21-gauge needles, incubated on ice for 20 min and then clarified by
centrifugation for 15 min at 14,000 rpm at 4°C. The lysates were then transferred into a
new 1.5 ml tubes and stored at -20˚C. The protein content was determined against bovine
serum albumin (BSA) standards using the Coomassie Plus Protein Assay Reagent
(Pierce, Rockford, IL).
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3.9.2. Protein Isolation from Cells
The cells were washed with ice cold phosphate buffer saline (PBS) and lysed in
200 µl of Lysis Buffer (50 mM Tris·HCl, pH 7.4; 1% NP-40; 0.25% sodium
deoxycholate; 150 mM NaCl; 1 mM EDTA, pH 8.0) containing protease inhibitors (1
µg/ml aprotinin; 1 µg/ml leupeptin; 170 µg/ml PMSF; 180 µg/ml sodium orthovanadate).
The lysates were agitated for 10 min on an orbital shaker, transferred to 1.5 ml tubes and
processed as described above.
3.9.3. Western Blot Analysis
Samples containing the same amount of proteins (50-100 µg) were mixed with 6X
SDS-PAGE sample buffer and heated at 100˚C for 5 min. The proteins were separated
using 4-15% (for Cytochrome C and Bax proteins) or 12% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) (Bio-Rad Laboratories, Hercules, CA)
at 100 volts for 80 min. Proteins were transferred to a Hybond Nitrocellulose membrane
(Amersham Biosciences) at 25 volts overnight. A full range molecular weight marker
(Amersham Biosciences) was used to confirm the protein size as well as the efficacy of
transfer. Following transfer, the membranes were blocked in tris-buffer saline (TBS)
containing 5% non-fat powdered milk and 0.05% Tween-20 for 1 to 2 hours (TBS-T).
Membranes were incubated with the primary antibody at different dilution in TBS-T/5%
milk, overnight at 4˚C with gentle agitation. The membranes were washed once with
TBS-T for 5 min and then incubated with the secondary antibodies for 2 hours at room
temperature. The membranes were washed additionally three times with TBS-T before
incubation with the ECL™ Western Blotting Detection Reagents (Amersham
Biosciences), as per the manufacturer’s instructions.

To visualize the bands, the
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membranes were exposed to Kodak Biomax MR film (Fisher Scientific) and developed
with Konica SRX-101A processor (Konica Minolta Medical Imagining, Wayne, NJ).
For additional probing, membranes were stripped by incubation in 100mM β–
mercaptoethanol /2%SDS/62.5 mM Tris-HCl pH 6.7 at 50˚C for 30 min and re-probed
with another primary antibody. To confirm that equivalent amounts of total protein were
added to each well, the membranes were stripped and re-probed with anti-β-actin
monoclonal antibody for analysis of cell lysates or anti-β-tubulin monoclonal antibody
for analysis of tissue homogenates.
3.9.4. Antibodies
The following primary antibodies were used at the following dilutions: 1:1000
anti-phospho-HER2/neu (Lab Vision; Fremont, CA) for cell lysate and 1:400 antiphospho-HER2/neu (Santa Cruz Biotechnology, Santa Cruz, CA) for tissue homogenate
respectively; 1:1000 anti-HER2/neu (EMD Biosciences; Darmstadt, Germany); 1:500
anti-Cyclin D1 (Invitrogen) for cell lysates; 1:1000 anti-phopho-JNK (Cell Signaling
Technology, Danvers, MA); 1:1000 anti-RAS (Cell Signaling Technology); 1:1000 antiCytochrome C (Santa Cruz Biotechnology); 1:10,000 anti-β-Actin (Millipore, Billerica,
MA); 1:10,000 anti-β-Tubulin (Sigma).

Anti-phospho-Akt 1/2/3; anti-phospho-Erk1/2

and anti-BAX were obtained from Santa Cruz Biotechnology and used at 1:1000. The
secondary antibodies, goat anti-mouse IgG- and goat anti-rabbit IgG-horseradish
peroxidase-conjugates were obtained from Bio-Rad Laboratories (Hercules, CA) and
used at 1:2000.
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3.10.

Transient Transfection
Cells were seeded in six-well plates (35mm) at a concentration ranging from 3.2

to 3.8x105 cells

per well, depending on the cell type, in order to reach 60-80%

confluency, 24 hours after seeding. Cells were starved for 2 hours with Opti-MEM®
Reduced Serum Medium (Invitrogen) before transfection. Transient transfections of 1, 2,
3 or 4 µg of DNA plasmids (pcR3.1 vector, pcDNA3.1/Rassf3, pcDNA3.1/H-RAS
(G12V) or pcDNA3.1/H-RAS (S17N)) alone or in different combinations (cotransfections) were performed using LipofectAMINE 2000 Reagent (Invitrogen)
according to the manufacturer’s recommendations. The total amount of transfected DNA
was maintained constant between compared samples.

The DNA-lipofectamine

transfection mixtures were applied on cells for 6 to 8 hours and then replaced by fresh
growth media. Transient transfected cells were harvested after 24 hours for protein
lysates and after 48 hours for apoptosis and proliferation assays.
3.11. Cell Proliferation MTS/PMS Assay
The transient transfected cell lines were harvested 48 hours after transfection,
counted and seeded in 96-well culture plates (6 to 8 wells per cell line) at a density of
10,000 cells per well in 200 µl of appropriate culture medium and grown as
recommended. After 24, 48, 72, 96 or 120 hours, the culture medium was removed and
100 µl of MTS/PMS solution (Promega Corp., Madison, WI) in PBS buffer (1:6 dilution)
was added to each well. The mixture was incubated for 3.5 hours at 37°C in a humidified
5% CO2 atmosphere.

The viability of the cells was determined by colorimetric

measurement of the reduction of MTS by the living cells using a Benchmark microplate
reader (Bio-Rad) measuring absorbance at 490 nm.

All transfection assays were
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performed in triplicate for BT-474, MCNeuA and HC11 cell lines and repeated 8 times
for SKBR3 cell line.

The cell viability was calculated as a percentage of control,

corresponding to pcR3.1 vector transfected cells. The data are represented as the mean ±
standard error of the mean (SEM) for all experiments.
3.12.

Apoptosis Assay
SKBR3 cells were seeded in six-well plates at a concentration of 3.6x105 cells per

well. After 24 hours, cells were transiently transfected with 2 µg of pcR3.1 vector, 4 µg
of pcR3.1 vector, 2 µg of pcDNA3.1/Rassf3 and 4 µg of pcDNA3.1/Rassf3 as described
above. Untransfected SKBR3 cells and camptothecin-treated SKBR3 cells (50µM; 24
hours) were used as negative control and positive control for induction of apoptosis,
respectively. Each sample was prepared in triplicate. Six hours later, the transfection
mixture was removed and 1.5 ml of fresh media was added per well. After 48 hours the
nonadherent apoptotic cells in the medium and the viable adherent cells from each
individual well were collected and transferred into 1.5 ml tubes and centrifuged at 310 g
for 5 min at 4˚C. The pellets were re-suspended in approximately 150 µl of growth
media and kept on ice. The re-suspended cells were diluted 1:10 to 1:20 in Guava®
ViaCount® Reagent (Guava Technologies, Hayward, CA) which contains two DNAbinding dyes, one of which selectively penetrates apoptotic and dead cells characterized
by compromised membrane integrity and one which penetrates all nucleated cells.
Following a five minute incubation, the stained cells were analyzed using a Guava
Personal Cytometer.

Each sample was analyzed using Guava CytoAnalysis software.

The amount of live/healthy cells, apoptotic cells and dead cells were expressed as a
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percentage of the total cellular population for each sample. Data are expressed as mean ±
SEM and are representative of two experiments.
3.13.

Generation and Study of Transgenic Mice

3.13.1. Generation of MMTV/Rassf3 Transgenic Mice
The 723 bp mouse Rassf3-His Tag cDNA was subcloned into the pMSG
expression vector (pMSG/Rassf3-His Tag) and fused to the MMTV-LTR promoter. The
3,180 bp MMTV-Rassf3-His Tag cDNA fragment was digested with Tth111 I and BamH
I enzymes, separated by electrophoresis, purified from the agarose gel, eluted in
microinjection TE buffer and microinjected into fertilized mouse single-cell embryos of
FVB mice (The Jackson Laboratory, Bar Harbor, ME) following standard protocol
(Wagner T. et al., 1981). The tyrosinase gene, responsible for the agouti fur color was
co-injected with the transgene of interest in order to have a convenient color marker.
Founder animals identified as transgene-positive mice were selected for further analysis
and for breeding.

Three founder lines were generated but only the MMTV/Rassf3

transgenic mice line #13 was expanded by mating MMTV/Rassf3 male mice with FVB
female mice.

All animals were maintained in barrier facilities and cared for in

accordance with the Institutional Animal Care and Use Committees (IACUC) guidelines
and policies.
3.13.2. Generation of MMTV/Rassf3-neu Bi-Transgenic Mice
The MMTV/neu transgenic mice line (N#202) was purchased from the The
Jackson Laboratory (Bar Harbor, ME) and expanded in our animal facility.
MMTV/Rassf3 heterozygotic male mice were bred with MMTV/neu homozygous
females to produce a new MMTV/Rassf3-neu bi-transgenic mice line. All offspring were
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heterozygous for MMTV/neu+/- transgene and 50% were positive for the MMTV/Rassf3
transgene and had the agouti fur color.
3.13.3. Identification of Transgenic Mice
The incorporation of the transgene was confirmed by PCR analysis using genomic
DNA isolated from ~0.5 cm mouse tail and digested with proteinase K in Direct PCR
(tail) Lysis Reagent (Viagen Inc., Los Angeles, CA). Specific primers for the transgene
were used.

The forward primer (5’-TGT TTG TGT CTG TTC GCC AT-3’) was

designed to anneal to a region on the MMTV promoter sequence whereas the reverse
primer (5’-TTT GCA GAG TTC CAT CTG CAC-3’) was designed to anneal to a region
located in the middle of the Rassf3 sequence. PCR was performed on a thermocycler
using 35 cycles of the following program: 94˚C for 30 sec, 58˚C for 1 min, 72˚C for 1
min, followed by a final extension step at 72˚C for 6 min. PCR products were analyzed
by electrophoresis on a 1% agarose gel. Transgene incorporation was checked for every
colored mouse from F1, F2 and F3 generations as well as for some white littermate mice
as negative control. Since every colored mouse showed positive transgene insertion and
the white littermates were always transgene-negative, the fur color was then the only
marker used to further identify the positive transgenic mice.
3.13.4. Tumor Incidence and Recurrence
Virgin female MMTV/Rassf3-neu bi-transgenic mice and virgin female
MMTV/neu+/- littermates were checked weekly for the development of primary
mammary tumors. The data are plotted as the percentage of tumor-free animals as a
function of age in days. Primary tumors were surgically removed from anesthetized mice
once the tumor dimension reached between 7 to 11 mm and the wounds were closed with
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surgical staples.

At the time of surgery, the tumor dimensions were recorded and

calculated on the assumption of an ellipsoidal volume: V = 4/3 x Π (A/2)2 (B/2) with “A”
as the short dimension and “B” as the long dimension. The mice were then inspected for
the recurrence of the primary tumor at the site of surgery or for the development of a
secondary tumor at a different site, in one of the other mammary glands. The index of
the inverse of tumor aggressiveness (S) was calculated based on the following formula: S
= T1 + T2 x 1/(V).

The formula was developed based on the fact that the tumor

aggressiveness (S) is a function of different factors including the mouse’s age at the time
of appearance of the primary tumor (T1), the mouse’s age at the time of primary tumor
recurrence or secondary tumor development (T2) and the tumor volume (V) at the time of
surgery. The formula indicates that the higher the index is, the less aggressive is the
tumor. S is expressed in arbitrary units. The statistical differences between the groups
were determined using the non-parametric Kruskal-Wallis and Dunn’s multiple
comparison tests.
3.14. Mammary Gland Whole Mounts
The posterior (fourth or fifth inguinal) mammary gland was dissected from female
mice in the diestrus stage of the estrous cycle and placed on a glass slide. The fresh
tissue was fixed overnight in freshly prepared Carnoy’s fixative at room temperature.
The following day, the glands were systematically re-hydrated in ethanol/water solutions
of decreasing ethanol concentration over a period of 2 hours. The glands were then
stained overnight in Carmine Alum Stain. The next day, the glands were dehydrated with
ethanol/water solutions containing systematically increasing ethanol concentration over a
period of 90 min. The fat pad was cleared with xylene (Sigma) for approximately 1 hour.
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A cover-slip was then secured over the glands with SecureMout (Fisher Scientific). The
glands were documented via digital photography and photos were compared for
mammary gland morphology.
3.15.

Statistical Analyses
Statistical analyses were performed using GraphPad Prism software. Survival

curves were computed using the method of Kaplan-Meier and the statistical differences
were calculated using the Log Rank test. Statistical differences between the groups were
determined using one-way ANOVA and Tukey’s multiple comparison tests unless
otherwise mentioned.
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4.

RESULTS

4.1.
Comparison of the Mammary Gland Morphology of the MMTV/neu
Transgenic Mice
The morphology of the mammary gland of 6 month old virgin female MMTV/neu
mice, which overexpress the neu oncogene in the mammary gland, was compared to the
mammary gland morphology of age-matched non-transgenic virgin female FVB mice as
shown in Figure 6. Similar degrees of ductal elongation and density were observed;
however, the MMTV/neu mice displayed a significant increase in terminal end bud
formation and lobulo-alveolar structures as compared to the non-transgenic mice. These
changes reflected a higher degree of proliferation in the mammary gland of the
MMTV/neu mice.
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FVB mice

6m

MMTV/neu transgenic mice

Figure 6. Images of the mammary gland whole mounts of MMTV/neu transgenic
mice (R) and non-transgenic FVB mice (C). The fourth inguinal mammary glands
were dissected from MMTV/neu transgenic mice (R) and non-transgenic FVB mice (C)
at 6 months of age. The mammary glands were mounted and stained in carmine alum
stain. The whole mounts were digitally photographed to compare the branching density,
the bud formation and lobulo-alveolar structures in the mammary glands. The images are
representative of three mice from each group. Inserts correspond to an enlargement of the
smaller regions indicated by the boxes.
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4.2.
Identification of Differentially Expressed Genes by cDNA Microarray
Analysis
The total RNA samples prepared from mammary glands of tumor-susceptible
MMTV/neu transgenic mice (R-MG), tumor-resistant MMTV/neu transgemic mice (R)
and FVB non-transgenic (C) mice were processed for hybridization to an oligonucleotide
microarray to compare the gene expression profiles via the MAS 5.0 software from the
Keck Affymetrix Resource Group. The three comparative analyses (R-MG vs. R, R-MG
vs. C and R vs. C) are represented by scatter plots as shown in Figure 7. On each scatter
plot, the log of the signal intensity of the probe sets are reported for the two compared
samples. Attention was accorded to the genes demonstrating at least a 2 fold change in
expression between the two compared samples, thus, corresponding to the probe sets
located above the upper diagonals or below the lower diagonals indicated on the scatter
plots. Interestingly, the majority of the genes that are differentially expressed (2 fold) in
R group when compared to C or R-MG are mostly up-regulated (76% and 65%
respectively), whereas the genes that are differentially expressed (2 fold) in R-MG group
when compared to C (69%) or R are mostly down-regulated.
Two approaches were designed to analyse the microarray data in order to identify
the candidate genes which may be responsible for the resistance to HER2/neu-initiated
mammary tumor development in tumor-resistant MMTV/neu mice.
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Figure 7. Scatter-plot representation of the comparative analysis of samples
analyzed by microarray technology. The plots represent the 3 comparative analyses (R
vs. R-MG, R vs. C and R-MG vs. C) obtained from microarray analyses. Each dot
corresponds to one probe set on the microarray chip. The graphs show the log of the
signal intensity of probe sets in the compared samples. The probe sets located above the
upper diagonal or below the lower diagonal show a 2 fold difference in signal intensity
between the two compared samples. The probe sets colored in red correspond to the
genes that show a 2 fold increase in signal intensity in the mammary gland of tumorresistant MMTV/neu transgenic mice (R) compared to tumor-susceptible MMTV/neu
transgenic littermates (R-MG).
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4.2.1. Approach 1: Search for Differentially Expressed Genes in Tumor-resistant
Mice
The first approach aimed at searching for genes that exhibited an opposing pattern
of expression between R and R-MG mammary glands. Particular attention was accorded
to the genes that are up-regulated in the mammary glands of tumor-resistant mice (R) but
down-regulated in the mammary glands of tumor-susceptible mice (R-MG). The result
of this comparison is presented in Table 2. This list includes genes that are involved in
different cellular functions such as signal transduction, cell/tissue structure, transport and
metabolism.

We particularly turned our attention towards genes involved in signal

transduction and towards genes which could fit and interact with members of the
HER2/neu receptor tyrosine kinase pathway. Three candidate genes were selected for
further analysis. Two of these genes encode for intracellular proteins involved in signal
transduction and correspond to the Socs2 gene, which is a well-characterized suppressor
of cytokine signaling and the novel Rassf3 gene which belongs to the Ras Association
domain Family (RalGDS/AF-6) gene. The third gene is the Etv1 gene which belongs to
the ETS family of transcription factors.
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Table 2. List of genes that are overexpressed in the mammary glands of tumorresistant MMTV/neu female transgenic mice compared to tumor-susceptible MMTV/neu
littermates, obtained by cDNA microarray analysis.

Gene Name
Signal Transduction
Intracellular signaling molecules
Suppressor of cytokine signaling 2
Socs2
Ras association (RalGDS/AF-6) domain family 3
Rassf3
Transcription factors
Cbp/p300-interacting transactivator, with Glu/AspCited4
richcarboxy-terminal domain, 4
Ets variant gene 1
Etv1
Tcfap2c
Transcription factor AP-2, gamma
Etv5
Ets variant gene 5
Hey1
Hairy/enhancer-of-split related with YRPW motif 1
Growth factors and growth factor receptors
Mia
Melanoma inhibitory activity 1
Tm4sf3
Tetraspanin 8
Cell tissue structure
Cytoskeleton
Mylpc
Myosin, light polypeptide 2, regulatory, cardiac, slow
Tncc
Troponin C, cardiac/slow skeletal
Tpm3
Tropomyosin 3, gamma
Homer2
Homer homolog 2 (Drosophila)
Tnnt1
Troponin T1, skeletal, slow
Mylc
Myosin, light polypeptide 3
Myh7
Myosin, heavy polypeptide 7, cardiac muscle, beta
Myh2
Myosin, heavy polypeptide 2, skeletal muscle, adult
Tnni1
Troponin I, skeletal, slow 1
Extracellular matrix protein, cell adhesion
Col9a1
Procollagen, type IX, alpha 1
Col11a1
Procollagen, type XI, alpha 1
Ceacam10
CEA-related cell adhesion molecule 10
Npnt
Nephronectin
Comp
Cartilage oligomeric matrix protein
Ceacam1
CEA-related cell adhesion molecule 1
Protein modification, proteases and proteases inhibitor
Papln
Papilin, proteoglycan-like sulfated glycoprotein
Spag5
Sperm associated antigen 5
Timp4
Tissue inhibitor of metalloproteinase 4

GenBank

Fold
Change

NM_007706
BC011511

2.8
2.4

BC025116

2.2

NM_007960
BC003778
BG966751
BG966751

2.2
2.1
2.1
2.0

NM_019394
BC025461

3.2
2.1

NM_010861
NM_009393
NM_022314
AB017136
NM_011618
X67685
NM_080728
BC008538
NM_021467

5.8
3.6
3.2
2.9
2.9
2.9
2.5
2.2
2.1

NM_007740
NM_007729
NM_007675
AW553512
NM_016685
NM_011926

3.7
3.3
3.0
3.0
2.2
2.1

BC005747
BM208112
BI788452

2.4
2.4
2.0
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Table 2. List of genes that are overexpressed in the mammary glands of tumorresistant MMTV/neu female transgenic mice compared to tumor-susceptible MMTV/neu
littermates, obtained by cDNA microarray analysis (Continued).

Gene Name
Transporter
Electron transporter
2410043F08Rik
Filamin binding LIM protein 1
Ion transporter
Potassium intermediate/small conductance
Kcnn4
calcium-activatedchannel, subfamily N, member 4
Kcnk1
Potassium channel, subfamily K, member 1
Other transporter
Aqp5
Aquaporin 5
Solute carrier family 29 (nucleoside transporters),
Slc29a1
member 1
Lman1
Lectin, mannose-binding, 1
Solute carrier organic anion transporter family,
Slc21a2
member 2a1
Metabolism
Fatty acid biosynthesis
Scd2
Stearoyl-Coenzyme A desaturase 2
UDP-Gal:betaGlcNAc beta 1,4B4galt6
galactosyltransferase, polypeptide 6
9430020A05Rik
Acyl-CoA synthetase long-chain family member 4
Glycolysis
Aldo3
Aldolase 3, C isoform
Hk1
Hexokinase 1
Amino acid metabolism
Got1
Glutamate oxaloacetate transaminase 1, soluble
Other
2310047E01Rik
Carbonic anyhydrase 12
Egln3
EGL nine homolog 3 (C. elegans)
4930555L11Rik
Ethanolamine kinase 1
Cp
Ceruloplasmin
Rdh12
Retinol dehydrogenase 12
Ckmt2
Creatine kinase, mitochondrial 2
Other genes
Xlr3a
Scrg1
--4931430I01Rik
--Emu1-pending

X-linked lymphocyte-regulated 3a
Scrapie responsive gene 1
Similar to Shb-like adapter protein, Shf - human
EF hand domain containing 1
Tumor differentially expressed 1
EMI domain containing 1

GenBank

Fold
Change

NM_133754

2.3

NM_008433

2.9

NM_008430

2.0

NM_009701

4.6

AF305501

3.0

AK011495

2.0

NM_033314

2.0

BG060909

2.0

BG066773

2.0

BI153391

2.0

BM941201
NM_010438

3.6
3.0

AA792094

2.0

AK009873
NM_028133
BG066916
BB531328
BC016204
AK009042

3.0
2.8
2.4
2.3
2.1
2.1

NM_011726
NM_009136
BB798279
BC019531
BM239368
NM_080595

3.6
3.4
2.4
2.2
2.1
2.1
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4.2.2. Approach 2: Search for Differentially Expressed Genes in Tumor-resistant
Mammary Tissue
The second analytical approach was designed to identify the candidate genes that
were overexpressed in the mammary glands of both tumor-resistant mice (R) and tumorsusceptible mice (R-MG) compared to the control mice (C). The genes up-regulated in
the two following comparisons R-MG vs. C (94 genes) and R vs. C (20 genes) were first
identified, and then the genes present in both comparisons were selected. Thirteen genes
were identified through this second approach out of which only ten have been
characterized and reported in the literature (Table 3). This list includes genes involved in
cell/tissue structure, cell metabolism and transport. Among those genes, we turned our
attention towards a novel gene whose function has not been reported yet. The transporter
gene Mup1, or major urinary protein 1 which encodes for a secreted protein, was selected
as a candidate gene.
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Table 3. List of genes that are overexpressed in the mammary glands of both
female tumor-resistant MMTV/neu transgenic mice and tumor-susceptible MMTV/neu
transgenic mice, compared to the mammary gland of non-transgenic mice.

Gene Name
Cell tissue structure
Extracellular matrix protein, cell adhesion
Col9a1
Procollagen, type IX, alpha 1
Npnt
Nephronectin
Transporter
Aqp5
Mup1
Metabolism
Fatty acid biosynthesis
Facl4
Other
Lalba
Car6
Other
Secreted protein
C2a-pending
Csnk
Spp1

4.3.

Gen Bank

Fold
Change

AK004383
AA223007

11.7
10.6

NM_009701
NM_031188

9.5
7.2

AB033886

4.0

Lactalbumin, alpha
Carbonic anhydrase 6

NM_010679
NM_009802

9.1
3.7

Androgen binding protein beta
Casein kappa
Secreted phosphoprotein 1

BC024677
NM_007786
NM_009263

7.0
2.7
2.0

Aquaporin 5
Major urinary protein 1

Acyl-CoA synthetase long-chain family member 4

Analysis of the Differentially Expressed Candidate Genes

4.3.1. Confirmation of the Differentially Expressed Candidate Genes by RT-PCR
Analysis
The expression patterns of the candidate genes selected from the two analytical
approaches were confirmed by semi-quantitative RT-PCR analyses on the total RNA
samples isolated from the mammary glands of the three groups of mice. As demonstrated
in Figure 8, Rassf3, Socs2 and Etv1 genes are overexpressed in the mammary glands of
tumor-resistant MMTV/neu mice (R) compared to tumor-susceptible MMTV/neu
mice (R-MG) and control mice (C), whereas, the Mup1 gene is overexpressed in the
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mammary gland of both tumor-resistant mice (R) and tumor-susceptible mice (R-MG)
compared to control mice (C). These observations confirm that Rassf3, Socs2, Etv1 and
Mup1 genes are differentially expressed between the R, R-MG and C mammary glands as
indicated in the microarray analysis.

R-MG

R

C

Rassf3
G3DPH
Socs2
G3PDH
Etv1
G3PDH
Mup1
G3PDH

Figure 8. Confirmation of the microarray data for the four selected candidate genes
by RT-PCR analysis. Total RNA was isolated from the mammary glands of 11 months
old tumor-resistant (R) and tumor-susceptible (R-MG) MMTV/neu transgenic mice and
of age-matched non-transgenic mice (C). RT-PCR analyses were conducted using
appropriate primers for Rassf3, Socs2, Etv1 and Mup1 genes and the RT-PCR products
were resolved on 1% agarose electrophoresis-gels. G3PDH was used as a loading
control.
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4.3.2. Comparison of Gene Expression of Rassf3, Socs2, Etv1 and Mup1 in
Mammary Tumors and Adjacent Normal Tissues
The expression patterns of Rassf3, Socs2, Etv1 and Mup1 genes in the mammary
tumors and the adjacent normal mammary tissues were compared. Total RNA was
isolated from four pairs of mammary tumors (T) and adjacent normal tissues (R-MG)
dissected from MMTV/neu mice that developed tumors at the age of 6, 7, 9 or 11 months
and used for RT-PCR analyses (Figure 9). Surprisingly, the results showed that the
expression levels of the Rassf3 gene are consistently higher in the mammary tumors (T)
than in the adjacent normal mammary tissues (R-MG), independently of the age at which
the tumor appeared. Sequencing analyses of the Rassf3 gene cloned from 6 mammary
tumors revealed no consensus mutation in the gene (data not shown). The expression
levels of the Etv1 gene and, to a lesser extent, the Socs2 gene presented a similar pattern
than Rassf3. In contrast, the expression of the Mup1 gene was high in the adjacent
normal mammary tissues (R-MG), but totally absent in the tumor tissues (T).
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6 mo
R-MG

T

7 mo
R-MG

11 mo

9 mo
T

R-MG

T

R-MG

T

Rassf3
G3PDH
Socs2
G3PDH
Etv1
G3PDH
Mup1
G3PDH

Figure 9. Comparison of gene expression in mammary tumors and adjacent normal
tissues by RT-PCR analysis. Total RNA was isolated from pairs of mammary tumors
(T) and adjacent normal tissues (R-MG) of MMTV/neu transgenic mice that developed
tumors at the age of 6, 7, 9 and 11 months (mo). RT-PCR analyses were conducted using
appropriate primers for Rassf3, Socs2, Etv1 and Mup1 genes and the RT-PCR products
were resolved on 1% agarose electrophoresis-gels. G3PDH was used as a loading control.

To further study the expression pattern of Rassf3, Socs2, Etv1 and Mup1 genes in
tumor tissues, the expression levels of these genes were compared in epithelial cells
(MCNeuA) vs. fibroblasts (N202Fb3), both derived from a Her2/neu mammary tumor
(Campbell M. et al., 2002). Interestingly, even though Rassf3 expression is high in
Her2/neu primary tumor, Rassf3 expression appeared to be absent in both established cell
lines (Figure 10A). On the other hand, the Mup1 gene was not detectable in MCNeuA
and N202Fb3 cells. This observation was expected since Mup1 expression was not
detectable in Her2/neu tumor. The expression of Socs2 and Etv1 genes was significantly
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higher in MCNeuA cells compared to N202Fb3 cells, indicating that Socs2 and Etv1
genes are preferentially expressed in epithelial cells (Figure 10A).
The obvious discrepancy of Rassf3 expression levels in established tumor cell
lines and the primary tumor tissue, reflects the fact that cells are exposed to different
environmental pressure in culture dishes and in whole tissue which can result in a change
in gene expression between tumor tissue and isolated cultured tumor cells.
The expression pattern of Rassf3 in the primary cultured cells from a Her2/neu
mammary tumor was also examined at different passages (24 and 72 hours) by RT-PCR
analysis. The results showed that Rassf3 gene is expressed in primary cells at early
passage (24 hours), but that its expression is diminished after further passages (72 hours)
(Figure 10B). At the same time, the morphology of the primary culture, recorded under a
microscope at 24 hours and 72 hours passages, revealed a switch of the cell population
with passages, corresponding to an increase in the fibroblast (F) population and a
progressive loss of the epithelial cells (E) population (Figure 10C). This last observation
is probably due to the difference in doubling time of these two cell types. This finding
suggests that Rassf3 is preferentially expressed in the epithelial compartment compared
to the fibroblast compartment.
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Socs2
Etv1
G3PDH

C.

Passage 1

Passage 3

(F)
(E)

Figure 10. Comparison of the gene expression patterns in the epithelial vs.
fibroblast cells derived from a HER2/neu mammary tumor by RT-PCR analysis. A)
Total RNA was isolated from established epithelial cells (MCNeuA) and fibroblasts
(N202F3) derived from the mammary tumor of MMTV/neu transgenic mice and
analyzed by RT-PCR experiments for Rassf3, Mup1, Socs2 and Etv1 gene expression.
The RT-PCR products were resolved on 1% agarose electrophoresis-gels. G3PDH was
used as a loading control. B) Total RNA was isolated from a primary HER2/neu
mammary tumor of a MMTV/neu mice and from the primary cultured cells of the tumor
at 24 hours and 72 hours passages and analyzed by RT-PCR experiment for Rassf3 gene
expression. The RT-PCR products were resolved on a 1% agarose electrophoresis-gel.
C) The cell morphology of the primary culture at 24 hours and 72 hours passages was
recorded under a microscope to demonstrate the different cell populations (F, fibroblast,
E, epithelium).
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4.3.3. Comparison of the Gene Expression Pattern of the Ras Association domain
Family genes (Rassf -1, -2, -3, -4, -5) in Various Mouse Mammary Tissues
The expression patterns of the members of the Rassf family in mammary tumors
(T) and adjacent normal mammary tissues (R-MG) of MMTV/neu mice and in mammary
glands of age-matched non-transgenic mice (C) were compared by RT-PCR analysis.
The results indicated that the expression levels of Rassf3 are higher in tumors than in
normal tissue and that it was the lowest in the mammary gland of non-transgenic mice
(Figure 11). This expression pattern was consistent, whether the mice developed tumor
at 6, 9 or 11 months. On the contrary, the expression levels of Rassf2, Rassf4 and Rassf5
were not significantly different between T, R-MG and C tissues, whereas, Rassf1 gene
showed a different pattern of expression between the three tissues at the three different
time points. Therefore, these observations strengthen the belief that the Rassf3 gene
plays a particular role in HER2/neu-induced breast tumor.
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6 mo
C

R-MG

9 mo
T

C

R-MG T

11 mo
C

R-MG

T

Rassf1
Rassf2
Rassf3
Rassf4
Rassf5
G3PDH

Figure 11. Comparison of the gene expression patterns of the Ras Association
domain Family genes (Rassf -1, -2, -3, -4, -5) in mouse mammary tissues by RT-PCR
analysis. Total RNA was isolated from pairs of mammary tumors (T) and adjacent
normal tissues (R-MG) of MMTV/neu transgenic mice that developed tumors at the age
of 6, 9 and 11 months old (mo), as well as from mammary glands of age-matched nontransgenic mice (C). RT-PCR analyses were conducted using specific primers for Rassf1,
Rassf2, Rassf3, Rassf4 and Rassf5 (also known as Nore1) genes and the RT-PCR
products were resolved on 1% agarose electrophoresis-gels. G3PDH was used as a
loading control.
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4.3.4. Relationship between RASSF3, SOCS2 and ETV1 Gene Expression and
HER2/p-HER2 Levels in Multiple Human Breast Cancer Cell Lines
A panel of 10 human breast cancer cell lines was analyzed by Western blot
analysis for the levels of HER2 and p-HER2 proteins and by RT-PCR analysis for the
expression level of RASSF3 gene. The results indicated that RASSF3 gene expression is
inversely correlated to HER2 expression levels among the 10 cell lines (Figure 12A).
RASSF3 expression is minimal or non-detectable in SKBR-3 and BT-474 cell lines,
which express high levels of HER2 and p-HER2. On the contrary, the levels of RASSF3
expression are high in MB-231 and MB-436 cell lines, which did not show expression of
HER2 protein. T47D cells show moderate levels of both endogenous RASSF3 and
HER2.
The RT-PCR analysis was further conducted on a panel of 5 human breast cancer
cell lines including SKBR-3, BT-474, T47D, MCF-7 and MB-231 to examine the
expression levels of SOCS2 and ETV1 genes (Figure 12B).

The levels of SOCS2

expression appeared to be inversely correlated to HER2 levels among the 5 cell lines.
However, the inverse correlation between SOCS2 expression and HER2 levels was not as
obvious as the trend observed for the RASSF3 gene. The ETV1 gene was expressed in
MB-231 cells but non-detectable in the 4 other cell lines. The expression of Mup1 gene
was not investigated in human breast cancer cell lines since it has no known human
homolog.
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Figure 12. Correlation between HER2/p-HER2 protein and RASSF3, SOCS2 and
ETV1 mRNA levels in multiple human breast cancer cell lines by Western blot and
RT-PCR analyses. Protein lysates and total RNA were collected from human breast
cancer cells and used for Western blot analyses for HER2 and p-HER2 proteins and RTPCR analyses for RASSF3, SOCS2 and ETV1 genes. A) HER2 and p-HER2 levels were
compared to the levels of RASSF3 mRNA in 10 cell lines. B) HER2 and p-HER2 levels
were compared to the levels of SOCS2 and ETV1 mRNA in 5 cell lines. β-ACTIN and
G3PDH were used as loading controls.
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4.3.5. RASSF3 Expression in Various Human Tumors versus Adjacent Normal
Tissues
To assess the status of the RASSF3 gene expression in human tumors compared to
adjacent normal tissues, total RNA samples from five pairs of human tumors and adjacent
normal tissues from breast, lung, uterus, colon and cervix were used for RT-PCR analysis
(Figure 13). The level of RASSF3 expression was higher in the tumor compared to the
adjacent tissue of the breast and the cervix samples (p<0.05). On the contrary, the level
of RASSF3 expression was lower in the tumor compared to the adjacent tissue of the
lung, uterus and colon organs. These observations indicate that the expression pattern of
RASSF3 is tumor-type specific.
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Figure 13. RT-PCR analysis of RASSF3 expression in tumors vs. adjacent normal
tissues of various human organs. Total RNA from pairs of tumor and adjacent normal
tissue from human breast, lung, uterus, colon and cervix were analyzed by RT-PCR
experiment using specific human RASSF3 primers to test the expression levels of
RASSF3 in various human tumor vs. adjacent normal tissue. The RT-PCR products were
resolved on 1% agarose electrophoresis-gels. G3PDH was used as a loading control. Gel
electrophoresis photography was analyzed with the Kodak 1D Image Analysis software
to compare the mean intensity of the bands. The mean intensity was set to 100% for the
normal breast tissue. The data are given in percentage and correspond to RASSF3
relative expression in the different tissues. The data represent the mean ± SEM of two
independent experiments. (*) p < 0.05.
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4.4.

Functional Studies of the Rassf3 Gene in HER2/neu-initiated Breast Cancer

4.4.1. Amino Acid Sequence Alignments of the Mouse RASSF3, Human RASSF3
and Human RASSF1
The mouse (m) Rassf3 and human (h) RASSF3 genes encode a 232 amino acid
protein (M.W. 26.7kDa) and a 247 amino acid protein (M.W. 28.6 kDa) respectively.
The proteins contain a highly conserved Ras association (RalGDS/AF-6) (RA) domain at
the C-terminus followed by a SARAH (Sav/RASSF/Hpo) domain like the other members
of the RASSF genes (Figure 14A). The hRASSF1A and hRASSF1C isoforms encode for a
340 amino acid protein and 270 amino acid protein, respectively.

The hRASSF1A

isoform encodes for a larger protein with a cysteine-rich domain (CRD) at the N-terminus
which is a putative diacylglycerol (DAG)-binding domain (Figure 14A).
Sequence alignment with ClustalW algorithm showed that the mRASSF3 and
hRASSF3 sequences share 94% identity at the amino acid level, whereas the hRASSF1A
and hRASSF1C isoforms share 81% identity at the amino acid level and that they differ
mainly at the N-terminus (Figure 14B). In addition, it was found that mRASSF3 and
hRASSF3 both share 40% and 44% identity with hRASSF1A and hRASSF1C proteins,
respectively.
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A.
hRASSF1A (340 aa) NH2hRASSF1C (270 aa)
hRASSF3 (247 aa)
mRASSF3 (232 aa)

-COOH

DAG

RA

SARAH

52-101

194-288

290-337

RA

SARAH

124-218

220-267

RA

SARAH

79-187

187-234

NH2NH2NH2-

-COOH
-COOH
-COOH

RA

SARAH

78-181

181-228

B.
1
1
1
1

MSGEPELIELRELAPAGRAGKGRTRLERANALRIARGTACNPTRQLVPGRGHRFQPAGPA
-MGEAEAPSF-EMTWSSTTSSGYCSQEDSDSE----------LEQYFTARTS-------------------------MSSGYSSLEEDA------------EDFFFTARTS-------------------------MSSGYSSLEED-------------EDFFFTARTS--------

hRASSF1A
hRASSF1C
hRASSF3
mRASSF3

61
41
23
22

THTWCDLCGDFIWGVVRKGLQCAHCKFTCHYRCRALVCLDCCGPRDLGWEPAVERDTNVD
--------------LARR-------------------------PR---------RDQ--D
--------------FFRR------------------------APQ------GKPRSGQQD
--------------FFRR------------------------APP------GKSRSGQPD

hRASSF1A
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hRASSF3
mRASSF3
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38

EPVEWETP-DLSQAEIEQKIKEYNAQINSNLFMSLNKDGSYTGFIKVQLKLVRPVSVPSS
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VEKEKETHSYLSKEEIKEKVHKYNLAVTDKLKMTLNSNGIYTGFIKVQMELCKPP----VEKEKETHNYLSKEEIKEKVHKYNSAVTDKLKMTLNSNGIYTGFIKVQMELCKPA-----

hRASSF1A
hRASSF1C
hRASSF3
mRASSF3

180
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94
93

KKPPSLQDARRGPGRGTSVRRRTSFYLPKDAVKHLHVLSRTRAREVIEALLRKFLVVDDP
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hRASSF1C
hRASSF3
mRASSF3
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AKFALYKRCHREDQVYACKLSDREHPLYLRLVAGPRTDTLSFVLREHEIG--EWEAFSLP
TKFALYKRCHREDQVYACKLSDREHPLYLRLVAGPRTDTLSFVLREHEIG--EWEAFSLP

hRASSF1A
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hRASSF3
mRASSF3
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Figure 14. Schematic comparison of the protein domains and amino acid sequences
of human RASSF1 (isoforms A and C), human RASSF3 and mouse RASSF3
proteins. A) The Ras Association (RA) (RalGDS/AF-6) domains, the putative
diacylglerol (DAG)-binding domain and the SARAH domains are represented by boxes
and their amino acid positions are indicated below. B) The alignment of hRASSF1A
(GenBank NM_007182), hRASSF1C (GenBank NM_170713), hRASSF3 (GenBank
BC100951) and mRASSF3 (GenBank NM_138956) were generated using the ClustalW
algorithm, using the MegAlign program from Lasergene (DNASTAR). Identical amino
acids are highlighted in gray. The RA domains are defined by the boxes.
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4.4.2. RASSF3 Expression Reduces Cell Proliferation and Induces Apoptosis
The SKBR3 human breast cancer epithelial cell line, which expresses very high
levels of HER2 protein, was selected to examine the effects of Rassf3 expression on cell
growth. As we were unable to generate stable cell lines expressing Rassf3, we used the
transient transfection approach to study the effects of Rassf3 in vitro.
Different amounts of pcDNA3.1/Rassf3 plasmid or vector were transfected into
SKBR3 cells. The results from the cell proliferation assay (at 24 hours) indicated that
Rassf3 expression reduces cell proliferation in a dose-dependent manner (Figure 15A).
With 1µg of pcDNA3.1/Rassf3 plasmid, a minimum inhibitory effect was observed. The
inhibitory effect reached a maximum with 2 µg and 4µg of pcDNA3.1/Rassf3 plasmid.
Rassf3 gene expression was confirmed by RT-PCR analysis and demonstrated a
progressive increase of gene expression level with the increase of transfected DNA
(Figure 15B).
The results from the time-course study indicated that the inhibitory effect of
Rassf3 (2µg) transient transfection reached a maximum after 24 hours of proliferation
(Figure 15C).

RT-PCR analysis showed that Rassf3 transient expression was still

detected after 72 hours (Figure 15D).
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Figure 15. The effects of the Rassf3 gene expression on SKBR3 human breast
cancer cell viability. A) SKBR3 cells were transiently transfected with 1, 2 and 4 µg of
vector or pcDNA3.1/Rassf3 plasmid. The cells were plated 48 hours after transfection
into 96-well plates to monitor their proliferation rate after 24 hours. Data are presented
as mean ± SEM of a percentage of pcDNA3.1/Rassf3 inhibition compared to vector. B)
Rassf3 gene expression was confirmed by RT-PCR analysis and gel-electrophoresis.
G3PDH was used as a loading control. (Data not shown for 1µg and 4µg of vector) C)
SKBR3 cells were transfected with 2 µg of vector or pcDNA3.1/Rassf3 plasmid. The
cells were plated 48 hours after transfection into 96-well plate to monitor their
proliferation rate with time. Data are expressed as mean ± SEM of a percentage of
pcDNA3.1/Rassf3 inhibition compared to vector. D) Rassf3 gene expression was
confirmed at 72 hours of proliferation by RT-PCR analysis and gel-electrophoresis.
G3PDH was used as a loading control.
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The inhibitory effect of Rassf3 on cell proliferation was further confirmed with
multiple epithelial cell lines (SKBR3, BT-474, MCNeuA and HC11) which express high
levels of HER2 protein. The cell lines were transfected with 2µg of pcDNA3.1/Rassf3
plasmid or vector and cellular proliferation was measured after 24 hours. The results
showed that Rassf3 transient expression reduced cell proliferation by 20% in SKBR3, 8%
in BT-474, 15% in MCNeuA and 10% in HC11 cells (Figure 16A). The expression of
the RASSF3 protein in the four cell lines was confirmed after transient transfection with a
specific anti-RASSF3 polyclonal antibody (Figure 16B).
To determine the potential mechanism behind the growth-inhibitory properties of
Rassf3, apoptosis assays were performed on transfected SKBR3 human breast cancer
cells (Figure 17).

SKBR3 cells were transfected with 2 or 4 µg of vector and

pcDNA3.1/Rassf3 and then collected 48 hours later to run the Guava ViaCount™ Assay.
The results indicated that Rassf3 transfection caused approximately 15%-20% reduction
in the number of live/healthy cells and 15%-20% increase in the number of apoptotic and
dead cells compare to non-specific vector transfection. These changes in cells numbers
were statistically very significant (p<0.01) in both cases with 2µg or 4µg of
pcDNA3.1/Rassf3 plasmid.
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Figure 16. The effects of the Rassf3 gene expression on cell viability of various cell
lines. A) Two human breast cancer cell lines (SKBR3 and BT-474), one mouse
mammary cancer cell line (MCNeuA) and one mouse mammary cell line (HC11) were
transiently transfected with 2 µg of vector or pcDNA3.1/Rassf3 plasmid. Forty-eight
hours after transfection, the cells were plated into 96-well plate. The proliferation rates
were monitored after 24 hours. Data are presented as mean ± SEM of a percentage of
pcDNA3.1/Rassf3 inhibition compared to vector.
Means are obtained from 8
independent experiments for SKBR3 cells and 3 independent experiments for BT-474,
MCNeuA and HC11 cells. B) RASSF3 protein expression was confirmed in the four cell
lines at 24 hours of proliferation by Western blot analysis. β-ACTIN was used as a
loading control and is representative of all the gels.
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Figure 17. The effects of the Rassf3 gene expression on apoptosis in SKBR3 human
breast cancer cell line. SKBR3 cells were transiently transfected with 2 or 4 µg of
vector and pcDNA3.1/Rassf3 and then collected 48 hours later to run the Guava
ViaCount™ Assay, which allows total cell counts, viability assessments and apoptotic
cell counts. Untransfected cells and camptothecin treated cells were used as negative and
positive controls respectively. The amount of live/healthy cells, apoptotic cells and dead
cells were expressed as a percentage of the total cellular population for each transfection
or treatment. Data are presented as mean ± SEM of triplicates and represent one of two
separate experiments. (**) p<0.01.
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4.4.3. Effects of RASSF3 Expression on Cellular Signaling Pathways
To determine if RASSF3 expression in SKBR3 human breast cancer cells alters
intracellular signaling pathways that are associated with overexpression of HER2 protein,
the status of several common intracellular biomarkers involved in survival (p-AKT,
AKT), proliferation and differentiation (p-ERK, ERK, JNK, RAS), cell cycle (Cyclin
D1), and apoptosis (Cytochrome C, BAX) were analyzed after Rassf3 transfection
(Figure 18). SKBR3 cells were transiently transfected with 2µg of pcDNA3.1/Rassf3
plasmid or vector and stimulated with EGF and the expression levels of the selected
markers were assessed by Western blot analysis after 24 and 72 hours. Changes in
protein levels of the intracellular markers due to RASSF3 protein expression were not
obvious at both time points; however, it appears that RASSF3 expression may decrease
AKT phosphorylation. The experiment was repeated with cell lysates collected 72 hours
after transfection and similar results were observed.
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Figure 18. Western blot analysis of the effect of Rassf3 gene expression on
intracellular signal transduction pathways in SKBR3 human breast cancer cell line.
SKBR3 cells were transiently transfected with 2 µg of vector and pcDNA3.1/Rassf3
plasmid. 24 hours after transfection, cells were treated with EGF (60 ng/ml) for 20
minutes and then proteins were extracted from cell lysates. The protein levels of
RASSF3, p-AKT, AKT, p-ERK, ERK, p-JNK, RAS, Cytochrome C, BAX and Cyclin D1
were analyzed by Western blot analysis. β-ACTIN was used as a loading control and is
representative of all the gels.
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4.4.4. Possible Interaction between RASSF3 and H-RAS Proteins
SKBR3 cells were transiently co-transfected with various amounts of vector,
pcDNA3.1/Rassf3 and pcDNA3.1/H-RAS (G12V) plasmids, such that the total amount of
transfected DNA remained constant; cells were collected after 24 hours for Western blot
analysis of RASSF3 and H-RAS protein levels. As shown in Figure 19, H-RAS protein
level progressively increased as the amount of transfected pcDNA3.1/H-RAS (G12V)
increased.

Interestingly, the H-RAS protein level was significantly reduced when

pcDNA3.1/Rassf3 plasmid was co-transfected (Figure 19). This suggests that RASSF3
transient expression can influence activated H-RAS protein level, possibly by interacting
with it at the protein level.
To study the effects of this possible interaction between RASSF3 and H-RAS on
cell proliferation, the Rassf3 gene was co-transfected with activated H-RAS
(pcDNA3.1/H-RAS (G12V)) or dominant-negative H-RAS (pcDNA3.1/H-RAS (S17N)) in
SKBR3 cells. The results showed that Rassf3 inhibited cell proliferation in a very
significant manner compared to activated H-RAS or dominant-negative H-RAS alone
(p<0.01) whose effects on cell proliferation were minimal (Figure 20A). However, the
results obtained from the co-transfections indicated that Rassf3 growth-inhibition effect
was enhanced in the presence of H-RAS (Figure 20B).
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Figure 19. Western blot analysis of the interaction of RASSF3 protein with
constitutively activated H-RAS in SKBR3 human beast cancer cell line. SKBR3
cells were transiently co-transfected with various combinations of vector,
pcDNA3.1/Rassf3 or pcDNA3.1/H-RAS (G12V) plasmids. Proteins lysates were
collected 24 hours after transfection and protein levels of RASSF3 and H-RAS were
analyzed by Western blot analysis using anti-RASSF3 and anti-RAS antibodies. βACTIN was used as a loading control.
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Figure 20. The effects of co-transfection of Rassf3 with activated H-RAS or
dominant negative H-RAS on cell viability in SKBR3 human breast cancer cell line.
A) SKBR3 cells were transfected with 2 µg of vector, pcDNA3.1/Rassf3, pcDNA3.1/HRAS (G12V) or pcDNA3.1/H-RAS (S17N). The cells were plated 48 hours after
transfection into 96-well plates to monitor their proliferation rate after 24 hours. The data
are presented as a percentage of Rassf3 cell proliferation inhibition compared to vector,
H-RAS (G12V) effect compared to vector and H-RAS (S17N) effect compared to vector.
The data correspond to the mean ± SEM of percentages obtained from 4 independent
experiments. (**) p<0.01. B) SKBR3 cells were co-transfected with 2 µg of each
plasmid in different combinations as indicated. Transfection with 4 µg of vector was
used as a reference to calculate the percentages. The cells were plated 48 hours after
transfection into 96-well plates to monitor their proliferation rate after 24 hours. The data
correspond to the mean ± SEM of percentages obtained from 3 independent experiments.
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4.5.
Generation and Analysis of Novel Transgenic Mouse Lines: The
MMTV/Rassf3 Transgenic Mice and MMTV/Rassf3-neu Bi-Transgenic Mice
In order to study the function of the Rassf3 gene in an in vivo model, two novel
transgenic mouse lines were generated: the MMTV/Rassf3 transgenic mice and the
MMTV/Rassf3-neu bi-transgenic mice.
4.5.1. Confirmation of the Transgenic Mouse Lines
The incorporation of the Rassf3 transgene was confirmed by PCR analysis on
genomic DNA isolated from mouse tail biopsies (Figure 21). Various tissues from
female MMTV/Rassf3 mice and their littermates were analyzed by RT-PCR for the
expression of the Rassf3 gene. The results indicated that the Rassf3 gene is expressed in
the mammary gland as well as in the brain, the small intestine and the muscle tissues of
MMTV/Rassf3 transgenic mice (Figure 22).
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Figure 21. Representative PCR analysis of the genomic DNA from MMTV/Rassf3
transgenic mice, MMTV/Rassf3-neu bi-transgenic mice and their littermates. The
presence of the transgene was confirmed by PCR analysis of genomic DNA from tail
biopsies of the MMTV/Rassf3 transgenic mice (1, 1’), FVB non-transgenic littermates (2,
2’), MMTV/Rassf3-neu bi-transgenic mice (3, 3’) and MMTV/neu+/- littermates (4, 4’).
A pair of specific primers that span the MMTV promoter and the Rassf3 cDNA sequence
was used for PCR analysis. The PCR products were resolved on 1% agarose
electrophoresis-gels and G3PDH was used as a loading control.
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Figure 22. RT-PCR analysis of the total RNA from various tissues of MMTV/Rassf3
transgenic mice and their littermates. Total RNA was isolated from the mammary
gland, brain, small intestine and muscle tissues of MMTV/Rassf3 female transgenic mice
(+) and of their littermates (-). Rassf3 gene expression was investigated by RT-PCR
analysis and RT-PCR products were resolved on a 1% agarose electrophoresis-gel.
G3PDH was used as a loading control.
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To further study the expression of Rassf3 gene, Western blot analysis was
conducted on mammary glands and brain tissues using a specific anti-RASSF3
polyclonal antibody. For the mammary gland tissues, the RASSF3 protein was not
detected on the immunoblots for the MMTV/Rassf3 mice and MMTV/Rassf3-neu bitransgenic mice, although the Rassf3 mRNA was present and amplified by RT-PCR
analysis of mammary gland homogenates (Figure 23A). However, the RASSF3 protein
was detected in the brain tissue of all the MMTV/Rassf3 transgenic mice and of the
MMTV/Rassf3-neu bi-transgenic mice whereas it was not detected in all the littermates
(Figure 23B).
There was no apparent overt phenotype in both male and female MMTV/Rassf3
transgenic mice up to currently 21 months of age. The MMTV/Rassf3 female mice were
fertile with normal litter size and showed no difference in maternal behavior compared to
the FVB non-transgenic littermates.
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Figure 23. Western blot and RT-PCR analyses of RASSF3 expression in mammary
gland and brain tissues of the transgenic mice. A) Tissue lysates and total RNA were
isolated from mammary gland tissues of transgenic mice and their littermates. Protein
lysates were used for Western blot analysis with an anti-RASSF3 antibody and total RNA
samples were used for RT-PCR analysis. RT-PCR products were resolved on 1%
agarose electrophoresis-gel. B) Tissue lysates were prepared from brain of transgenic
mice and their littermates at different ages (mo: months) for Western blot analysis with
an anti-RASSF3 antibody. 1: MMTV/Rassf3 mice; 2: non-transgenic FVB mice; 3:
MMTV/Rassf3-neu bi-transgenic mice; 4: MMTV/neu+/- littermates; and C: Purified
RASSF3 protein as positive control. β-TUBULIN and G3PDH were used as loading
controls.
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4.5.2. Comparison of the Mammary Gland Morphology of the Transgenic Mice
To determine the effects of Rassf3 on mammary gland development, the
mammary gland whole mounts obtained from the MMTV/Rassf3 transgenic mice and
their non-transgenic FVB littermates (Figure 24A) at the age of 3 and 7 months were
compared. The observed morphological differences are minimal. The overall ductal
density and end bud formation are similar; however, it appears that the amount of side
branching is slightly reduced in the MMTV/Rassf3 transgenic mice compared to their
littermates at the two time points. No morphological differences were detected between
the mammary gland whole mounts from the MMTV/Rassf3-neu bi-transgenic mice and
from the MMTV/neu+/- littermates at the age of 3 and 6 months (Figure 24B).

118

MMTV/Rassf3 mice

FVB littermates

7 mo

3 mo

A.

MMTV/Rassf3-neu mice

MMTV/neu+/- littermates

6 mo

3 mo

B.

Figure 24. Images of the mammary gland whole mounts of MMTV/Rassf3
transgenic mice, FVB non-transgenic mice, MMTV/Rassf3-neu bi-transgenic mice
and MMTV/neu+/- littermates. The fourth inguinal mammary glands were dissected
from 3, 6 and 7 months old (mo) mice, mounted and stained in carmine alum stain. The
mammary gland whole mounts were digitally photographed to compare the morphology.
Pictures are representative of mammary gland images of MMTV/Rassf3 transgenic mice
and littermates (n=2/group; panel A) and of MMTV/Rassf3-neu bi-transgenic mice and
MMTV/neu+/- littermates (n=3/group; panel B). Inserts correspond to an enlargement of
the smaller regions indicated by the boxes.
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4.5.3. Comparison of the Mammary Tumor Incidence in the MMTV/Rassf3-neu
Bi-Transgenic Mice and in their Littermates
To assess the effect of Rassf3 overexpression on HER2/neu mammary
tumorigenesis, the MMTV/Rassf3-neu transgenic mice and the MMTV/neu+/- littermates
were monitored for the development of palpable mammary tumors. The comparison of
the mammary tumor incidence revealed that there was a delay in tumor formation
(p=0.0552) in the bi-transgenic mice (Figure 25). The t50 of MMTV/Rassf3-neu bitransgenic mice (n=37; t50=262) was increased by 37 days compared to the t50 of
MMTV/neu+/- littermates (n= 32; t50 =225).

120

MMTV/Rassf3-neu mice (n=37)

100

Tumor-Free Mice (%)

MMTV/neu +/- mice (n=32)
80
60

t50=262
t50=225

40
20
0
0

100

200

300

400

500

Age (Days)

Figure 25. Comparison of the mammary tumor incidence in the MMTV/Rassf3-neu
bi-transgenic mice and the MMTV/neu+/- littermates. The data are plotted as the
percentage of tumor-free female mice (y-axis) as the function of age in days (x-axis).
The MMTV/Rassf3-neu bi-transgenic mice (n=37) are represented by closed circles (●),
and the MMTV/neu+/- littermates (n=32) are represented by closed squares (■). The t50
of MMTV/Rassf3-neu bi-transgenic mice and their littermates correspond to 262 and 225
days respectively. Log rank test, P = 0.0552.
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Western blot analysis of mammary tumors indicated that RASSF3 protein is
expressed in the tumors of MMTV/Rassf3-neu bi-transgenic mice and of MMTV/neu+/littermates (Figure 26). The expression levels of RASSF3 and p-HER2 proteins appeared
to be both higher in the tumors from the bi-transgenic mice than in the tumors from the
littermates.

MMTV/Rassf3-neu
mice

MMTV/neu+/mice

C
RASSF3
p-HER2
β-TUBULIN

Figure 26. Western blot analysis of RASSF3 expression in mammary tumors of the
MMTV/Rassf3-neu bi-transgenic mice and their littermates. Protein lysates were
isolated from mammary tumors of MMTV/Rassf3-neu bi-transgenic mice (6 to 8 months
old) and of MMTV/neu+/- littermates (7 to 9 months old) for Western blot analysis with
anti-RASSF3 and anti-phospho-HER2 antibodies. Purified RASSF3 protein was used as
a positive control (C). β-TUBULIN was used as a loading control.
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Primary mammary tumors were surgically removed from several mice to
investigate the incidence of recurrent mammary tumors and of secondary mammary
tumors.

The results suggested that Rassf3 overexpression did not influence the

recurrence of primary tumors nor the development of secondary tumors in
MMTV/Rassf3-neu bi-transgenic mice as indicated in Table 4. On the other hand, the
development of secondary tumors appeared to be more frequent than the recurrence of
primary tumors in MMTV/neu+/- littermates. However, the chi-square test indicated that
the distribution of recurrence and secondary tumor between the two groups of mice was
not significant (p> 0.05).

Table 4.
Mammary tumor recurrence and secondary mammary tumor
development in female MMTV/Rassf3-neu bi-transgenic mice compared to their
MMTV/neu+/- littermates.

MMTV/Rassf3-neu
bi-transgenic mice

MMTV/neu+/littermates

Secondary tumor

8 (47.1%)

7 (63.6%)

15 (51.7%)

Recurrence

9 (52.9%)

4 (36.4%)

13 (48.3%)

Total of Mice

17 (60.7%)

11 (39.3%)

28 (100%)

All mice

The index of tumor aggressiveness (S) was calculated for several recurrent
primary tumors and secondary mammary tumors. In the case of the MMTV/Rassf3-neu
bi-transgenic mice, there was no significant difference in the index of tumor
aggressiveness between the two types of tumors, recurrent primary tumors (Mean of
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S=252 units) and secondary tumors (Mean of S=209 units) (Figure 27). On the contrary,
the indexes of tumor aggressiveness were significantly different between the two types of
tumors for the MMTV/neu+/- littermates, with the recurrent primary tumors (Mean of
S=173 units) corresponding to a more aggressive type than the secondary tumors (Mean
of S=253 units).
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Figure 27. Analysis of the recurrence of mammary tumors in MMTV/Rassf3-neu
bi-transgenic mice and their littermates after surgical removal of the primary
tumor. After surgical removal of the primary tumors, the mice were monitored for
primary tumor recurrence (Recurrence) or for the development of a secondary tumor
from other site (Secondary). The data represent the index of the inverse of tumor
aggressiveness (S) calculated by the formula: S= T1 + T2 x 1/(V) which includes the
mouse’s age at the time of appearance of the primary tumor (T1), the mouse’s age at the
time of primary tumor recurrence or secondary tumor development (T2) and the tumor
volume (V) at the time of surgery. Tumors from MMTV/Rassf3-neu bi-transgenic mice
are represented by circles (● & ○), and tumors from the MMTV/neu+/- littermates are
represented by squares (■ & □). (*) p < 0.05.
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5.

5.1.

DISCUSSION

HER2/neu Human Breast Cancer and its Mouse Models
Amplification and/or overexpression of HER2/neu have been found in one-third

of human breast cancers (Slamon D. et al., 1987; Slamon D. et al., 1989). The HER2/neu
overexpression is associated with a poor clinical outcome in that women with a
HER2/neu-positive tumor experience earlier disease relapse and shorter survival time.
Evidence support that HER2/neu overexpression plays a direct causal role in
pathogenesis of the malignancy of breast cancer (Di Fiore P. et al., 1987; Hudziak R. et
al., 1987). The transforming potential of the HER2/neu protein is closely related to its
intrinsic tyrosine kinase activity (Guy C. et al., 1992). Overexpression of HER2/neu
oncogene in human breast cancer is also associated with enhanced metastatic potential
upon breast tumor cells (Paterson et al., 1991).
The molecular mechanism(s), by which HER2/neu overexpression stimulates
neoplastic cell growth and renders cancer cells chemoresistant, have not been completely
defined. It has been documented that HER2 overexpression can promote the growth and
malignancy of mammary epithelial cells in part by conferring resistance to the growth
inhibitory effects of TGF-β signaling which corresponds to the dominant system
opposing the stimulatory effect of growth factors and early oncogene activation in many
tissues, including the mammary gland (Brandt R. and Ebert A., 1998). This resistance to
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the anti-proliferative effects of TGF-β appears at an early stage of the tumor progression
in a number of human malignancies (Wilson C. et al., 2005). In addition, it has been
established that a link exists in breast cancer between HER2 amplification and cyclin D1
overexpression. The cyclin D1 gene has been reported to be amplified in up to 20% of
human breast cancers, while cyclin D1 protein is overexpressed in over 50% of human
mammary carcinomas and particularly in DCIS (75%) (Weinstat-Saslow D. et al., 1995;
Harari D. and Yarden Y., 2000; Yu Q. et al., 2001). Aberrant overexpression of cyclins
D can reduce and overcome the dependency of mitogenic stimulation for a cell, and thus
plays a role in the process of oncogenic transformation.

It is believed that HER2

overexpression results in hyper-activation of a signaling network that deregulates the
G1/S checkpoint of the cell cycle by up-regulation of cyclins D and of the cyclindependent kinase partners (CDK-4 and -6) (Harari D. and Yarden Y., 2000; Yang C. et
al., 2004). Hudziak R. and colleagues (1988) showed also that HER2/neu oncogene
expression allowed the tumor cells to resist to the cytotoxic effects of tumor necrosis
factor alpha (TNF-alpha) or macrophages and thereby to evade host immune defenses.
Furthermore, it was demonstrated that HER2-positive breast tumors can evade apoptosis
and resist to chemotherapeutic cytotoxic agents by up-regulating the CDK inhibitor
p21Waf1, which plays a central role in HER2 anti-apoptotic machinery (Yu Q. et al.,
2001).
To directly test the tumorigenic potential of the HER2/neu oncogene in the
mammary epithelium, transgenic mouse models carrying the rat neu oncogene under the
transcriptional control of the mouse mammary tumor virus promoter/enhancer (MMTV)
have been established (Muller W. et al, 1988; Guy C. et al. 1992). Two different models
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have been developed with either the normal form of neu or an activated form which
corresponds to a mutated form of neu with a change at position 664 in the transmembrane
domain from valine to glutamic acid (Bargmann C. and Weinberg R., 1988).
In several strains of MMTV/activated neu mice, early onset of the transgene
expression in the mammary gland resulted in the development of multifocal mammary
adenocarcinomas in both sexes by 78 to 95 days, with occasional progression to
pulmonary metastasis (Muller W. et al, 1988; Bouchard L. et al., 1989). These results
suggested that activated neu through mutation was sufficient (single step) for mammary
tumorigenesis (Muller W. et al, 1988).
On the other hand, expression of the normal form of neu in MMTV/neu
transgenic mice resulted in the development of mammary tumors with a longer latency
(120-337 days) than when activated neu is expressed (Muller W. et al, 1988). It is
believed that overexpression of the unactivated NEU protein is the primary mechanism
contributing to human breast cancer, since primary human breast cancers fail to reveal
any comparable mutations (Lemoine N. et al., 1990). Guy C. and colleagues (1992)
reported also that overexpression of the unactivated form of neu in the mammary
epithelium resulted in the appearance of focal mammary adenocarcinomas that
metastasized with high frequency to the lung in transgenic mice, suggesting that
overexpression of neu can confer an enhanced metastatic potential to the mammary tumor
cells. For one of their best characterized line (N#202), the study of the kinetic of tumor
occurrence revealed that approximately 50% of female virgin mice developed mammary
tumors at the age of 7 months (t50=205 days) and about 80% of the female virgin mice at
the age of 11 months or older (Guy C. et al., 1992). In addition, they reported that the
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neu transgene was expressed in both tumors and adjacent mammary epithelium, with
higher levels in tumors, whereas the NEU-associated tyrosine kinase showed high
activity in tumors but not in the adjacent mammary tissues. The delay in tumor onset in
the MMTV/neu transgenic mice implies that additional genetic events beyond neu
overexpression are required for mammary tissue transformation leading to tumor
formation (Guy C. et al., 1992). This reflects the multistep model of tumorigenesis
where more than one genetic event are involved. Therefore, elucidation of the molecular
alterations that occur during HER2/neu breast cancer initiation and progression is crucial
in the identification and development of therapeutic approaches to targeting HER2/neupositive tumors in breast cancer patients.
The HER2/neu animal model has been used in many studies since its
establishment (Muller W. et al, 1988). However, the focus of nearly all of those studies
was to investigate the mechanism by which the overexpression of HER2/neu oncogene in
epithelial cells initiates tumorigenesis. In the present study, we used the previously
developed MMTV/neu female transgenic mouse model but we focused on the small
proportion (approximately 20 %) of MMTV/neu transgenic mice which did not develop
mammary tumors at 11 months or older despite the overexpression of the neu oncogene
(Guy C. et al., 1992) and which seem to have naturally developed resistance to
HER2/neu-tumorigenesis.

We hypothesized that there may be one or more tumor

suppressor genes that are up-regulated in the mammary glands of these tumor-resistant
mice which might suppress the development of mammary tumors.
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5.2.
Identification of the Genes Responsible for the Tumor Resistant Phenotype
in MMTV/neu Transgenic Mice by cDNA Microarray Analysis
To test our hypothesis, cDNA microarray analysis was used to compare the
differences in gene expression profiles of mammary glands of R, R-MG and C mice, in
order to identify genes that may be responsible for the resistance to HER2/neu mammary
tumor development in the tumor-resistant mice. Two approaches were used in this study
to analyze the microarray data.
The first approach consisted in searching for differentially expressed genes in
tumor-resistant MMTV/neu mice (R) compared to tumor-susceptible MMTV/neu mice
(R-MG). The rationale of this first approach supported the notion that the genes that are
up-regulated in tumor-free mice but down-regulated in tumor-susceptible mice might be
responsible for the resistance to tumor formation (Table 2). Among the genes identified,
two genes encoding for intracellular signaling proteins associated with a suppressive
character, have attracted our attention: the Rassf3 and the Socs2 genes.
The Rassf3 gene is a novel gene that has been previously reported but remains
relatively uncharacterized. Indeed, Tommasi S. and colleagues (2002) identified two
homologues of RASSF1 gene by BLAST searches using the predicted amino-acid
sequence of RASSF1 RA domain and named them RASSF3 and Rassf3 for the human
and mouse genes respectively. They found that RASSF3 was expressed ubiquitously in
normal human tissues and tumor cell lines in a similar manner than the isoform C of
RASSF1. Based on their sequence homology with the tumor suppressor RASSF1 and on
the presence of a conserved RAS association domain (RA) at the C-terminus followed by
a SARAH (Sav/RASSF/Hpo) domain, the RASSF3 gene has been classified as a member
of the Ras Association domain (RalGDS/AF-6) Family gene (RASSF), which contains
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characterized RAS effectors and tumor suppressor genes (Hesson L. et al., 2003; Vos M.
et al., 2003; Eckfeld L. et al. 2004; Agathanggelou A. et al., 2005). The belonging to the
RASSF family suggests that RASSF3 may function in signal transduction pathways
involving RAS GTPases proteins. However, no functional studies of human RASSF3 and
mouse Rassf3 genes have been reported. RASSF1 and NORE1 genes have been the most
extensively studied members of the RASSF Family.

They encode both two major

isoforms, RASSF1A (340 aa), RASSF1C (270 aa) and NORE1A (418 aa), NORE1B
(265 aa) respectively. Only RASSF1A and NORE1A isoforms contain an additional
functional domain at the N-terminus, the cysteine-rich domain (CRD) which is a putative
diacylglycerol (DAG)-binding domain. (Vos M. et al., 2003; Agathanggelou A. et al.,
2005).
The role of the RASSF genes as tumor suppressors is supported by the loss of
expression in human tumor cell lines and tumors due to hypermethylation of CpG islands
in the promoter region (Agathanggelou A. et al., 2005). In fact, the RASSF1A isoform
(but not the RASSF1C isoform) has been reported to be down-regulated at the expression
level by promoter hypermethylation in the majority of cancer cell lines from lung,
glioma, breast (MCF-7, MDA-MB-157, MDA-MB-231, T47D and ZR75-1) and ovaries,
and to be inactivated in a wide range of human sporadic cancers such as in 80% of lung
(NSCLC) cancers, 60% of breast cancers (Dammann R. et al., 2001; Burbee D. et al.,
2001), 70% of prostate cancers, 90% of hepatocellular cancers, as well as in ovarian,
kidney, prostate, neuroblastoma, gliomas, thyroid and gastric cancers (Tommasi S. et al.,
2005; Agathanggelou A. et al., 2005). NORE1A promoter region was also found to be
hypermethylated in breast, lung, colorectal, kidney and glioma tumor cell lines and in
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24% of NSCLC primary tumors (Vos D. et al., 2003b). In a similar way, RASSF2
expression is reported to be frequently down-regulated or silenced by promoter
hypermethylation in human lung and gastric cancer cell lines and primary gastric cancers
(Endoh M. et al., 2005).

RASSF4 is broadly expressed in normal tissue but its

expression is also down-regulated by promoter hypermethylation in breast, lung,
colorectal and kidney cancer cell lines as well as in primary breast and lung tumors
(Agathanggelou A. et al., 2005). Some differences have been observed in promoter
methylation between the two isoforms of RASSF1 (A and C) and of NORE1 (A and B)
which reflects tissue-dependent differences in biological activity of the isoforms. In
addition, re-expression of RASSF1A in lung cancer cell lines by treatment with an
unmethylating agent was shown to reduce colony formation, suppress anchorageindependent growth and to inhibit tumor formation in nude mice (Burbee D. et al., 2001).
These characteristics all together reinforce a potential role for RASSF1A as a tumor
suppressor gene. The Rassf3 gene has been found unmethylated in human cancers, which
may suggest the existence of a different mechanism of regulation for Rassf3 expression
(Agathanggelou A. et al., 2005).
In addition, it has been documented that the RASSF proteins can interact with
specific RAS proteins in a GTP-dependent manner, therefore supporting a role as RAS
effectors. It has been shown that RASSF1 and NORE1 interact specifically with H-RAS,
whereas RASSF2 and RASSF4 both interact specifically with K-RAS (Vos M. et al.,
2000; Vos M. et al., 2003; Eckfeld K. et al, 2004).
The Socs2 gene encodes for the intracellular suppressor of cytokine signaling-2
protein which belongs to a family of proteins involved in the regulation of cytokine
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responses from the growth hormone receptor, insulin-like growth factor receptor and the
prolactin receptor. These SOCS proteins act in a classical feedback loop (Hilton D.,
1999; Johnston J., 2004). Their gene expression is induced by exposure to cytokines,
hormones, and growth factors. Once produced, they bind to various components of the
signaling apparatus and inhibit further signal transduction. The SOCS proteins can block
the cytokine signaling either by direct inhibition of the adaptor protein JACK2 or by
binding to the tyrosine phosphorylated receptor to prevent binding with other SH2 and
PTB-domain containing adaptor proteins (Raccurt M. et al., 2003). In fact, SOCS2 has
been found to bind to JAK2 and suppress its phosphorylation, thereby inhibiting the JAKSTAT intracellular signaling pathway (Larsen L. and Ropke C., 2002). The inhibitory
actions of SOCS proteins are also combined with a mechanism of targeting associated
signaling molecules for poly-ubiquitination and proteasome mediated degradation
(Johnston J., 2004).
Various effects of SOCS proteins have been demonstrated in the immune system
and immune pathology (Alexander W. and Hilton D., 2004; Elliot J. and Johnston J.,
2004); however, the role of SOCS proteins in other diseases is less well known. Several
studies have shown that the loss or inactivation of SOCS proteins (1, 2 and 3) correlates
with a growth promoting effect (Schultheis B. et al., 2002; Johnston J., 2004; Miller M. et
al., 2004). Others have shown that SOCS proteins can regulate cell proliferation and
differentiation and are involved in cross-talk between signaling pathways (Leung K.,
2003; Johnston J., 2004).

It seems that SOCS2 behavior shows some differences

compared to its cognate receptors SOCS1 and SOCS3. Favre H. et al. (1999) showed
that SOCS2 had two opposite effects, i.e. it inhibited growth hormone-induced STAT5-

132

dependent gene transcription at low concentrations, but restored growth hormone
signaling when present at higher concentrations. These findings suggested that SOCS2,
which is often induced later than SOCS1 and SOCS3 in response to cytokines, may
restore the sensitivity to cytokines by suppressing the initial inhibitory effect of SOCS1
and SOCS3. In breast cancer, conflicting data have been reported on SOCS proteins
(Raccurt M. et al., 2003; Miller M. et al., 2004) and therefore further studies are
necessary. Based on the facts reported in the literature, it seems that the Socs2 gene may
interfere with HER2/neu signaling pathway by interacting with the JAK2 adaptor protein.
In addition, through the first analytical approach, a number of transcription factors
were found up-regulated in tumor-resistant mice. These transcription factors such as the
ETV1 are correlated with HER2/neu expression. The ETV1 transcription factor (also
known as ER81) belongs to the ETS family of transcription factors, characterized
primarily by a highly conserved DNA binding domain known as the ETS domain. The
ETS transcription factors play an important role in mammalian development and
hematopoeitic development. Loss of function of various ETS transcription factors has
been indeed correlated with embryonic lethality (Gilliland G., 2001). They have also
been implicated in the pathogenesis of a spectrum of human cancers and seem to function
by influencing the promoter activity of TGF-β type II receptor, which behaves as a tumor
suppressor (Im Y., 2000; Gilliland G., 2001; Dowdy C. et al., 2003; Kopp J. et al., 2004).
ETV1 belongs to the PEA3 transcription factor subfamily and its activity has been found
to be regulated and enhanced by the HER2/NEU tyrosine kinase (Goel A. and Janknecht
R., 2004) through RAS-RAF-MAPK and/or JNK downstream signaling pathways.
Phosphorylation of ETV1 transcription factor leads to its association with the Cbp/p300

133

transcriptional co-activator in the nucleus and further stimulation of gene transcription
such as the human telomerase reverse transcriptase hTERT involved in the control of
replicative capacity and senescence (O’ Hagan R. and Hassell J., 1998; Goueli B. and
Janknecht R., 2004).
In respect to the second analytical approach, the rationale to analyzing the
microarray data comes from evidence demonstrating that a primary tumor sends
circulating signals to its surrounding environment to suppress the development of
metastases. Folkman and colleagues were the first ones to show that the inhibition of
metastases by a primary mouse tumor is mediated, at least in part, by an angiogenesis
inhibitor angiostatin (O'Reilly M. et al., 1994; Folkman J., 2002; Naumov G. et al.,
2006). In consequence, we realized that in our model of study, the normal adjacent
mammary gland, dissected from tumor-susceptible MMTV/neu mice that had developed
tumors, may express considerable suppressive signals.

Thus, the adjacent normal

mammary glands could be considered as tumor-resistant mammary glands (R-MG).
Therefore, we hypothesized that the mammary glands of tumor-resistant mice (R) and of
tumor-susceptible mice (R-MG) may present similar patterns of gene expression.
Among the genes identified through this second approach, the Mup1 gene,
characterized by a high fold change, was further studied. Mup1 or major urinary protein
1 gene belongs to a large family consisting of 35 to 40 highly homologous genes and
pseudogenes. It is expressed in a number of different secretory tissues of the mouse,
including the liver, the submaxillary gland and the lachrymal, sublingual, parotid and
mammary glands (Shaw et al., 1983). The expression of Mup mRNA is under the control
of different developmental and hormonal stimuli in different tissues (Shaw et al., 1983).
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The secreted MUP proteins belong to the lipocalin superfamily and share with other
members of this family the capacity to bind hydrophobic molecules such as pheromones
(Shahan et al., 1987). No known function has yet been identified for Mup1 gene.
However, Mup genes have been defined as negative tumor markers of mouse
hepatocarcinomas (Dragani T. et al., 1989), because the expression of Mup genes was
found to be decreased in the early development of mouse liver tumors compared to
normal.
5.3.

Analysis of the Candidate Genes
The overexpression of the Rassf3 gene in mouse mammary tumors compared to

adjacent normal mammary tissues may be the result of a cellular defensive response to
the high levels of HER2/NEU proteins in the mammary tumors of the MMTV/neu
transgenic mice (Figure 9 and 11). This particular expression pattern has been previously
documented for genes with tumor suppressor activity, notably for TGF-β, p53 and SOCS
tumor suppressors (Oft M. et al., 1998; Gonzalez-Palacios F. et al., 1997; Raccurt M. et
al., 2003; Rowland B. and Peeper D., 2006).

Contrary to the notion that tumor

suppressor proteins are down-regulated in cancers, it has been found that there is a
marked increase in their expression in specific cancers.
Evidence report that TGF-β demonstrates a biphasic action during multistage
carcinogenesis, acting as a tumor suppressor by inhibiting cell-cycle progression and
tumor growth during early tumor development but enhancing the malignant phenotype
(invasiveness and metastasis) in late stage human carcinogenesis of the pancreas, colon,
stomach, lung, endometrium, prostate, breast, brain and bone (Gold I., 1999). Late-stage
tumors show an increased expression of TGF-β accompanied by a loss of the growth-
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inhibitory response to TGF-β (Oft M. et al., 1998). The mechanism for up-regulation of
TGF-β is still unknown; however, the loss of TGF-β growth-inhibitory effect appears to
result from the decrease in the levels of cyclin-dependent kinase inhibitors p21Waf and
p27Kip1 in tumors (Gold I., 1999; Rowland B. and Peeper D., 2006). Because of this dual
role, members of the TGF-β signaling pathway are being considered as predictive
biomarkers for progressive tumorigenesis, as well as molecular targets for prevention of
cancer and metastasis (Bachman E. and Park B., 2005).
The overexpression of the tumor suppressor p53 has been observed in various
forms of cancer and was not always indicating the presence of a gene mutation (Soong R.
et al., 1966).

In fact, overexpression of p53 has been observed in invasive breast

carcinomas, lung adenocarcinomas and colorectal carcinomas. (Gonzalez-Palacios F. et
al., 1997). Accumulation of the p53 protein has been found to occur during the transition
from early to advanced stages of the cancer (Kawasaki M. et al., 1996). In invasive
colorectal carcinomas, p53 overexpression was found to be associated with increased
metastatic potential (Sory A. et al., 1997).

These observations suggested that

overexpression of the tumor suppressor p53 could be used as a useful clinical indicator of
the degree of tumor malignancy and as a strong prognostic marker.
Overexpression of the SOCS(-1,-2,-3) genes and increased SOCS protein levels
have been found in breast ductal carcinomas compared to normal breast tissue (Raccurt
M. et al., 2003).

Farabegoli F. et al. (2005) reported that SOCS2 expression was

associated with high differentiation and low proliferation rate, but not with an overall
survival and that it was inversely correlated with the cyclin A, the retinoblastoma protein
(pRb) and the epidermal growth factor receptor (EGFR). This supports a role for SOCS2
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in the regulation of cell proliferation and tumor growth in breast carcinoma which may
vary depending on its level of expression (Farabegoli F. et al., 2005). Others postulated
that the increase of SOCS expression in breast cancers may be a response to the induction
of an intense production of inflammatory cytokines, mammotrophic, PRL and GH
hormones, all involved during tumorigenesis and invasion (Raccurt M. et al., 2003).
In comparison, we speculate that Rassf3 may function in a classical feedback
loop. Overexpression of the Rassf3 gene may be induced by HER2/neu proteins in
mammary tissues. In our experiments, we also found that Rassf3 expression was not
detectable in a spontaneous mammary tumor (neu negative) derived from a nontransgenic FVB mouse (data not shown). The analysis of human tumors and adjacent
normal tissues also revealed that RASSF3 overexpression pattern varies between
tissue/cancer types (Figure 13). These observations suggest that Rassf3 overexpression in
tumors is dependent on the tumor type and the context (HER2/neu oncogene-specific).
Therefore, Rassf3 overexpression may become an interesting biomarker in breast cancer.
As also observed in our results, the Etv1 transcription factor has been reported to
be overexpressed in mammary tumors of MMTV/neu transgenic mice and is believed to
play a role in neu-mediated mammary oncogenesis (Shepherd T. et al., 2001). The
expression of the Mup1 gene in normal mammary tissue, but its absence in mammary
tumors, suggest that Mup1 may be a negative tumor marker of mouse mammary tumor in
a similar way that it is for hepatocarcinomas (Dragani T. et al., 1989)
The comparison of HER2 protein and RASSF3 mRNA levels among multiple
human breast cancer cell lines, revealed an inverse correlation of expression between
these two genes (Figure 12).

After literature searching, the inverse correlation of
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expression between an oncogene and a tumor suppressor gene has been reported in
different cancers and often suggests a cooperative role between the two genes in
carcinogenesis.
Xing M. et al. (2004) have reported that RASSF1A epigenetic inactivation by
methylation was an early step in thyroid tumorigenesis and that RASSF1A methylation
status and B-RAF mutations were inversely correlated in thyroid tumor cell lines with a
mutually exclusive relationship. This indicates that thyroid tumor cell lines characterized
by RASSF1A epigenetic inactivation did not simultaneously contain activating mutations
in B-RAF. An identical inverse correlation with mutual exclusivity was documented in
non-small cell lung cancers (NSCLC) between K-RAS mutation and NORE1A
methylation (Irimia M. et al., 2004). The same inverse correlation between K-RAS
mutation and RASSF1A methylation was observed in colorectal cancers (Van Engeland
M. et al., 2003) and pancreatic adenocarcinomas (Damman R. et al., 2003). Similarly,
Hesson L. and colleagues (2005) reported that K-RAS mutation and RASSF2 promoter
hypermethylation are mutually exclusive. These observations suggest that inactivation of
RASSF gene by methylation or activating RAS mutation can provide alternative
pathways for affecting RAS signaling pathway (Xing M. et al., 2004). The mutual
exclusivity of the two alterations in genes involved in the same pathway suggests that
these genes play a critical and cooperative role in human tumorigenesis (Agathanggelou
A. et al., 2005). However, in some cancer patients, epigenetic inactivation of RASSF1A
was found with K-RAS mutations in NSCLC or with B-RAF mutations in melanomas
and was associated with a poorer outcome which suggested a synergistic mechanism of
action between the alterations (Reifenberger J. et al., 2004).
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Other types of correlation/cooperativity have been reported in the literature
involving different genes including the telomerase enzyme activity and the expression of
the p16 cell cycle negative regulator in NSCLC (Gonzalez-Quevedo R. et al., 2001),
where telomerase activity is often correlated with loss of expression of the tumor
suppressor p16 and with poorer prognosis.
Therefore, in comparison, the inverse correlation between HER2 protein levels
and RASSF3 expression in human breast cancer cell lines may suggest that HER2 and
RASSF3 genes have a cooperative role in breast carcinogenesis and that they are involved
in the same pathway.
5.4.

Functional Studies of the Rassf3 Gene in HER2/neu-positive Cell Lines
The complexity of genetic alterations in cancer is increased by the recently

emerging evidence that some genes seem to have dual functions, i.e. the same gene can
have tumor suppressor-like activities in one type of cancer, but function as an oncogene
in a different cancer setting (Rowland B. and Peeper D., 2006). Remarkably, although
RAS oncoproteins are usually associated with loss of growth control and tumorigenic
transformation (Lowy D. et al., 1993), increasing evidences have demonstrated that RAS
proteins have the ability to activate a variety of growth-inhibiting pathways including
apoptosis and cell cycle arrest (Chen C. and Faller D., 1995; Chen, C. et al., 1998; Shao
J. et al., 2000; Khokhlatchev A. et al., 2002). These contrasting activities suggest that the
activation of powerful oncogenes such as RAS can promote conflicting biological
processes in a potential tumor cell. This capacity to induce transformation or death has
also been reported for other oncoproteins, as for example c-MYC, NOTCH1 and
CDKN1A (Hueber A. and Evans G., 1998; Rowland B. and Peeper D., 2006).
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The recent discovery of the RASSF family of RAS effectors helps to understand
partly the growth inhibitory action of the RAS proteins. It has been demonstrated that
these effectors serve as tumor suppressors directly activated by RAS. Indeed, it was
shown that ectopic overexpression of NORE1 or RASSF1 genes induced growth
inhibition and apoptosis, effects which were enhanced by co-expression of activated HRAS and antagonized by co-expression of dominant inhibitory H-RAS (Vos D. et al.,
2000).

The same observations were obtained for RASSF2 and RASSF4 ectopic

expressions with activated K-RAS (Vos D. et al., 2003a; Ecfeld K. et al., 2004). The
similarity between RASSF2 and RASSF4 behavior was reinforced by the fact that they
shared 60% identity at the amino acid level (Ecfeld K. et al., 2004). Additional evidence
suggested that cyclin D1 regulation is responsive to native RASSF1A activity and that
RASSF1A can induce cell cycle arrest in NSCL (A549) cell lines (Shivakumar L. et al.,
2002).
In our study, we have identified through microarray analyses another member of
the RASSF family, the mouse homologue of the RASSF3 gene noted Rassf3. Due to the
close homology of Rassf3 gene with the other member of the RASSF family, we
hypothesized that Rassf3 may serve as a negative regulator of RAS proteins which have
been shown to be aberrantly activated (Clark G. and Der C., 1995; Von Lintig F. et al.,
2000) due to persistent upstream signaling from the HER2 receptors, often overexpressed
in breast cancer (Von Lintig F. et al., 2000). Therefore, since the novel Rassf3 gene has
remained uncharacterized, we devoted most of our efforts to determine its role in
HER2/neu tumorigenesis.

140

We demonstrated that Rassf3 ectopic expression inhibits cell proliferation of
various cell lines including the SKBR3 and BT474 human breast cancer cell lines, the
MCNeuA mouse cancer cell line and the HC11 mouse cell line, all characterized by the
expression of high levels of HER2 protein (Figure 16).

The investigation of the

mechanism by which Rassf3 promotes growth inhibition in SKBR3 cells suggested that
Rassf3 promotes cell apoptosis (Figure 17). These findings support a role for Rassf3 as a
tumor suppressor gene. In addition, our results suggested that activated H-RAS protein
interacts indirectly with RASSF3 protein (Figure 19) and enhances its growth-inhibitory
properties (Figure 20), insinuating that RASSF3 is a RAS effector.

The limited

augmentation of Rassf3 cell growth-inhibition effect by activated H-RAS co-transfection
can be explained by the fact that SKBR3 cells exhibit elevated levels of RAS-GTP
proteins and have therefore persistent RAS activation (Eckert L. et al., 2004). The
observation that a dominant-negative form of H-RAS did not abrogate Rassf3 growthinhibition may suggest that RASSF3 biological activity is not entirely dependent on HRAS activity in SKBR3 cells or that RASSF3 does not function downstream of H-RAS
for promoting its growth-inhibition effect (Figure 20). In addition, RASSF3 effector
activity may be influenced by a RAS isoform other than H-RAS. Indeed, differences in
effector binding and signaling between the different RAS isoforms have been reported for
the RASSF proteins (Yan J. et al., 1998; Rodriguez-Viciana P. et al., 2004). It is
important to note that effector utilization and activation by RAS proteins are complex and
have shown significant cell context variations (Kivinen L. et al., 1999; Coleman M. et al.,
2003).
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To further understand the mechanisms contributing to the biological activity of
the RASSF proteins, a number of studies have started identifying RASSF-interacting
proteins and potential target genes that are differentially regulated by RASSF proteins by
transfecting these proteins into various RASSF-negative cell lines (Agathanggelou A. et
al., 2003). Evidence show that RASSF1A can interact with different target molecules
including microtubules to increase their stability, with MST1 pro-apoptotic kinase to
induce apoptosis and with cell cycle regulators to arrest cell cycle progression
(Khokhlatchev A. et al., 2002; Shivakumar L. et al., 2002; Agathanggelou A. et al.,
2005). Liu L. et al. (2003) presented evidence that RASSF1A and RASSF1C may play a
role in genomic stability by binding to and regulating microtubules dynamics at the
mitotic apparatus (Song M. et al., 2004; Vos M. et al., 2004). Other scientifics showed
that exogenous RASSF1A can also block the JNK pathway in lung cancer cells (Whang
Y. et al., 2005), whereas NORE1A can inhibit MAPK activation with no apparent effect
on AKT.
The mechanism by which RASSF1 and NORE1 can promote apoptosis has been
further investigated. Researchers revealed that activated RAS can bind to RASSF1 and
NORE1 which can efficiently homodimerize and heterodimerize with each other and
further form a complex with the MST1 (Mammalian sterile 20-like kinase 1) protein
kinase through the SARAH domain to mediate a novel RAS-regulated apoptotic pathway
(Ortiz-Vega S. et al., 2002; Scheel H. and Hofman K., 2003; Praskova M. et al., 2004;
Oh J. et al., 2006). The MST1 protein is a serine/threonine kinase that contains caspase
cleavage sites and that can become activated by autophosphorylation to initiate apoptosis
(Khokhlatchev A. et al., 2002). The SARAH domain is a novel interaction motif which
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has been shown to mediate heterotypic and homotypic interactions between tumor
suppressors and MST kinases (Scheel H. and Hofman K., 2003). Since RASSF3 possess
also the SARAH domain it is not excluded that it may participate into a similar pathway
(Figure 14).

We speculate that activated RAS may bind to RASSF3 and induce

homodimerization or heterodimerization with other members of the RASSF family and
then further complex with the MST kinase to promote apoptosis.
An attempt was made to identify the molecular signaling pathways altered by
transient transfection of Rassf3 in SKBR3 cells (Figure 18). No obvious changes in
protein levels of intracellular markers involved in RAF-MAPK or JNK pathways due to
ectopic expression of RASSF3 protein were detected, which suggested that RASSF3
growth-inhibition must occur by different mechanisms. The slight decrease in p-AKT
levels may suggest that RASSF3 growth-inhibition results in a decreased activity of the
survival PI3K-AKT pathway. These observations may vary in other cell lines since the
genetic background of individual cell lines can influence the expression profile of
candidate RASSF3 target genes. Thus, the effect of Rassf3 transient expression on
intracellular signaling pathways needs further investigation.
On the other hand, the observation that RASSF3 protein reduces the level of HRAS protein following co-transfection suggest a role for RASSF3 as a negative regulator
of H-RAS proteins (Figure 19).
5.5.

Functional Study of the Rassf3 Gene in Transgenic Mice
The use of transgenic mouse technology is a powerful tool to study specific

questions in developmental and cancer biology.

Transgenic mice that carry one

particular transgene can provide deep insight into the function of a particular transgene in
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a specific tissue. So far, only one animal model used for studying a member of the
RASSF family, the RASSF1A, has been described by Tommasi S. et al. (2005). They
created a mouse knockout for Rassf1a, where the Rassf1a was specifically inactivated, to
closely mimic the situation in human tumors. They showed that Rassf1a+/- and Rassf1a-/were prone to spontaneous tumorigenesis in advanced age (18 to 20 months) and more
susceptible to chemical carcinogen-induced tumor formation. The tumors included lung
adenomas, lymphomas and breast carcinomas. These data reinforced the role of RASSF1
gene as a tumor suppressor.
Because tumor progression is a complex multi-step process involving different
signaling pathways, oncogenes or tumor suppressor genes (Huand D. et al., 1997), the
development of transgenic mice carrying more than one transgene have been shown to be
more adequate to address simultaneously multiple aspects of tumorigenesis and to
investigate the synergy between transgenes. The aim of the second part of our study was
to develop a bi-transgenic mouse line to investigate the synergy between the neu
oncogene and the Rassf3 gene in mammary glands, in order to further elucidate the role
of Rassf3 in HER2/neu-initiated breast cancer. To reach this goal, we generated two
novel transgenic mouse lines.

First, the MMTV/Rassf3 transgenic mouse line was

generated by standard cDNA microinjection technique (Wagner T. et al., 1981). Second,
the MMTV/Rassf3-neu bi-transgenic mouse line was produced by cross-breeding
MMTV/Rassf3 transgenic mice with MMTV/neu transgenic mice.
A number of bi-transgenic mouse models carrying simultaneously the neu
oncogene and other transgene have been reported in the literature. These models have
been very useful in studying the synergy between the neu oncogene and other oncogenes,
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tumor suppressors or signaling mediators and in identifying parallel and interconnected
pathways involved in HER2/neu tumorigenesis.

For example, bi-transgenic mice

generated by crossing the MMTV/neu transgenic mice with MMTV/p53 mutant mice or
null mice have demonstrated a direct cooperativity between HER2/neu and p53 pathways
in human breast cancer (Li B. et al., 1997; Blackbum A. and Jerry J., 2002). It was
reported that the introduction of the mutant p53 transgene in bi-transgenic mice reduced
tumor latency to 154 days (Blackbum A. and Jerry J., 2002).

These observations

demonstrated that p53 mutation is an important event in HER2/neu-mediated
tumorigenesis. Several bi-transgenic models studied the interaction between neu and
TGF-β, a naturally occurring potent inhibitor of cell growth. These models highlighted
that TGF-β overexpression in mammary gland is not sufficient to block neu tumorigenic
potential (Muraoka R. et al., 2003; Siegel P. et al., 2003; Gorska A. et al., 2003) and
furthermore, that TGF-β may contribute to tumor invasion and metastasis once the
carcinomas have developed. These observations reinforce the notion of a biphasic role
for TGF-β which has an anti-mitogenic effect and a prometastatic effect simultaneously
(Gold I., 1999; Rowland B. and Peeper D., 2006). Yu Q. et al. (2001) reported the cross
between cyclin D1-/- knockout mice with MMTV/neu mice. Remarkably, they showed
that the bi-transgenic mice bearing the neu oncogene but lacking cyclin D1 were
completely resistant to neu-induced mammary carcinogenesis as the mice remained
tumor-free. These findings indicated that intact cyclin D1 functions are essential for
transformation by HER2/neu. Others showed that overexpression of the p16 tumor
suppressor, which specifically blocks cyclin-dependent kinase (CDK) -4 and -6 activity,
was also able to block neu-induced tumorigenesis (Yang C. et al., 2004).

In
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consequence, it was discovered that the deregulation of the cyclin D1-CDK4/6
interactions, involved in the cell-cycle machinery, is an essential target for HER2/neu
function in breast cancer. This last discovery raised the exciting possibility that inhibitors
of cyclin D1 could specifically target human breast cancers that overexpress the
HER2/neu oncogene (Chodosh L., 2002).
The production of the novel MMTV/Rassf3 transgenic mouse line which
overexpresses the Rassf3 gene in the mammary glands under the control of the MMTV
promoter suggested that overexpression of Rassf3 does not impair mammary gland
development since the mice were viable and fertile with normal litter size and parental
behavior during weaning. The observation that the transgene transcript is also detected in
lower amounts in other tissues (e.g. brain, muscle and small intestine) beside the
mammary gland has been documented in the literature (Figure 22) (Ross S. et al., 1990;
Wagner K. et al., 1997; Guy C. et al., 1992); however, the high amount of transgene
expression in the brain tissue was a surprise.
The bi-transgenic mouse model overexpressing both the Rassf3 gene and the neu
oncogene in the mammary glands under the transcriptional control of the MMTV LTR
promoter permitted to determine the influence of Rassf3 overexpression on HER2/neu
mammary tumor formation in an in vivo model.

The results revealed that Rassf3

overexpression delays the tumor onset in the bi-transgenic mouse line (Figure 25). The
appearance of tumors in the bi-transgenic mice indicates that Rassf3 overexpression alone
is insufficient to fully suppress tumor initiation. Therefore, the resistance to HER2/neu
tumor development in the naturally tumor-resistant MMTV/neu mice may be due to the
activation of more than one suppressor or suppressor pathway. This reflects the multi-
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step model of HER2/neu tumorigenesis where more than one genetic event are involved
(Guy C. et al., 1992).

Thus, tumor heterogeneity and multiple step-tumorigenesis

emphasize the difficulty to pin point one single factor that is responsible for altering the
process of tumorigenesis and reinforce the advantages of using combined therapies which
are aimed at attacking different pathways involved in cancer development at the same
time or in a sequential manner.
The detection through Western blot analysis of the RASSF3 protein in the brain
tissue but not in the mammary gland suggested that the expression level of the RASSF3
protein is too low in the mammary glands to react with the polyclonal anti-RASSF3
antibody rather than concluding to the total absence of RASSF3 protein (Figure 23). In
addition, the presence of RASSF3 protein in the brain of the MMTV/Rassf3 and the
MMTV/Rassf3-neu transgenic mice and its absence in the littermates confirmed the
generation of Rassf3-positive transgenic mice. Therefore, the increase in mammary
tumor latency in the MMTV/Rassf3-neu bi-transgenic mice compared to their littermates
can be attributed to the expression of the Rassf3 gene in mammary tissues. We believe
that if RASSF3 expression levels and activity was boosted in the mammary gland of the
bi-transgenic mouse line, the delay in tumor onset would have been further increased for
the bi-transgenic line compared to their littermates.
RASSF3 and p-HER2 protein levels in mammary tumors of the MMTV/Rassf3neu bi-transgenic mice and the MMTV/neu+/- littermates are positively correlated,
suggesting that RASSF3 protein does not interfere directly with HER2 activity (Figure
26). We speculate that the high level of RASSF3 found in tumors is not the causal factor
but actually reflects the results of a cellular/host defensive response in this case. It

147

appears that RASSF3 expression is induced in response to HER2 activity in HER2/neupositive tumors and that RASSF3 inhibits tumor growth by acting as a negative regulator
of constitutively activated RAS.
Finally, the findings that Rassf3 is overexpressed in the mammary gland of tumorresistant MMTV/neu female transgenic mice and in addition that Rassf3 delays tumor
onset in the bi-transgenic mouse model are strong indicators that a particular RASeffector pathway, involving the RASSF3 effector, plays a role in HER2/neutumorigenesis.
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6.

CONCLUSION

The overexpression of the HER2/neu oncogene in human breast cancer is
associated with increased disease recurrence and worse prognosis.

A better

understanding of the fundamental biology and pathogenetic effects of HER2/neu
overexpression in human breast cancer remains a major focus. In this study, we used the
well-characterized MMTV/neu female transgenic mouse model to study HER2/neu breast
cancer and in particular the factors involved in the inhibition of HER2/neu-initiated
tumorigenesis.
By focusing on the MMTV/neu mice that naturally become tumor-resistant and
by using comparative genetic profiling, we identified a novel gene, the Ras Association
domain (RalGDS/AF-6) Family 3 (Rassf3), as one of the candidate genes that may
influence the mammary tumor incidence in female MMTV/neu transgenic mice.
We provided evidence suggesting an important role for the Rassf3 gene in the
process of HER2/neu-initiated mammary tumorigenesis. Our data demonstrated: 1) that
the Rassf3 gene is overexpressed in the mammary gland of tumor-resistant MMTV/neu
mice compared to the tumor-susceptible MMTV/neu transgenic littermates or agematched non-transgenic FVB mice, and 2) that the Rassf3 gene is significantly upregulated in neu-specific mouse mammary tumors compared to adjacent normal
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tissues. The expression pattern of the Rassf3 gene in mammary tumors and adjacent
mammary glands varies depending on the tissue/cancer type and the context (HER2/neu
oncogene).
Furthermore, we reported the first functional study for the Rassf3 gene using in
vitro and in vivo models. Our results showed that Rassf3 overexpression inhibits cell
proliferation in HER2/neu-positive human and mouse breast cancer cell lines, possibly
through induction of apoptosis. In addition, our results suggest a possible interaction
between RASSF3 and H-RAS proteins.

Through the establishment of a novel

MMTV/Rassf3-neu bi-transgenic mouse line which overexpresses both Rassf3 and neu
genes in the mammary glands, we demonstrated that Rassf3 overexpression delays the
onset of mammary tumor formation.
These findings suggest that the Rassf3 gene exhibits the properties of a RAS
effector and tumor suppressor gene similar to other members of the RASSF family
already characterized by other researchers. Overexpression of the Rassf3 gene may be
induced by the high levels of HER2/neu proteins in the mammary gland. Rassf3 may
then inhibit cell proliferation and tumor growth by acting as a negative regulator of
activated RAS. We speculate that the high levels of RASSF3 found in tumors are the
results of a cellular defensive response in this case. However, the molecular mechanism
of growth-inhibition of the Rassf3 gene and its particular role in HER2/neu tumor
initiation and progression needs further investigation
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Finally, this study presented an innovative approach for studying the already welldocumented MMTV/neu transgenic mouse model. The focus on the naturally tumorresistant MMTV/neu female transgenic mice allowed the identification of the novel
Rassf3 gene as a candidate tumor suppressor involved in the resistance to HER2/neuinitiated mammary tumorigenesis.

151

BIBLIOGRAPHY

Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S.,
Palmiter R.D., Brinster R.L. The c-myc oncogene driven by immunoglobulin
enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985 Dec 1218;318(6046):533-8.
Agathanggelou A. , Bieche I., Ahmed-Choudhury J., Nicke B., Dammann R., Baksh S.,
Gao B., Minna J.D., Downward J., Maher E.R., Latif F. Identification of novel gene
expression targets for the Ras association domain family 1 (RASSF1A) tumor
suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Res. 2003
Sep 1;63(17):5344-51.
Agathanggelou A., Cooper W.N., Latif F. Role of the Ras-association domain family 1
tumor suppressor gene in human cancers. Cancer Res. 2005 May 1;65(9):3497-508.
Alaoui-Jamali M.A., Song D.J., Benlimame N., Yen L., Deng X., Hernandez-Perez M.,
Wang T. Regulation of multiple tumor microenvironment markers by overexpression
of single or paired combinations of ErbB receptors. Cancer Res. 2003 Jul
1;63(13)3764-74.
Alexander W.S., Hilton D.J. The role of suppressors of cytokine signaling (SOCS)
proteins in regulation of the immune response. Annu Rev Immunol. 2004;22:503-29.
Aoyama Y., Avruch J., Zhang X.F. Nore1 inhibits tumor cell growth independent of Ras
or the MST1/2 kinases. Oncogene. 2004 Apr 22;23(19):3426-33.
Arteaga C.L., Moulder S.L., Yakes F.M. HER(erbB) tyrosine kinase inhibitors in the
treatment of breast cancer. Semin Oncol. 2002 Jun;29(3 Suppl 11): 4-10.
Auerbach A.B. Production of functional transgenic mice by DNA pronuclear
microinjection. Acta Biochim Pol. 2004;51(1):9-31.
Aviel-Ronen S., Blackhall F.H., Shepherd F.A., Tsao M.S. K-ras mutations in nonsmall-cell lung carcinoma: a review. Clin Lung Cancer. 2006 Jul;8(1):30-8.
Bachman K.E., Park B.H. Duel nature of TGF-beta signaling: tumor suppressor vs. tumor
promoter. Curr Opin Oncol. 2005 Jan;17(1):49-54.

152

Baert J.L., Monte D., Musgrove E.A., Albagli O., Sutherland R.L., de Launoit Y.
Expression of the PEA3 group of ETS-related transcription factors in human breastcancer cells. Int J Cancer. 1997 Mar 4;70(5):590-7.
Bargmann C.I., Weinberg R.A. Oncogenic activation of the neu-encoded receptor protein
by point mutation and deletion. EMBO J. 1988 Jul;7(7):2043-52.
Baselga J., Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer
therapy. Pharmacol Ther. 1994 Oct;64(1):127-54.
Bazley L.A., Gullick W.J. The epidermal growth factor receptor family. Endocr Relat
Cancer. 2005 Jul;12 Suppl 1: S17-27.
Belsches-Jablonski A.P., Biscardi J.S., Peavy D.R., Tice D.A., Romney D.A., Parsons
S.J. Src family kinases and HER2 interactions in human breast cancer cell growth and
survival. Oncogene. 2001 Mar 22;20(12):1465-75.
Ben-Levy R., Paterson H.F., Marshall C.J., Yarden Y. A single autophosphorylation site
confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP
kinase pathway. EMBO J. 1994;13:3302-3311.
Bertram J., Killian M., Brysch W., Schlingensiepen K.H., Kneba M. Reduction of erbB2
gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine
kinase consensus phosphorothioate antisense oligonucleotides. Biochem Biophys Res
Commun. 1994 Apr 15;200(1):661-7.
Blackburn A.C., Jerry D.J. Knockout and transgenic mice of Trp53: what have we
learned about p53 in breast cancer? Breast Cancer Res. 2002;4(3):101-111.
Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 1989 Sep 1;49(17):46829.
Bouchard L., Lamarre L., Tremblay P.J., Jolicoeur P. Stochastic appearance of mammary
tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell. 1989 Jun
16;57(6):931-6.
Brandt R., Ebert A.D. Growth inhibitors for mammary epithelial cells. Prog Mol Subcell
Biol. 1998;20:197-248.
Burbee D.G., Forgacs E., Zochbauer-Muller S., Shivakumar L., Fong K., Gao B., Randle
D., Kondo M., Virmani A., Bader S., Sekido Y., Latif F., Milchgrub S., Toyooka S.,
Gazdar A.F., Lerman M.I., Zabarovsky E., White M., Minna J.D. Epigenetic
inactivation of RASSF1A in lung and breast cancers and malignant phenotype
suppression. J Natl Cancer Inst. 2001 May 2;93(9):691-9.

153

Campbell M.J., Wollish W.S., Lobo M., Esserman L.J. Epithelial and fibroplast cell lines
derived from a spontaneous mammary carcinoma in a MTV/neu transgenic mouse. In
Vitro Cell Dev Biol Anim. 2002 Jun;38(6):326-33.
Capecchi M.R. The new mouse genetics: altering the genome by gene targeting. Trends
Genet. 1989 Mar;5(3):70-6.
Caponigro F. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy?
Naples, 12 April 2002. Anticancer Drugs. 2002 Sep;13(8):891-7.
Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland
A.M., Kotts C., Carver M.E., Shepard H.M. Humanization of an anti-p185HER2
antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992
May15;89(10):4285-9.
Chen C.Y., Faller D.V. Direction of p21 ras-generated signals towards cell growth or
apoptosis is determined by protein kinase C and Bcl-2. Oncogene. 1995 Oct
19;11(8):1487-98.
Chen C.Y., Liou J., Forman L.W., Faller D.V. Differential regulation of discrete
apoptotic pathways by Ras. J Biol Chem. 1998 Jul 3;273(27):16700-9.
Chen Y., Emtage P., Zhu Q., Foley R., Muller W., Hitt M., Gauldie J., Wan Y. Induction
of ErbB-2/neu-specific protective and therapeutic antitumor immunity using
genetically modified dendritic cells: enhanced efficacy by cotransduction of gene
encoding IL-12. Gene Ther. 2001 Feb;8(4):316-23.
Chodosh L.A. The reciprocal dance between cancer and development. N Engl J Med.
2002 Jul 11;347(2):134-6.
Chong H., Vikis H.G., Guan K.L. Mechanisms of regulating the Raf kinase family. Cell
Signal. 2003 a May;15(5):463-9.
Chong H., Guan K.L. Regulation of Raf through phosphorylation and N terminus-C
terminus interaction. J Biol Chem. 2003 b Sep 19;278(38):36269-76.
Choy E., Chiu V.K., Silletti J., Feoktistov M., Morimoto T., Michaelson D., Ivanov I.E.,
Philips M.R. Endomembrane trafficking of ras: the CAAX motif targets proteins to
the ER and Golgi. Cell. 1999 Jul 9;98(1):69-80.
Christofori G., Semb H. The role of the cell-adhesion molecule E-cadherin as a tumorsuppressor gene. Trends Biochem Sci. 1999 Feb;24(2):73-6.
Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the
epidermal growth factor receptor. Clin Cancer Res. 2001 Oct;7(10):29958-70.

154

Clark G.J., Der C.J. Aberrant function of the Ras signal transduction pathway in human
breast cancer. Breast Cancer Res Treat. 1995 Jul;35(1):133-44.
Coleman M.L., Marshall C.J., Olson M.F. Ras promotes p21(Waf1/Cip1) protein stability
via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J. 2003
May 1;22(9):2036-46.
Cox A.D., Der C.J. Ras family signaling: therapeutic targeting. Cancer Biol Ther. 2002
Nov-Dec;1(6):599-606.
Cox A.D., Der C.J. The dark side of Ras: regulation of apoptosis. Oncogene. 2003 Dec
8;22(56):8999-9006.
Cuatrecasas M., Villanueva A., Matias-Guiu X., Prat J. K-ras mutations in mucinous
ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer. 1997
Apr 15;79(8):1581-6.
Dammann R., Yang G., Pfeifer G.P. Hypermethylation of the CpG island of Ras
association domain family 1A (RASSF1A), a putative tumor suppressor gene from
the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res.
2001 Apr 1;61(7):3105-9.
Dammann R., Schagdarsurengin U., Liu L., Otto N., Gimm O., Dralle H., Boehm B.O.,
Pfeifer G.P., Hoang-Vu C. Frequent RASSF1A promoter hypermethylation and K-ras
mutations in pancreatic carcinoma. Oncogene. 2003 Jun 12;22(24):3806-12.
Dancey J.E. Agents targeting ras signaling pathway. Curr Pharm Des. 2002;8(25):225967.
De Risi J., Penland L., Brown P.O., Bittner M.L., Meltzer P.S., Ray M., Chen Y., Su Y.
A., Trent J.M. Use of a cDNA microarray to analyse gene expression patterns in
human cancer. Nat Genet. 1996 Dec;14(4):457-60.
De Santes K., Slamon D., Anderson S.K., Shepard M., Fendly B., Maneval D., Press O.
Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res. 1992
Apr 1;52(7):1916-23.
Di Fiore P.P., Pierce J.H., Kraus M.H., Segatto O., King C.R., Aaronson S.A. erbB-2 is a
potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987 Jul
10;237(4811):178-82.
Dowdy S.C., Mariani A., Janknecht R. HER2/Neu- and TAK1-mediated up-regulation of
the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81. J Biol
Chem.. 2003 Nov 7;278(45):44377-84.

155

Dragani T.A., Manenti G., Sacchi M.R., Colombo B.M., Della Porta G. Major urinary
protein as a negative tumor marker in mouse hepatocarcinogenis. Mol Carcinog.
1989;2(6):355-60.
Drebin J.A., Link V.C., Weinberg R.A., Greene M.I. Inhibition of tumor growth by a
monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl
Acad Sci USA. 1986 Dec;83(23):9129-33.
Dressman M.A., Baras A., Malinowski R., Alvis L.B;, Kwon I., Walz T.M.,
Polymeropoulos M.H. Gene expression profiling detects gene amplification and
differentiates tumor types in breast cancer. Cancer Res. 2003 May 1;63(9):2194-9.
Eberharter A., Becker P.B. Histone acetylation: a switch between repressive and
permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep.
2002 Mar;3(3):224-9.
Eckert L.B., Repasky G.A., Ulku A.S., McFall A., Zhou H., Sartor C.I., Der C.J.
Involvement of Ras activation in human breast cancer cell signaling, invasion, and
anoikis. Cancer Res. 2004 Jul 1;64(13):4585-92.
Eckfeld K., Hesson L., Vos M.D., Bieche I., Latif F., Clark G.J. RASSF4/AD037 is a
potential ras effector/tumor suppressor of the RASSF family. Cancer Res. 2004 Dec
1;64(23):8688-93.
Elliott J., Johnston J.A. SOCS: role in inflammation, allergy and homeostasis.Trends
Immunol. 2004 Aug;25(8):434-40.
Endoh M., Tamura G., Honda T., Homma N., Terashima M., Nishizuka S., Motoyama T.
RASSF2, a potential tumor suppressor, is silenced by CpG island hypermethylation in
gastric cancer. Br J Cancer. 2005 Dec 12;93(12):1395-9.
Farabegoli F., Ceccarelli C., Santini D., Taffurelli M. Suppressor of cytokine signaling 2
(SOCS-2) expression in breast carcinoma. J Clin Pathol. 2005 Oct;58(10):1046-50.
Favre H., Benhamou A., Finidori J., Kelly P.A., Edery M. Dual effects of suppressor of
cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett.
1999 Jun 18;453(1-2):63-6.
Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002
Dec;29(6 Suppl 16):15-8.
Furth P.A., Hennighausen L., Baker C., Beatty B., Woychick R. The variability in
activity of the universally expressed human cytomegalovirus immediate early gene 1
enhancer/promoter in transgenic mice. Nucleic Acids Res. 1991 Nov 25;19(22):62058.

156

Gasparini G., Gullick W.J., Maluta S., Dalla Palma P., Caffo O., Leonardi E., Boracchi
P., Pozza F., Lemoine N.R., Bevilacqua P. c-erbB-3 and c-erbB-2 protein expression
in node-negative breast carcinoma – an immunocytochemical study. Eur J Cancer.
1994;30A(1):16-22.
Gill G.N., Kawamoto T., Cochet C., Le A., Sato J.D., Masui H., McLeod C., Mendelsohn
J. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors
of epidermal growth factor binding and antagonists of epidermal growth factor
binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase
activity. J Biol Chem. 1984 Jun 25; 259(12):7755-60.
Gille H., Downward J. Multiple ras effector pathways contribute to G(1) cell cycle
progression. J Biol Chem. 1999 Jul 30;274(31):22033-40.
Gilliland D.G. The diverse role of the ETS family of transcription factors in cancer. Clin
cancer Res. 2001 Mar;7(3):451-3.
Goel A., Janknecht R. Acetylation-mediated transcriptional activation of the ETS protein
ER81 by p300, P/CAF, and HER2/Neu. Mol Cell Biol. 2003 Sep;23(17):6243-54.
Goel A., Janknecht R. Concerted activation of ETS protein ER81 by p160 coactivators,
the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J Biol Chem.
2004 Apr 9;279(15):14909-16.
Gold L.T. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit
Rev Oncog. 1999;10(4):303-60.
Gonzalez-Quevedo R., Iniesta P., Moran A., de Juan C., Sanchez-Pernaute A., Fernandez
C., Torres A., Diaz-Rubio E., Balibrea J.L., Benito M. Cooperative role of telomerase
activity and p16 expression in the prognosis of non-small-cell lung cancer. J Clin
Oncol. 2002 Jan 1;20(1):254-62.
Gonzalez-Palacios F., Sancho M., Martinez J.C., Bellas C. Microvessel density, p53
overexpression, and apoptosis in invasive breast carcinoma. Mol. Pathol. 1997
Dec;50(6):304-9.
Gordon J.W., Scangos G.A., Plotkin D.J., Barbosa J.A., Ruddle F.H. Genetic
transformation of mouse embryos by microinjection of purified DNA. Proc Natl Acad
Sci USA. 1980 Dec;77(12):7380-4.
Gordon J.W., Ruddle F.H. Integration and stable germ line transmission of genes injected
into mouse pronuclei. Science. 1981 Dec 11;214(4526):1244-6.

157

Gorska A.E., Jensen R.A., Shyr Y., Aakre M.E., Bhowmick N.A., Moses H.L.
Transgenic mice expressing a dominant-negative mutant type II transforming growth
factor-beta receptor exhibit impaired mammary development and enhanced mammary
tumor formation. Am J Pathol. 2003 Oct;163(4):1539-49.
Gossen M., Bujard H. Tight control of gene expression in mammalian cells by
tetracycline-responsive promoters. Proc Natl Acad Sci USA. 1992 Jun
15;89(12):5547-51.
Goueli B.S., Janknecht R. Upregulation of the Catalytic Telomerase Subunit by the
Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol.
2004 Jan;24(1):25-35.
Guy C.T., Webster M.A., Schaller M., Parsons T.J., Cardiff R.D., Muller W.J. Expression
of the neu protooncogene in the mammary epithelium of transgenic mice induces
metastatic disease. Proc Natl Acad Sci USA. 1992 Nov 15;89(22):10578-82.
Guzman R.C., Yang J., Rajkumar L., Thordarson G., Chen X., Nandi S. Hormonal
prevention of breast cancer: mimicking the protective effect of pregnancy. Proc Natl
Acad Sci USA. 1999 Mar 2;96(5):2520-5.
Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70.
Hann B.C., Lane D.P. The dominating effect of mutant p53. Nat Genet. 1995 Mar;
9(3):221-2.
Harari D., Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast
cancer. Oncogene. 2000 Dec 11;19(53):6102-14.
Harley C.B., Kim N.W. Telomerase and cancer. Important Adv Oncol. 1996;57-67
Harries M., Smith I. The development and clinical use of trastuzumab (Herceptin).
Endocr Relat Cancer. 2002 Jun;9(2):75-85.
Harris A.L., Nicholson S., Sainsbury J.R., Farndon J., Wright C. Epidermal growth factor
receptors in breast cancer: association with early relapse and death, poor response to
hormones and interactions with neu. J Steroid Biochem. 1989;34(1-6):123-31.
Hennighausen L. Mouse models for breast cancer. Breast Cancer Res. 2000;2(1):2-7.
Herrmann C. Ras-effector interactions: after one decade. Curr Opin Struct Biol. 2003
Feb;13(1):122-9.
Hesson L., Dallol A., Minna J.D., Maher E.R., Latif F. Nore1A, a homologue of
RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene. 2003
Feb 13;22(6):947-54.

158

Hesson L., Bieche I., Krex D., Criniere E., Hoang-Xuan K., Maher E.R., Latif F.
Frequent epigenetic inactivation of RASSF1A and BLU genes located within the
critical 3p21.3 region in gliomas. Oncogene. 2004 Mar 25;23(13):2408-19.
Hesson L.B., Wilson R., Morton D., Adams C., Walker M., Maher E.R., Latif F. CpG
island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early
event in colon carcinogenesis and correlates inversely with K-ras mutations.
Oncogene. 2005 Jun 2;24(24):3987-94.
Hilton D.J. Negative regulators of cytokine signal transduction. Cell Mol Life Sci. 1999
Sep;55(12):1568-77.
Hofker M.H., van Deursen J. Transgenic mouse: Methods and Protocols. Humana Press,
Totowa N.J., 2003;392 p.
Howell A., Osborne C.K., Morris C., Wakeling A.E. ICI 182,780 (Faslodex):
development of a novel, “pure” antiestrogen. Cancer. 2000 Aug 15;89(4):817-25.
Hu C.D., Kariya K., Tamada M., Akasaka K., Shirouzu M., Yokoyama S., Kataoka T.
Cysteine-rich region of Raf-1 interacts with activator domain of post-translationally
modified Ha-Ras. J Biol Chem. 1995 Dec 22;270(51):30274-7.
Huang D.P., Ng M.H., Lo K.W., Lee J.C. Molecular basis of cancer. Hong Kong Med J.
1997 Jun;3(2):186-194.
Huang Y., Li X., Jiang J., Frank S.J. Prolactin modulates phosphorylation, signaling and
trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Oncogene. 2006 Jun 19.
Hudziak R.M., Schlessinger J., Ullrich A. Increased expression of the putative growth
factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.
Proc Natl Acad Sci USA. 1987 Oct;84(20):7159-63.
Hudziak R.M., Lewis G.D., Winget M., Fendly B.M., Shepard H.M., Ullrich A.
p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes
human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989
Mar;9(3):1165-72.
Hueber A.O., Evan G.I. Traps to catch unwary oncogenes. Trends Genet. 1998
Sep;14(9):364-7.
Hussain S.A., Palmer D.H., Moon S., Rea D.W. Endocrine therapy and other targeted
therapies for metastatic breast cancer. Expert Rev Anticancer Ther. 2004
Dec;4(6):1179-95.

159

Im Y.H., Kim H.T., Lee C., Poulin D., Welford S., Sorensen P.H., Denny C.T., Kim S.J.
EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all
suppress transcription of transforming growth factor beta type II receptor gene.
Cancer Res. 2000 Mar 15;60(6):1536-40.
Irimia M., Fraga M.F., Sanchez-Cespedes M., Esteller M. CpG island promoter
hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wildtype K-ras in lung cancer. Oncogene. 2004 Nov 11;23(53):8695-9.
Jacks T., Fazeli A., Schmitt E.M., Bronson R.T., Goodell M.A., Weinberg R.A. Effects
of an Rb mutation in the mouse. Nature. 1992 Sep 24;359(6393):295-300.
Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T.,
Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994 Jan
1;4(1):1-7.
Jaenisch R. Germ line integration and Mendelian transmission of the exogenous Moloney
leukemia virus. Proc Natl Acad Sci USA. 1976 Apr;73(4):1260-4.
Jiang X., Sorkin A. Coordinated traffic of Grb2 and Ras during epidermal growth factor
receptor endocytosis visualized in living cells. Mol Biol Cell. 2002 May;13(5):152235.
Jiang X., Roth L., Lai C., Li X. Profiling activities of transcription factors in breast
cancer cell lines. Assay Drug Dev Technol. 2006 Jun;4(3):293-305.
Johnston J.A. Are SOCS suppressors, regulators, and degraders? J Leukoc Biol.
2004;75:743-8.
Johnston J.A. Are SOCS suppressors, regulators, and degraders? J Leukoc Biol. 2004
Johnston S.R., Kelland L.R. Farnesyl transferase inhibitors-a novel therapy for breast
cancer. Endocr Relat Cancer. 2001 Sep;8(3):227-35.
Karunagaran D., Tzahar E., Beerli R.R., Chen X., Graus-Porta D., Ratzkin B.J., Seger R.,
Hynes N.E., Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF
receptors: implications for breast cancer. EMBO J. 1996 Jan 15; 15(2):254-64.
Katz M.E., McCormick F. Signal transduction from multiple Ras effectors. Curr Opin
Genet Dev. 1997 Feb;7(1):75-9.
Kauraniemi P., Barlund M., Monni O., Kallioniemi A. New amplified and highly
expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA
microarrays. Cancer Res. 2001 Nov 15;61(22):8235-40.

160

Kawasaki M., Noguchi M., Morikawa A., Matsuno Y., Yamada T., Hirohashi S., Kondo
H., Shimosato Y. Nuclear p53 accumulation by small-sized adenocarcinomas of the
lung. Pathol Int. 1996 Jul;46(7):486-90.
Kelly P.A., Bachelot A., Kedzia C., Hennighausen L., Ormandy C.J., Kopchick J.J.,
Binart N. The role of prolactin and growth hormone in mammary gland
development. Mol Cell Endocrinol. 2002 Nov 29;197(1-2):127-31.
Kelsey J.L., Gammon M.D., John E.M. Reproductive factors and breast cancer.
Epidemiol Rev. 1993;15(1):36-47.
Kenney N.J., Saeki T., Gottardis M., Kim M., Garcia-Morales P., Martin M.B.,
Normanno N., Ciardiello F., Day A., Cutler M.L., et al. Expression of transforming
growth factor alpha antisense mRNA inhibits the estrogen-induced proliferation of
estrogen-responsive human breast cancer cells. J Cell Physiol. 1993 Sep;156(3):497514.
Khokhlatchev A., Rabizadeh S., Xavier R., Nedwidek M., Chen T., Zhang X.F., Seed B.,
Avruch J. Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol.
2002 Feb 19;12(4):253-65.
Kilby N.J., Snaith M.R., Murray J.A. Site-specific recombinases: tools for genome
engineering. Trends Genet. 1993 Dec;9(12):413-21.
King R.J.B. Cancer biology. Second Edition. Prentice Hall, Harlow England, 2000;308 p.
Kivinen L., Tsubari M., Haapajarvi T., Datto M.B., Wang X.F., Laiho M. Ras induces
p21Cip1/Waf1 cyclin kinase inhibitor transcriptionally through Sp1-binding sites.
Oncogene. 1999 Nov 4;18(46):6252-61.
Knowlden J.M., Gee J.M., Seery L.T., Farrow L., Gullick W.J., Ellis I.O., Blamey R.W.,
Robertson J.F., Nicholson R.I. c-erbB3 and c-erbB4 expression is a feature of the
endocrine responsive phenotype in clinical breast cancer. Oncogene. 1998 Oct
15;17(15):1949-57.
Kopp J.L., Wilder P.J., Desler M., Kim J.H., Hou J., Nowling T., Rizzino A. Unique and
selective effects of five Ets family members, Elf3, Ets1, Ets2, PEA3, and PU.1, on the
promoter of the type II transforming growth factor-beta receptor gene. J Biol Chem..
2004 May 7;279(19):19407-20.
Kordon E.C., Smith G.H. An entire functional mammary gland may comprise the
progeny from a single cell. Development. 1998 May; 125(10):1921-30.
Kuhn R., Schwenk F. Conditional knockout mice. Methods Mol Biol. 2003;209:159-85.

161

Lambert J.M., Lambert Q.T., Reuther G.W., Malliri A., Siderovski D.P., Sondek J.,
Collard J.G., Der C.J. Tiam 1 mediates Ras activation of Rac by a PI(3)Kindependent mechanism. Nat Cell Biol. 2002 Aug;4(8):621-5.
Largaespada D.A. Haploinsufficiency for tumor suppression: the hazards of being single
and living a long time. J Exp Med. 2001 Feb 19;193(4):F15-8.
Largaespada D.A. Genetically modified mice in cancer research. Methods Mol Biol.
2003;209:311-32.
Larsen L., Ropke C. Suppressors of cytokine signaling: SOCS. APMIS.2002
Dec;110(12):833-44.
Lee P.D., Sladek R., Greenwood C.M., Hudson T.J. Control genes and variability:
absence of ubiquitus reference transcripts in diverse mammalian expression studies.
Genome Res. 2002 Feb;12(2):292-7.
Lemoine N.R., Staddon S., Dickson C., Barnes D.M., Gullick W.J. Absence of activating
transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer.
Oncogene. 1990 Feb;5(2):237-9.
Leung K.C., Doyle N., Ballesteros M., Sjogren K., Watts C.K., Low T.H., Leong G.M.,
Ross R.J., Ho K.K. Estrogen inhibits GH signaling by suppressing GH-induced JAK2
phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci USA. 2003 Feb
4;100(3):1016-21.
Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 1997 Feb
7;88(3):323-31.
Levitzki A. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and
dissectors of signal transduction. FASEB J. 1992 Nov;6(14):3275-82.
Li B., Rosen J.M., McMenamin-Balano J. Muller W.J., Perkins A.S. neu/ERBB2
cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol
Cell Biol. 1997 Jun;17(6):3155-63.
Linnemann T., Geyer M., Jaitner B.K., Block C., Kalbitzer H.R., Wittinghofer A.,
Herrmann C. Thermodynamic and kinetic characterization of the interaction between
the Ras binding domain of AF6 and members of the Ras subfamily. J Biol Chem.
1999 May 7;274(19):13556-62.
Linnemann T., Kiel C., Herter P., Herrmann C. The activation of RalGDS can be
achieved independently of its Ras binding domain. Implications of an activation
mechanism in Ras effector specificity and signal distribution. J Biol Chem. 2002 Mar
8;277(10):7831-7.

162

Liu L., Tommasi S., Lee D.H., Dammann R., Pfeifer G.P. Control of microtubule
stability by the RASSF1A tumor suppressor. Oncogene. 2003 Nov 6; 22(50):8125-36.
Lodish H., Berk A., Zipursky S.L., Baltimore D., Darnell J. Molecular Cell Biology.
Fourth Edition. W. H. Freeman and Company, New York, 2001; 1084p.
Lonardo F., Di Marco E., King C.R., Pierce J.H., Segatto O., Aaronson S.A., Di Fiore
P.P. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with
constitutive activity in the absence of ligand. New Biol. 1990 Nov;2(11):992-1003.
Lowy D.R., Johnson M.R., DeClue J.E., Cen H., Zhang K., Papageorge A.G., Vass W.C.,
Willumsen B.M., Valentine M.B., Look A.T. Cell transformation by ras and
regulation of its protein product. Ciba Found Symp. 1993;176:67-80.
Mackay A., Jones C., Dexter T., Silva R.L., Bulmer K., Jones A., Simpson P., Harris
R.A., Jat P.S., Neville A.M., Reis L.F., Lakhani S.R., O’Hare M.J. cDNA microarray
analysis of genes associated with ERBB2 (HER2/neu) overexpression in human
mammary luminal epithelial cells. Oncogene. 2003 May 1;22(17):2680-8.
McLellan E.A., Owen R.A., Stepniewska K.A., Sheffield J.P., Lemoine N.R. High
frequency of K-ras mutations in sporadic colorectal adenomas. Gut. 1993
Mar;34(3):392-6.
Medema R.H, Bos J.L. The role of p21ras in receptor tyrosine kinase signaling. Crit Rev
Oncog. 1993; 4(6):615-61.
Medina D., Smith G.H. Chemical carcinogen-induced tumorigenesis in parous, involuted
mouse mammary glands. J Natl Cancer Inst. 1999 Jun 2;91(11):967-9.
Medina D. Mammary developmental fate and breast cancer risk. Endocr Relat Cancer.
2005 Sep;12(3): 483-95.
Mendelson J. Blockade of receptors for growth factors: an anticancer therapy - the fourth
annual Joseph H Burchenal American Association of Cancer Research Clinical
Research Award Lecture. Clin Cancer Res. 2000 Mar;6(3):747-53.
Mendelsohn J., Baselga J. Status of epidermal growth factor receptor antagonists in the
biology and treatment of cancer. J Clin Oncol. 2003 Jul 15;21(14):2787-99.
Miles D.W. Update on HER-2 as a target for cancer therapy: herceptin in the clinical
setting. Breast Cancer Res. 2001; 3(6):380-4.
Miller M.E., Michaylira C.Z., Simmons J.G., Ney D.M., Dahly E.M., Heath J.K., Lund
P.K. Suppressor of cytokine signaling-2: a growth hormone-inducible inhibitor of
intestinal epithelial cell proliferation. Gastroenterology. 2004 Aug;127(2):570-81.

163

Morris C., Wakeling A. Fulvestrant (‘Faslodex’) - a new treatment option for patients
progressing on prior endocrine therapy. Endocr Relat Cancer. 2002 Dec; 9(4):267-76.
Muller W.J., Sinn E., Pattengale P.K., Wallace R., Leder P. Single-step induction of
mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.
Cell. 1988 Jul 1;54(1):105-15.
Muraoka R.S., Koh Y., Roebuck L.R., Sanders M.E., Brantley-Sieders D., Gorska A.E.,
Moses H.L., Arteaga C.L. Increased malignancy of Neu-induced mammary tumors
overexpressing active transforming growth factor beta1. Mol Cell Biol. 2003
Dec;23(23):8691-703.
Naumov G.N., Akslen L.A., Folkman J. Role of angiogenesis in human tumor dormancy:
animal models of the angiogenic switch. Cell cycle. 2006 Aug;5(16);1779-87
Neve R.M., Sutterlüty H., Pullen N., Lane H.A., Daly J.M., Krek W., Hynes N.E. Effects
of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene.
2000;19:1647-1656.
Oft M., Heider K.H., Beug H. TGFbeta signaling is necessary for carcinoma cell
invasiveness and metastasis. Curr Biol. 1998 Nov 19;8(23):1243-52.
Oh J.J., Grosshans D.R., Wong S.G., Slamon D.J. Identification of differentially
expressed genes associated with HER-2/neu overexpression in human breast cancer
cells. Nucleic Acids Res. 1999 Oct 15;27(20):4008-17.
Oh H.J., Lee K.K., Song S.J., Jin M.S., Song M.S., Lee J.H., Im C.R., Lee J.O., Yonehara
S., Lim D.S. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis.
Cancer Res. 2006 Mar 1;66(5):2562-9.
O’Hagan R.C., Hassel J.A. The PEA3 Ets transcription factor is a downstream target of
the HER2/Neu receptor tyrosine kinase. Oncogene. 1998 Jan 22;16(3):301-10.
Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network:
receptor heterodimerization in development and cancer. EMBO J. 2000 Jul 3;
19(13):3159-67.
Olayioye M.A. Intracellular signaling pathways of ErbB2/HER-2 and family members.
Breast Cancer Res. 2001a;3:385-389.
Olayioye M.A. Update on HER-2 as a target for cancer therapy: intracellular signaling
pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001b;3(6):3859.

164

O’Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S.,
Cao Y., Sage E.H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that
mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994 Oct
21;79(2):315-28.
Ortiz-Vega S., Khokhlatchev A., Nedwidek M., Zhang X.F., Dammann R., Pfeifer G.P.,
Avruch J. The putative tumor suppressor RASSF1A homodimerizes and
heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene. 2002 Feb
21;21(9):1381-90.
Osborne C.K., Shou J., Massarweh S., Schiff R. Crosstalk between estrogen receptor and
growth factor receptor pathways as a cause for endocrine therapy resistance in breast
cancer. Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):865s-70s.
Pacold M.E., Suire S., Perisic O., Lara-Gonzalez S., Davis C.T., Walker E.H., Hawkins
P.T., Stephens L., Eccleston J.F., Williams R.L. Crystal structure and functional
analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell. 2000
Dec 8;103(6):931-43.
Paige A.J. Redefining tumour suppressor genes: exceptions to the two-hit hypothesis.
Cell Mol Lif Sci. 2003 Oct;60(10):2147-63.
Palmiter R.D., Chen H.Y., Brinster R.L. Differential regulation of metallothioneinthymidine kinase fusion genes in transgenic mice and their offspring. Cell. 1982
Jun;29(2):701-10.
Paterson M.C., Dietrich K.D., Danyluk J., Paterson A.H., Lees A.W., Jamil N., Hanson
J., Jenkins H., Krause B.E., McBlain W.A., et al. Correlation between c-erbB-2
amplification and risk of recurrent disease in node-negative breast cancer. Cancer
Res. 1991 Jan 15; 51(2):556-67.
Perez-Escamilla R., Guerrero M.L. Epidemiology of breastfeeding: advances and
multidisciplinary applications. Adv Exp Med Biol. 2004;554:45-59.
Petit A.M., Rak J., Hung M.C., Rockwell P., Goldstein N., Fendly B., Kerbel R.S.
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor
tyrosine kinases down-regulate vascular endothelial growth factor production by
tumor cells in vitro and in vivo: angiogenic implications for signal transduction
therapy of solid tumors. Am J Pathol. 1997 Dec;151(6):1523-30.
Pierce J.H., Arnstein P., DiMarco E., Artrip J., Kraus M.H., Lonardo F., Di Fiore P.P.,
Aaronson S.A. Oncogenic potential of erbB-2 in human mammary epithelial cells.
Oncogene. 1991; 6:1189-1194.

165

Praskova M., Khokhlatchev A., Ortiz-Vega S., Avruch J. Regulation of the MST1 kinase
by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and
by Ras. Biochem J. 2004 Jul 15;381(Pt 2):453-62.
Pritchard C.A., Samuels M.L., Bosch E., McMahon M. Conditionally oncogenic forms
of the A-Raf and B-Raf protein kinases display different biological and biochemical
properties in NIH 3T3 cells. Mol Cell Biol. 1995 Nov;15(11):6430-42.
Raccurt M., Tam S.P., Lau P., Mertani H.C., Lambnert A., Garcia-Caballero T., Li H.,
Brown R.J., McGuckin M.A., Morel G., Waters M.J. Suppressor of cytokine
signaling gene expression is elevated in breast carcinoma. Br J Cancer. 2003 Aug 4;
89(3):524-32.
Rajkumar L., Guzman R.C., Yang J., Thordarson G., Talamantes F., Nandi S. Prevention
of mammary carcinogenesis by short-term estrogen and progestin treatments. Breast
Cancer Res. 2004;6(1):R31-7.
Reifenberger J., Knobbe C.B., Sterzinger A.A., Blaschke B., Schulte K.W., Ruzicka T.,
Reifenberger G. Frequent alterations of Ras signaling pathway genes in sporadic
malignant melanomas. Int J Cancer. 2004 Apr 10;109(3):377-84.
Repasky G.A., Chenette E.J., Der C.J. Renewing the conspiracy theory debate: does Raf
function alone to mediate Ras oncogenesis? Trends Cell Biol. 2004 Nov; 14(11):63947.
Reya T., Morrison S.J, Clarke M.F, Weissman I.L. Stem cells, cancer, and cancer stem
cells. Nature. 2001 Nov 1;414(6859):105-11.
Rodriguez-Viciana P., Sabatier C., McCormick F. Signaling specificity by Ras family
GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol.
2004 Jun;24(11):4943-54.
Roh H., Pippin J.A., Green D.W., Boswell C.B., Hirose C.T., Mokadam N., Drebin J.A.
HER2/neu antisense targeting of human breast carcinoma. Oncogene. 2000 Dec
11;19(53):6138-43.
Ross S.R., Hsu C.L., Choi Y, Mok E., Dudley J.P. Negative regulation in correct tissuespecific expression of mouse mammary tumor virus in transgenic mice. Mol Cell
Biol. 1999 Nov;10(11):5822-9.
Rowland B.D., Peeper D.S. KLF4, p21 and context-dependent opposing forces in cancer.
Nat Rev Cancer. 2006 Jan;6(1):11-23.
Rugo H.S. Bevacizumab in the treatment of breast cancer: rationale and current data.
Oncologist. 2004;9 Suppl 1:43-9.

166

Russo I.H., Koszalka M., Russo J. Comparative study of the influence of pregnancy and
hormonal treatment on mammary carcinogenesis. Br J Cancer. 1991 Sep;64(3):481-4.
Russo J., Mailo D., Hu Y.F., Balogh G., Sherif F., Russo I.H. Breast differentiation and
its implication in cancer prevention. Clin Cancer Res. 2005a Jan 15;11(2 Pt 2): 931s6s.
Russo J., Moral R., Balogh G.A., Mailo D., Russo I.H. The protective role of pregnancy
in breast cancer. Breast Cancer Res. 2005b;7(3):131-42.
Sakai Y., Morrison B.J., Burke J.D., Park J.M., Terabe M., Janik J.E., Forni G.,
Berzofsky J.A., Morris J.C. Vaccination by genetically modified dendritic cells
expressing a truncated neu oncogene prevents development of breast cancer in
transgenic mice. Cancer res. 2004 Nov 1; 64(21):8022-8.
Schedin P., Mitrenga T., McDaniel S., Kaeck M. Mammary ECM composition and
function are altered by reproductive state. Mol Carcinog. 2004 Dec;41(4):207-20.
Scheel H., Hofmann K. A novel interaction motif, SARAH, connects three classes of
tumor suppressor. Curr Biol. 2003 Dec 2;13(23):R899-900.
Schultheis B., Carapeti-Marootian M., Hochhaus A., Weisser A., Goldman J.M., Melo
J.V. Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia:
possible inadequacy of a negative feedback mechanism. Blood.2002 Mar
1;99(5):1766-75.
Sewing A., Wiseman B., Lloyd A.C., Land H. High-intensity Raf signal causes cell cycle
arrest mediated by p21Cip1. Mol Cell Biol. 1997 Sep;17(9):5588-97.
Shahan K., Denaro M., Gilmartin M., Shi Y., Derman E. Expression of six mouse major
urinary protein genes in the mammary, parotid, sublingual, submaxillary, and
lachrymal glands and in the liver. Mol Cell Biol. 1987 May;7(5):1947-54.
Shao J., Sheng H., DuBois R.N., Beauchamp R.D. Oncogenic Ras-mediated cell growth
arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1
degradation. J Biol Chem. 2000 Jul 28;275(30):22916-24.
Shaw P.H., Held W.A., Hastie N.D. The gene family for major urinary proteins:
expression in several secretory tissues of the mouse. Cell. 1983 Mar;32(3):755-61.
Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer.
1997 Apr; 33(5):787-91.
Shepherd T.G., Kockeritz L., Szrajber M.R., Muller W.J., Hassell J.A. The pea-3
subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis.
Curr Biol. 2001 Nov 13;11(22):1739-48.

167

Shivakumar L., Minna J., Sakamaki T., Pestell R., White M.A. The RASSF1A tumor
suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol
Cell Biol. 2002 Jun;22(12):4309-18.
Siegel P.M., Shu W., Cardiff R.D., Muller W.J., Massague J. Transforming growth factor
beta signaling impairs Neu-induced mammary tumorigenesis while promoting
pulmonary metastasis. Proc Natl Acad Sci USA. 2003 Jul 22;100(14):8430-5.
Sinn E., Muller W., Pattengale P., Tepler I., Wallace R., Leder P. Coexpression of
MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of
oncogenes in vivo. Cell.1987 May 22;49(4):465-75.
Sivaraman L., Stephens L.C., Markaverich B.M., Clark J.A., Krnacik S., Conneely O.M.,
O’Malley B.W., Medina D. Hormone-induced refractoriness to mammary
carcinogenesis in Wistar-Furth rats. Carcinogenesis. 1998 Sep;19(9):1573-81.
Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human
breast cancer: correlation of relapse and survival with amplification of the HER-2/neu
oncogene. Science. 1987 Jan 9;235(4785):177-82.
Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J.,
Stuart S.G., Udove J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in
human breast and ovarian cancer. Science. 1989 May 12;244(4905):707-12
Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T.,
Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus
a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses
HER2. N Engl J Med. 2001 Mar 15;344(11):783-92.
Slamon D.J., Romond E.H., Perez E.A., CME Consultants, Inc. Advances in adjuvant
therapy for breast cancer. Clin Adv Hematol Oncol. 2006 Mar;4(3):suppl 1,4-9.
Smith I.E. Aromastase inhibitors - extending the benefits of adjuvant therapy beyond
tamoxifen. Breast. 2004 Dec; 13 Suppl 1:S3-9.
Song M.S., Song S.J., Ayad N.G., Chang J.S., Lee J.H., Hong H.K., Lee H., Choi N.,
Kim J., Kim H., Kim J.W., Choi E.J., Kirschner M.W., Lim D.S. The tumor
suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat
Cell Biol. 2004 Feb;6(2):129-37.
Soong R., Knowles S., Williams K.E., Hammond I.G., Wysocki S.J., Iacopetta B.J.
Overexpression of p53 protein is an independent prognostic indicator in human
endometrial carcinoma. Br J Cancer. 1996 Aug;74(4):562-7.

168

Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen
M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O.,
Botstein D., Eystein Lonning P., Borresen-Dale A.L. Gene expression patterns of
breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 2001 Sep 11;98 (19):10869-74.
Sory A., Minamoto T., Ohta T., Yamashita K., Sawaguchi K., Mai M., Misiuna P. Does
p53 overexpression cause metastases in early invasive colorectal adenocarcinoma?
Eur J Surg. 1997 Sep;163(9):685-92.
Stewart T.A., Pattengale P.K., Leder P. Spontaneous mammary adenocarcinomas in
transgenic mice that carry and express MMTV/myc fusion genes. Cell. 1984 Oct;
38(3):627-37.
Tanabe K., Kim R., Inoue H., Emi M., Uchida Y., Toge T. Antisense Bcl-2 and HER-2
oligonucleotide treatment of breast cancer cells enhances their sensitivity to
anticancer drugs. Int J Oncol. 2003 Apr;22(4):875-81.
Thordarson G., Jin E., Guzman R.C., Swanson S.M., Nandi S., Talamantes F.
Refractoriness to mammary tumorigenesis in parous rats: is it caused by persistent
changes in the hormonal environment or permanent biochemical alterations in the
mammary epithelia? Carcinogenesis. 1995 Nov;16(11):2847-53.
Threadgill D.W., Dlugosz A.A., Hansen L.A., Tennenbaum T., Lichti U., Yee D.,
LaMantia C., Mourton T., Herrup K., Harris R.C., et al. Targeted disruption of mouse
EGF receptor: effect of genetic background on mutant phenotype. Science. 1995 Jul
14;269(5221):230-4.
Tiwari R.K., Borgen P.I., Wong G.Y., Cordon-Cardo C., Osborne M.P. HER-2/neu
amplification and overexpression in primary human breast cancer is associated with
early metastasis. Anticancer Res. 1992 Mar-Apr;12(2):419-25.
Tommasi S., Dammann R., Jin S.G., Zhang Xf XF, Avruch J., Pfeifer G.P. RASSF3 and
NORE1: identification and cloning of two human homologues of the putative tumor
suppressor gene RASSF1. Oncogene. 2002 Apr 18;21(17):2713-20.
Tommasi S., Dammann R., Zhang Z., Wang Y., Liu L., Tsark W.M., Wilczynski S.P., Li
J., You M., Pfeifer G.P. Tumor susceptibility of Rassf1a knockout mice. Cancer Res.
2005 Jan 1;65(1):92-8.
Torregrosa D., Bolufer P., Lluch A., Lopez J.A., Barragan E., Ruiz A., Guillem V.,
Munarriz B., Garcia Conde J. Prognostic significance of c-erbB-2/neu amplification
and epidermal growth factor receptor (EGPR) in primary breast cancer and their
relation to estradiol receptor (ER) status. Clin Chim Acta. 1997 Jun 27;262(1-2):99119.

169

Travis A., Pinder S.E., Robertson J.F., Bell J.A., Wencyk P., Gullick W.J., Nicholson
R.I., Poller D.N., Blamey R.W., Elston C.W., Ellis I.O. C-erbB-3 in human breast
carcinoma: expression and relation to prognosis and established prognostic indicators.
Br J Cancer. 1996 Jul;74(2):229-33.
Tworoger S.S., Hankinson S.E. Prolactin and breast cancer risk. Cancer Lett. 2006 Mar 9.
Tycko B. Epigenetic gene silencing in cancer. J Clin Invest. 2000 Feb;105(4):401-7.
Utomo A.R., Nikitin AY., Lee W.H. Temporal, spatial, and cell type-specific control of
Cre-mediated DNA recombination in transgenic mice. Nat Biotechnol. 1999
Nov;17(11):1091-6.
van Engeland M., Weijenberg M.P., Roemen G.M., Brink M., de Bruine A.P., Goldbohm
R.A., van den Brandt P.A., Baylin S.B., de Goeij A.F., Herman J.G. Effects of dietary
folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the
Netherlands cohort study on diet and cancer. Cancer Res. 2003 Jun 15; 63(12):31337.
Varner J.A, Cheresh D.A. Integrins and cancer. Curr Opin Cell Biol. 1996 Oct;8(5):72430.
Viel A., Genuardi M., Capozzi E., Leonardi F., Bellacosa A., Paravatou-Petsotas M.,
Pomponi M.G., Fornasarig M., Percesepe A., Roncucci L., Tamassia M.G., Benatti
P., Ponz de Leon M., Valenti A., Covino M., Anti M., Foletto M., Boiocchi M., Neri
G. Characterization of MSH2 and MLH1 mutations in Italian families with hereditary
nonpolyposis colorectal cancer. Genes Chromosomes Cancer. 1997 Jan;18(1):8-18.
Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat Med. 2004
Aug;10(8):789-99.
Vogt U., Bielawski K., Schlotter C.M., Bosse U., Falkiewicz B., Podhajska A.J.
Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in
primary human breast cancer. Gene. 1998 Nov 26;223(1-2):375-80.
Voice J.K., Klemke R.L., Le A., Jackson J.H. Four human ras homologs differ in their
abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol
Chem. 1999 Jun 11;274(24):17164-70.
von Lintig F.C., Dreilinger A.D., Varki N.M., Wallace A.M., Casteel D.E., Boss G.R.
Ras activation in human breast cancer. Breast Cancer Res Treat. 2000 Jul;62(1): 5162.
Vos M.D., Ellis C.A., Bell A., Birrer M.J., Clark G.J. Ras uses the novel tumor
suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem. 2000 Nov 17;
275(46):35669-72.

170

Vos M.D., Ellis C.A., Elam C., Ulku A.S., Taylor B.J., Clark G.J. RASSF2 is a novel KRas-specific effector and potential tumor suppressor. J Biol Chem. 2003a
Jul25;278(30):28045-51.
Vos M.D., Martinez A., Ellis C.A., Vallecorsa T., Clark G.J. The pro-apoptotic Ras
effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J Biol
Chem. 2003b Jun 13;278(24):21938-43.
Wagner K.U., Wall R.J., St-Onge L., Gruss P., Wynshaw-Boris A., Garrett L., Li M.,
Furth P.A., Hennighausen L. Cre-mediated gene deletion in the mammary gland.
Nucleic Acids Res. 1997 Nov 1;25(21):4323-30.
Wagner T.E., Hoppe P.C., Jollick J.D., Scholl D.R., Hodinka R.L., Gault J.B.
Microinjection of a rabbit beta-globin gene into zygotes and its subsequent expression
in adult mice and their offspring. Proc Nat Acad Sci USA. 1981 Oct;78:6376-6380.
Wallasch C., Weiss F.U., Niederfellner G., Jallal B., Issing W., Ullrich A. Heregulindependent regulation of HER2/neu oncogenic signaling by heterodimerization with
HER3. EMBO J. 1995 Sep 1;14(17):4267-75.
Warburg O. On the origin of cancer cells. Science. 1956 Feb 24;123(3191):309-14.
Weinberg R.A. The biology of cancer. Garland Science, New York, 2006; 864p.
Weinstat-Saslow D., Merino M.J., Manrow R.E., Lawrence J.A., Bluth R.F., Wittenbel
K.D., Simpson J.F., Page D.L., Steeg P.S. Overexpression of cyclin D mRNA
distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat
Med. 1995 Dec;1(12):1257-60.
Whang Y.M., Kim Y.H., Kim J.S., Yoo Y.D. RASSF1A suppresses the c-Jun-NH2kinase pathway and inhibits cell cycle progression. Cancer Res. 2005 May
1;65(9):3682-90.
Wickstrom E. Oligonucleotide treatment of ras-induced tumors in nude mice. Mol
Biotechnol. 2001 May;18(1):35-55.
Wilson C.A., Cajulis E.E., Green J.L., Olsen T.M., Chung Y.A., Damore M.A., Dering J.,
Calzone F.J., Slamon D.J. HER-2 overexpression differentially alters transforming
growth factor-beta responses in luminal versus mesenchymal human breast cancer
cells. Breast Cancer Res. 2005;7(6):R1058-79.
Woelfle U., Cloos J., Sauter G., Riethdorf L., Janicke F., van Diest P., Brakenhoff R.,
Pantel K. Molecular signature associated with bone marrow micrometastasis in
human breast cancer. Cancer Res. 2003 Sep 15;63(18):5679-84.

171

Woods D., Parry D., Cherwinski H., Bosch E., Lees E., McMahon M. Raf-induced
proliferation or cell cycle arrest is determined by the level of Raf activity with arrest
mediated by p21Cip1. Mol Cell Biol. 1997 Sep;17(9):5598-611.
Xing M., Cohen Y., Mambo E., Tallini G., Udelsman R., Ladenson P.W., Sidransky D.
Early occurrence of RASSF1A hypermethylation and its mutual exclusion with
BRAF mutation in thyroid tumorigenesis. Cancer Res. 2004 Mar 1;64(5):1664-8.
Yamauchi T., Yamauchi N., Ueki K., Sugiyama T., Waki H., Miki H., Tobe K., Matsuda
S., Tsushima T., Yamamoto T., Fujita T., Taketani Y., Fukayama M., Kimura S.,
Yazaki Y., Nagai R., Kadowaki T. Constitutive tyrosine phosphorylation of ErbB-2
via Jak2 by autocrine secretion of prolactin in human breast cancer. J Biol Chem.
2000 Oct 27; 275(43):33937-44.
Yan J., Roy S., Apolloni A., Lane A., Hancock J.F. Ras isoforms vary in their ability to
activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem. 1998 Sep
11;273(37):24052-6.
Yan P.S., Shi H., Rahmatpanah F., Hsiau T.H., Hsiau A.H., Leu Y.W., Liu J.C., Huang
T.H. Differential distribution of DNA methylation with the RASSF1A CpG island in
breast cancer. Cancer Res. 2003 Oct 1;63(19):6178-86.
Yang C., Ionescu-Tiba V., Burns K., Gadd M., Zukerberg L., Louis D.N., Sgroi D.,
Schmidt E.V. The role of the cyclin D1-dependent kinases in ErbB2-mediated breast
cancer. Am J Pathol. 2004 Mar;164(3):1031-8.
Yarwood S.J., Woodgett J.R. Extracellular matrix composition determines the
transcriptional response to epidermal growth factor receptor activation. Proc Natl
Acad Sci USA. 2001 Apr 10;98(8):4472-7.
Yu J.S., Chen W.J., Ni M.H., Chan W.H., Yang S.D. Identification of the regulatory
autophosphorylation site of autophosphorylation-dependent protein kinase (autokinase). Evidence that auto-kinase belongs to a member of the p21-activated kinase
family. Biochem J. 1998 Aug 15;334 (Pt 1):121-31.
Yu Q., Geng Y., Sicinski P. Specific protection against breast cancers by cyclin D1
ablation. Nature. 2001 Jun 28;411(6841):1017-21.
Zanssen S., Schon E.A. Mitochondrial DNA Mutations in Cancer. PLoS Med. 2005
Nov;2(11):e401.

172

